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There is a worldwide increase in the abuse of new psychoactive substances, 
which pose a threat to public health. The fast‐paced nature of the NPS market 
and increased availability is drawing international concern. There is a general 
lack of comprehensive evidence on the toxicity and abuse risks associated 
with long-term use. The rapid pace of NPSs development means that they 
remain as an area of concern and interest; this shows the technical challenges 
in terms of development of analytical methods for the detection and 
determination of these substances. 
There is a knowledge gap in terms of chromatographic methods of detection, 
separation and quantification of diphenidine and its derivatives, in particular 
HPLC approaches. Currently, there is more research applying GC methods for 
NPSs analysis. The aim of this project is to develop a reliable, rapid, sensitive 
and robust HPLC method for the analysis of this group of NPSs.   
Regioisomeric compounds, 2-, 3- and 4-methoxphenidine (MXP) were used to 
develop a robust high performance liquid chromatography (HPLC) method 
using mobile phase (acetonitrile:ammonium acetate 55:45% v/v) whilst the 
stationary phase was ACE-5 C18 AR column (150 x 4.6 mm, 5 µm particle 
size). The method was validated according to the International Conference on 
Harmonisation of Technical Requirements of Pharmaceutical for Human Use 
(ICH) guidelines and shown to be both selective and sensitive (Limit of 
Detection, LOD = 0.04-0.15 µg mL-1, Limit of Quantification, LOQ = 0.38-0.47 
µg mL-1). The reference materials used for this study were characterised using 
1H NMR, 13C NMR, IR, UV and GC-MS.  
The scope of the study was applied to the recently reported diphenidine 
derivatives, 2-, 3- and 4-fluephenidines, in addition to 2-, 3- and 4-
fluorocyanophenidines and the halogenated diphenidine compounds. 
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Accuracy, precision, robustness and specificity of these substances were 
investigated.  
As an average, limit of detection (LOD) was between 0.05 and 0.60 µg mL-1, 
whereas, limit of quantification (LOQ) was between 0.16-1.84 µg mL-1 for all 
the diphenidine derived regioisomers tested in this study. Additionally, total run 
time of just 10 minutes with resolution values (Rs) of greater than 2 in the case 
of both MXP isomers and all tested halogenated diphenidine isomers indicates 
that the applied HPLC method was rapid and sensitive, therefore it can be 
implemented to examine any samples that might contain these substances.  
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Chapter 1:  Introduction and literature review 
There are many reasons for substance use including positive impact on 
performance and experience, such as pleasure, fun, improved concentration 
and attention, enhanced work performance, relaxation and sleep.[1] Drug 
abuse and addiction have negative consequences on human health and on 
society. Drug addiction can be prevented effectively via programmes that 
include families, schools, communities, and the media. Thus, education and 
outreach are key in helping youth and the general public understand the risks 
of drug abuse in general and the new emerging classes of new psychoactive 
substances (NPS) in particular. Education is one of the most important 
preventive interventions to counter destructive NPS marketing approaches. It 
is essential to inform people that there is not anything “smart” concerning these 
drugs. Because these are the product of profit-motivated individuals with the 
technical knowledge to produce, market and distribute them exploiting the 
gaps and cracks of the legal systems.  
In order to control substances of concern (including NPS), reducing the supply 
and reducing the demand are two basic strategies/policies, besides, the 
burden falls on national and international legal for controlling these drugs, in 
terms of adding, transferring of the substance from one schedule to another, 
or removal from any of the schedules of the corresponding Convention. 
Several countries have early warning systems that aim to offer timely 
information so that policymakers will be able to make evidence-based 
judgements. Therefore, these drugs need to be regulated to supress unlawful 
drug abuse. [2] 
1.1 Laws controlling substances of concern in the UK 
The biggest challenge of substances with the potential for misuse or abuse is 
having in place a legislative response that can respond to emerging new 
substances in a timely and effective way. The UK Government’s existing 
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approach is defined within the Misuse of Drugs Act (1971), although it is 
essential to review the current legal framework available to authorities to 
govern the possession, production and supply of controlled substances.  This 
section provides an overview about the development of the legal framework 
for the control of harmful substances in the United Kingdom. The history of 
drug related legislation in the United Kingdom began with the Pharmacy Act 
(1868); this Act is the first regulation of poisons and dangerous substances. 
Five decades later, the Dangerous Drugs Act (1920) came into force, to limit 
the production, import, export, possession, sale and distribution of opium, 
cocaine, morphine or heroin to licensed persons. Five years later, The 
Dangerous Drugs Act (1925) was amended, which regulated the controlled 
importation of coca leaf and cannabis, and after three years this Act was 
amended by criminalising possession of cannabis. However, doctors still have 
the ability to prescribe any drugs as treatments (including for addiction). Later 
in 1961, the United Nations 1961 Single Convention on Narcotic Drugs was 
passed as a law to combat drug abuse by coordinated international action, it 
banned countries from treating addicts by prescribing illicit drugs, permitting 
only scientific and medical uses of drugs. This act was not itself obligatory on 
countries, which had to pass their specific laws. Three years later, The 
Dangerous Drugs Act (1964) was amended, this Act criminalised cultivation of 
cannabis.[3],[4]  
In the same year (1964), the Drugs Prevention of Misuse Act criminalized 
possession of amphetamines. In 1967, in an amendment to the Dangerous 
Drugs Act, doctors were then required to inform the Home Office of addicted 
patients and also included restriction on the prescription of heroin and cocaine 
for addiction treatment. In 1971, The Misuse of Drugs Act was announced.[5] 
The laws controlling drug use are complicated but there are three main statutes 




(i) The Medicines Act (1968), this law governs the manufacture and 
supply of medicine. It divides medical drugs into three categories: 
prescription only medicines, pharmacy medicines and general sales 
list medicines.[6] 
(ii) The Misuse of Drugs Act (1971) and the Misuse of Drugs 
Regulations (2001) outlines the law around drugs that have been 
deemed to be harmful and are therefore ‘controlled’ by law.[5]   
(iii) The Psychoactive Substances Act (2016) is intended to restrict the 
production, sale and supply of a new class of psychoactive 
substances often referred to as "legal highs".[7] 
1.1.1 The Misuse of Drugs Act 1971 (MDA 1971) 
The Misuse of Drugs Act (MDA) was passed in the UK parliament in 1971.[5] 
It represents action in line with treaty commitments under the Single 
Convention on Narcotic Drugs (1961) [4] and the Convention on Psychotropic 
Substances (1971).[8] The main purpose of the MDA 1971 is to prevent the 
misuse of controlled drugs and achieves this by imposing a complete ban on 
the possession, supply, manufacture, import and export of controlled drugs 
except as allowed by regulations or by licence from the Secretary of State.[5]  
The Misuse of Drugs (Safe Custody) Regulations 1973 supports the MDA and 
prescribes the steps individuals (or organisations) need to undertake to 
facilitate the storage and safe custody for Controlled Drugs. 
The MDA 1971 places drugs into A, B, or C classification - according to how 
harmful they are considered to be. Higher classification is associated with 
stricter penalties for possession, supply and importation. The MDA 1971, as 
amended, prohibits certain activities in relation to ‘Controlled Drugs’, in 
particular their manufacture, supply, and possession (except where permitted 
by the 2001 Regulations or under licence from the Secretary of State). The 
penalties applicable to offences involving the different drugs are graded 
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broadly according to the harmfulness attributable to a drug when it is misused 
and for this purpose the drugs are defined in the following three classes: 
Class A includes: alfentanil, cocaine, diamorphine hydrochloride (heroin), 
dipipanone hydrochloride, fentanyl, lysergide (LSD), methadone 
hydrochloride, 3,4-methylenedioxymethamfetamine (MDMA, ‘ecstasy’), 
morphine, opium, oxycodone hydrochloride, pethidine hydrochloride, 
phencyclidine, remifentanil, and class B substances when prepared for 
injection. 
Class B includes: oral amphetamines, barbiturates, cannabis, Sativex® 
(nabiximols), codeine phosphate, dihydrocodeine tartrate, ethylmorphine, 
glutethimide, ketamine, nabilone, pentazocine, phenmetrazine, and 
pholcodine. 
Class C includes: certain drugs related to the amphetamines such as 
benzphetamine and chlorphentermine, buprenorphine, mazindol, 
meprobamate, pemoline, pipradrol, most benzodiazepines, tramadol 
hydrochloride, zaleplon, zolpidem tartrate, zopiclone, androgenic and anabolic 
steroids, clenbuterol, chorionic gonadotrophin (HCG), non-human chorionic 
gonadotrophin, somatotropin, somatrem, and somatropin. 
1.1.2 Misuse of Drugs Regulations 1985 
These schedules are similar to those in MDA 1971 with some modifications as 
shown at the end of this section. The 1973 regulations were revoked after the 
Misuse of Drugs Regulations 1985 were presented, the latter enabling certain 
classes of person to possess, produce, supply, prescribe or administer 
controlled drugs. For the purposes of these regulations, drugs are divided into 
Schedules as follows:  
Schedule 1 Prohibited drugs except with a Home Office licence, no medical 
uses, e.g. cannabis, LSD, MDMA.  
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Schedule 2 Only available as prescription medicines with some restrictions 
(full controlled drug requirements in relation to prescribing and safe custody, 
keeping of registers), most opiates and cocaine.  
Schedule 3 Only available on prescription e.g. most barbiturates, temazepam, 
flunitrazepam.  It is an offence to possess the drug unless the individual can 
prove that it was lawfully supplied.  
Schedule 4 Benzodiazepines (except temazepam and flunitrazepam), 
anabolic steroids. Can be lawfully possessed without a prescription.  
Schedule 5 Available without prescription, preparations containing a small 
amount of controlled drugs.[9] 
The Misuse of Drugs Regulations 1985 restructure the provisions of the Misuse 
of Drugs Regulations 1973, which were overridden. They offer certain 
exemptions from the provisions of the MDA 1971 that prohibit the production, 
importation, exportation, possession and supply of controlled drugs. The 
Regulations also create provision with regard to prescriptions, records and the 
furnishing of information relating to controlled drugs and for the supervision of 
the destruction of such drugs. The changes of substance made by the 
Regulations can be summarised below: 
(i) the addition of those substances which are made subject to control 
under the Act of 1971 by virtue of the MDA 1971 (modification) Order 
1985; the new Class B, and a number of Class C, drugs are included 
in Schedules 2 and 3 to the 1973 Regulations) but the largest group 
(benzodiazepines) compromise a new Schedule 4 and are exempted 
from the prohibition on importation and exportation.  
(ii) the extension of the general authority to possess controlled drugs 




(iii) amendments regarding supply and possession of controlled drugs on 
ships and off-shore installations (Regulation 8 to 10).  
(iv) an increase in the range of controlled drugs which midwives are 
authorised to possess and administer (Regulation 11). 
(v) an additional exemption from labelling requirements for controlled 
drugs used in clinical trials and animal tests (Regulation 18). 
(vi) the application of certain record-keeping and destruction provisions to 
drugs specified in Schedules 3 and 4, with exemptions for certain 
categories of people (Regulation 22, 24 and 26).  
(vii) a new requirement that certain persons, on demand by the Secretary 
of State, should finish records and information concerning dealings in 
controlled drugs (Regulation 25).[10] 
1.1.3 The Misuse of Drugs Regulations 2001  
The Misuse of Drugs Regulations 2001 allow for the lawful possession and 
supply of controlled (illegal) drugs for legitimate purposes. They cover 
prescribing, administering, safe custody, dispensing, record keeping, 
destruction and disposal of controlled drugs to prevent diversion for 
misuse.[11] Two changes of substance are made by the regulations, the 
addition of 35 phenethylamine derivatives which are made subject to control 
under the MDA 1971 (Modification). The second change is that the 33 
benzodiazepines and 8 other substances formerly in Schedule 4 Part II are 
now in Part I of that Schedule. In addition, the 54 anabolic substances formerly 
in Schedule 4 Part I are now in Part II of that Schedule.[11] 
The Misuse of Drugs Regulations (2001) (MDR) and its subsequent 
amendments, retains drugs in five schedules (1-5) and specifies the 
requirements governing such activities as import, export, production, supply, 
possession, prescribing, and record keeping which apply to them.  The 
Regulations also define the types of professional person(s) who are authorised 
to supply and possess Controlled Drugs and stipulates the conditions under 
which these activities may be carried out. In the 2001 regulations, drugs are 
7 
 
divided into five Schedules, each specifying the requirements governing such 
activities as import, export, production, supply, possession, prescribing, and 
record keeping which apply to them. 
Schedule 1 includes drugs not used medicinally such as hallucinogenic drugs 
(e.g. LSD), ecstasy-type substances, raw opium, and cannabis. A Home Office 
licence is generally required for their production, possession, or supply. A 
Controlled Drug register must be used to record details of any Schedule 1 
Controlled Drugs received or supplied by a pharmacy. 
Schedule 2 includes opiates (e.g. diamorphine hydrochloride (heroin), 
morphine, methadone hydrochloride, oxycodone hydrochloride, pethidine 
hydrochloride), major stimulants (e.g. amphetamines), quinalbarbitone 
(secobarbital), cocaine, ketamine, and cannabis-based products for medicinal 
use in humans. Schedule 2 Controlled Drugs are subject to the full Controlled 
Drug requirements relating to prescriptions, safe custody (except for 
quinalbarbitone (secobarbital) and some liquid preparations), and the need to 
keep a Controlled Drug register, (unless exempted in Schedule 5). Possession, 
supply and procurement is authorised for pharmacists and other classes of 
persons named in the 2001 Regulations. 
Schedule 3 includes the barbiturates (except secobarbital, now Schedule 2), 
buprenophine, mazindol, meprobamate, midazolam, pentazocine, 
phentermine, temazepam, and tramadol hydrochloride. They are subject to the 
special prescription requirements. Safe custody requirements do apply, except 
for any 5,5 disubstituted barbituric acid (e.g. phenobarbital), mazindol, 
meprobamate, midazolam, pentazocine, phentermine, tramadol 
hydrochloride, or any stereoisomeric form or salts of the above. Records in 
registers do not need to be kept (although there are requirements for the 




Schedule 4 includes in Part I drugs that are subject to minimal control, such as 
benzodiazepines (except temazepam and midazolam, which are in Schedule 
3), non-benzodiazepine hypnotics (zaleplon, zolpidem tartrate, and zopiclone) 
and Sativex®. Part II includes androgenic and anabolic steroids, clenbuterol, 
chorionic gonadotrophin (HCG), non-human chorionic gonadotrophin, 
somatotropin, somatrem, and somatropin. Controlled drug prescription 
requirements do not apply and Schedule 4 Controlled Drugs are not subject to 
safe custody requirements. Records in registers do not need to be kept (except 
in the case of Sativex®). 
Schedule 5 includes preparations of certain Controlled Drugs (such as 
codeine, pholcodine or morphine) which due to their low strength, are exempt 
from virtually all Controlled Drug requirements other than retention of invoices 
for two years. 
The illicit drugs have been a noticeable concern in public policy in the United 
Kingdom at least since the 1970s, much debated by politicians and the 
media.[12] In the 1980s, reduction of supply of controlled drugs was 
emphasised in UK government policy, while in the 1990s the focus was on 
minimising demand and in the 2000s the emphasis was on reducing harm.[13] 
One of the most important reasons why the drug policy makers in the UK 
intervened by introducing a new legislation (the Psychoactive Substance Act 
(PSA) 2016) was due to the unprecedented popularity of NPS linked with 
reported death and toxicity cases not only in the UK but also all over the world. 
The widespread use of these harmful/dangerous substances is for a number 
of reasons. Some users had the misconception that NPS were legal, thus 
meaning they are safe to use, whereas other people are “novelty seekers” who 
want to try new and exciting things. Due to NPS being easy to obtain, these 
novelty seekers have been readily exposed.[14] At present, the Internet is 
considered as a perfect platform to promote and market these substances, 
forming a worldwide platform for marketing them.[15] In addition to their ease 
of synthesis and low cost, resourceful marketing/advertising have contributed 
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to the problem. Information available via the Internet, plus negligible difficulty 
in the manufacturing and transportation from distant areas, together with 
careless legal prosecution/enforcement, has led to high prevalence of these 
substances.[16] All these reasons led to a change to the law in the UK 
regarding NPS. Resultantly, the PSA (2016)  was passed as a law. It was 
intended to plug gaps in the existing legislation, which did not deal sufficiently 
with NPS. 
In the last decade, New Psychoactive Substances (NPS) have emerged on the 
(inter)national drug scene.[17, 18] These substances are similar in their 
chemical structures (with minor structural modifications) to other controlled 
drugs, and as a result produce similar pharmacological effects, albeit that 
these effects can be either up- or down-regulated depending on the NPS in 
question (e.g. amphetamines vs. synthetic cathinones). There are many terms 
given to unregulated NPS, which are mislabelled intentionally to circumvent 
the existing laws of controlled drugs. “Legal highs”, “herbal highs”, “bath salts”, 
“plant food”, “plant feeders”, “research chemicals”, “designer drugs”, “synthetic 
drugs”,” and “smart drugs” are some of the names/terms used for NPS. In 
some cases, NPS have been labelled ‘not for human use’ or ‘not tested for 
hazards or toxicity’ in an effort to further circumvent law.[17, 19, 20] It is 
noteworthy that the highlighting of potential new dangers is not just applicable 
to healthcare professionals, but also to the general public, as the latter also 
need to be clearly informed and aware of dangers resulting from NPS spread 
and use.[20, 21] This situation is exacerbated when the legislative process for 
prohibiting individual compounds is considered; it is regarded as being too 
slow, especially as the manufacturers can rapidly replace newly prohibited 
compounds with new uncontrolled substances.[22] This thesis will be 
concerned with a specific class of NPS known as the dissociative anaesthetics, 
such as diphenidine (1) and its substituted derivatives e.g. methoxphenidine 
(2-, 3- and 4-MXP, 2, 3 and 4 respectively).  Before we discuss the specific 
class of NPS (dissociative anaesthetics) that this study focuses on, and its 
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chemistry, pharmacology and methods of analysis, it will be useful to 
contextualise the NPS situation and provide an overview about popularity, 
prevalence and classification of these substances. 
1.2 Popularity of NPS 
As mentioned earlier, despite the existing laws and regulations governing drug 
availability and use, nonetheless NPS are still emerging nearly on a daily basis. 
The appearance of new substances mean new toxicological threats for body 
organs, new analytical challenges in detecting them and new questions for 
emergency doctors and toxicologists about the treatments to carry out for 
adverse drug reactions to their consumption and overdose.[23] 
In the last ten years, NPSs have extensively dominated the drug scene in 
Europe and the US. Many drug users have switched from their traditional drugs 
to NPS use. Several factors have contributed to their increasing popularity 
including, as mentioned earlier, their falsely legal image, their more reasonable 
costs, and their distribution based on the new technologies. However, major 
health issues have emerged in relation to the somatic, mental, and addictive 
consequences of their use with persistent unknowns for the future. All this 
explains the urgent requirement to developing clinical research and improving 
the management of addiction and poisonings attributed to these NPS.[24]  In 
parallel with the physical drugs market, the last decade has seen the 
development of online marketplaces, facilitated by the emergence of new 
internet technologies. Some online vendors utilise the surface web, typically 
retailing non-controlled precursor chemicals, NPS or medicines, which may be 
falsified or counterfeit. This shows the complexity and therefore the difficulty of 
controlling the current drug market.  
On one hand, modern technology such as social media, YouTube and 
smartphone applications are used for selling NPS. On the other hand, it is 
important to bear in mind that these substances are sold under many names. 
To conceal both transactions and physical locations of servers, many 
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strategies can be used. Anonymization techniques such as Tor and I2P that 
encrypt the computer internet protocol address and cryptocurrencies such as 
bitcoin [25] and litecoin are utilised to make communications between drug 
dealers and consumers undetectable.[26] Consequently, the same technology 
can be utilised for raising awareness among people particularly youth about 
the harm caused by these drugs of abuse.[15]  
1.3 Prevalence of NPS 
The data of NPS spread can be obtained from UNODC World Drug Report and 
from the other UNODC programmes in the region on the production and use 
of recreational drugs.[27] According to UNODC, in 2018, opioids are causing 
the most harm to public health in comparison to other drugs of misuse. 
Besides, the use of analgesics such as fentanyl in North America and tramadol 
in regions of Africa and Asia remain a big issue because these drugs are made 
by traffickers who manufacture them illegally and promote these substances 
in unlawful markets causing significant harm to health. 
In February 2019, substances that have stimulant effects were the largest 
reported NPS drug group reported to UNODC (36%). Synthetic cannabinoid 
receptor agonists (30%) and classic hallucinogens (15%) were the next largest 
classes. Other groups, such as dissociative substances and 
sedatives/hypnotics, remained constant at 3%. The number of opioids nearly 
doubled in the course of 2018 to reach 62 different opioids or 7% of all 
substances listed in the system as of December 2018. The rising importance 




Figure 1. Proportion of NPS, by psychoactive effect group, as of December 
2018 [56] 
 
Although, the use of NPS is primarily a Western phenomenon, Asian countries 
are considered to be a fertile region for the production of NPS, particularly in 
China and India.[29] At a country-level, prevalence of NPS can be available 
but the lack of international data increases a knowledge gap that limits the 
capacity for agencies such as the World Health Organisation (WHO), UNODC, 
United Nations Programme on HIV and AIDS (UNAIDS) and other international 





Figure 2. Number and categories of NPS notified to the EU Early Warning 
System for the first time, 2005-2017[59] 
 
In 2017, according to the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), more than 670 NPS were detected in Europe. The issue 
is that these substances are not under control by international drug regulations 
and include a wide range of drugs, for example synthetic cannabinoids, 
opioids, stimulants, and benzodiazepines. From Figure 2, the main trend 
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observed is the increase in the number of NPS, with about 100 substance 
reported to the EMCDDA in both 2014 and 2015, followed by subsequent drop 
to just below 70 in 2016 and just over 50 in 2017. In addition, there is a 
significant rise in the percentage of opioids and benzodiazepines, particularly 
between 2014 and 2017 in comparison to the years from 2005 to 2013.[31]  
The efforts made by European countries in terms of controlling NPS in general 
is one reason behind the decrease in the total number of NPS reported in 2016 
and 2017. Another cause might be due to the closure of many laboratories that 
synthesise these substances in China following applying law enforcement 
systems.[32] 
In 2018, the number of substances reported in Europe was approximately 650 
substances in total and 300 in France. In a recent ten-year (2008-2018) 
overview of the situation in France compared with Europe (Figure 3) has 
shown that the number of NPS identified per year in Europe has declined in 
recent years: 67 in 2016, 51 in 2017, and 32 in 2018. The 32 compounds 
identified in Europe in the first semester of 2018 is considered as an increase 
in the number of NPS.  A similar trend was seen in France with only two 
substances reported in the first quarter of 2018. Overall, this decline does not 
seem to be linked to law enforcement service activities, which have stated a 
growing number of seizures each year with approximately 900 in 2015 and 
over 2,000 in 2017. Again, this decline might be as a result of the measures 
taken by authorities in producer countries, in addition to the international 
control of precursors may have hindered NPS production and that producers 
eventually focus on making substances most wanted by users/consumers.[33]   
While in the UK, in a report published by the Home Office, in total, there were 
1,523 seizures of NPS in 2017/18. Synthetic cannabinoids were most often 
seized (858 seizures, followed by other NPS (448 seizures), NPS powders 




Figure 3. Number of NPS identified per year, in the EU and in France 
All the above mentioned data and statistics on prevalence, drug use, drug 
harmful effects and the level of NPS usage show the importance of carrying 
out chemical analysis and pharmacological studies on these drugs. 
International and local authorities should take all the appropriate actions and 
measures to avoid the expansion of this new threat.  
1.3.1 Psychoactive Substances Act (2016) 
In response to the rapidly proliferating new psychoactive substance market, 
the UK Government implemented steps to restrict the supply, production and 
import of psychoactive substances.  The resulting legislation was the 
Psychoactive Substances Act (PSA).  The PSA (2016) came into force on 26 
May 2016 and made a blanket ban on the production, distribution, sale and 
supply of psychoactive substances in the United Kingdom for human 
consumption with the exemption of caffeine, nicotine, alcohol and medicinal 
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products as defined by Human Medicines Regulations (2012). PSA (2016) 
does not replace the MDA (1971); controlled drugs laws are still the same.  
The PSA (2016) gives police and other enforcement agencies a range of 
powers including: powers to seize and destroy psychoactive substances as 
defined by the PSA; search persons, premises and vehicles; and enter 
premises by warrant. It also includes a number of civil sanctions to enable a 
proportionate enforcement response.[7, 34]  
In general, the Act demonstrates many aspects such as possession, 
importation, supply, production, penalties (Table 1), powers to stop and 













Not an offence  
 
Not an Offence 
  
Possession in a 
custodial institution  
Up to 12 months and/or 
a fine  
Up to 2 years and/or a 
fine  
Possession with intent to 
supply  
Up to 12 months and/or 
a fine  
Up to 7 years and/or a 
fine  
Supply/offer to supply 
etc.  
Up to 12 months and/or 
a fine 
Up to 7 years and/or a 
fine  
Production  Up to 12 months and/or 
a fine  
Up to 7 years and/or a 
fine  
Importation/exportation  Up to 12 months and/or 
a fine  
Up to 7 years and/or a 
fine  
Failure to comply with a  
Prohibition or Premises 
notice  
Up to 12 months and/or 
a fine 
Up to 2 years and/or a 
fine  
 
In the UK, the maximum penalties for scheduled drug possession, supply 
(selling, dealing or sharing) and production depend on what type or ‘class’ the 
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drug is. For class A drug possession, up to 7 years in prison, unlimited fine or 
both. While, for class B drug possession, up to 5 years in prison, unlimited fine 
or both. The penalty of possession of class C drug is up to 2 years in prison, 
unlimited fine or both. Penalties of supply and production of class A are up to 
life in prison, an unlimited fine or both.  Whereas, for classes B and C the 
penalties are up to 14 years, an unlimited fine or both. 
At a national level, an official Home Office review (November 2018) assessed 
the influence of the UK’s PSA (2016) that banned the production, distribution, 
sale, and supply of majority of psychoactive substances. The review found that 
the sales of NPS in shops and online had been “fundamentally eliminated” by 
the legislation, but this had led to the sale of these substances underground. 
Nowadays, street dealers are the key source of supply for NPS, in particular 
with regard to synthetic cannabinoids. 
The review also reported there had been a substantial decrease in the number 
of NPS users among the overall adult population since PSA was introduced. 
However, the use of these substances among homeless people and children 
had not decreased, similarly, there was no reduction in the use of nitrous oxide 
by adults. Additionally, the use of these substances in prisons showed no 
reduction, what is more is that synthetic cannabinoids were identified as being 
dominant. The violence in prisons (because of NPS use) has not dropped since 
the introduction of the Act.  Despite adults’ use of NPS decreasing, this finding 
could not be attributed to overall drug use having fallen as a result of the Act, 
as people may have moved to other illicit substances instead. Among 
vulnerable users, including homeless people, it found that many users had 
shifted from synthetic cannabinoids to “traditional” controlled drugs.  Since the 
introduction of PSA, deaths directly related to NPS appear to have dropped in 
England and Wales but have increased in Scotland. However, there is no 
evidence regarding a decrease in social harm, such as violence, resulting from 
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the PSA, this is down to the fact that some NPS users may have used other 
drugs instead. 
From the findings, the new substances, which are not controlled under the 
MDA 1971, have continued to appear since the Act was introduced.[35] One 
of the goals of the act was to reduce the various health and social harms 
associated with NPS, this aim seems to has been mainly reached. There have 
been considerable reductions in the numbers of medical enquiries, concerns 
reported by users, and persons presenting to treatment since the Act was 
introduced.[36] 
1.3.2 Changes in the NPS market since the introduction of the PSA (2016)  
A recent review of the PSA (2016) presented by the Home Office (November 
2018) provided an assessment of the changes in the market of NPS associated 
to the application of the PSA. According to the review, the act has led to a rise 
in NPS prices and reduction in their availability. A shift away from vendors to 
street sellers has been observed, in particular for synthetic cannabinoids, with 
the Internet remaining a key source for obtaining NPS for users.  
Approximately 330 retailers were identified as having stopped the sale of NPS; 
490 arrests related to NPS were made in the months prior to December 2016 
and 990 seizures prior to March 2017. This proposes that the Act has not totally 
eradicated the supply of NPS, because of the large numbers of offences and 
seizures of alleged NPS that have been documented. Additionally, the supply 
of NPS by street dealers is currently another issue, the continuous 
development of new substances, the possible shift from NPS to other harmful 
substances, and continued high levels of synthetic cannabinoid use amongst 
the homeless and prisoners.[37] 
At an international level, the UNODC World Drug Report 2018 entitled “NPS 
pose great harm to vulnerable user groups”, detailed that in numerous 
countries, ways of NPS use among marginalized, vulnerable and socially 
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disadvantaged people, including homeless persons and individuals with 
mental health conditions, continues to be extensively recognized. 
Administration of stimulant NPS by injections also represents a concern, 
especially due to reported related high-risk injecting practices. Using NPS in 
prison remains an issue of concern in some European countries, North 
America and Oceania.[38]  
In Europe, a new update from the EU Early Warning System (EWS) on NPS, 
led to the EMCDDA releasing its latest insights into NPS in Europe entitled 
“Fentanils and synthetic cannabinoids: driving greater complexity into the drug 
situation” (report covers the time-frame January 2016 until December 2017). 
One of the biggest issues is that laboratory personnel may be at danger of 
poisoning from work-related contact with substances such as the new synthetic 
opioids (particularly the fentanyls) and the synthetic cannabinoids. The latter 
are also easy to smuggle, with a few grams adequate to create many 
thousands of doses/amounts for the drug market.[39] Indeed, detection 
abilities and screening tools affect various fields and settings, involving seized 
products analysis, emergency departments, workplace, drug addiction 
treatment surgeries, autopsy and criminal caseworks, health involvements and 
law enforcement.[40]  
 
In November 2018, a new legislation — bringing faster response to new drugs 
— strengthens the EU Early Warning System (EU EWS) and risk assessment 
processes on NPS and shortens control procedures. Europe’s ability to rapidly 
respond to public health and social threats caused by new psychoactive 
substances (NPS/new drugs’) will be significantly strengthened. The legislation 
was introduced in response to the recent growth in the availability of NPS. This 
new legislative package involves: a Regulation about information exchange 
on, and an early-warning system and risk-assessment process for, NPS; a 
Directive, which permits NPS to be controlled at EU level as 'drugs'.[41] 
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According to the Global Drug Survey (GDS 2018), the risk profile of NPS is 
different due to their inconsistent composition and potency. e.g. the deaths in 
recent months associated with the use of extremely potent hallucinogens (e.g. 
the substituted phenethylamine compound, NBOMe) and potent amphetamine 
analogues (e.g. 4-flouro-amphetamine) are of real concern across Europe and 
Australia.[42] This contrasts with the findings of GDS 2017, which suggested 
powerful novel opioid drugs such as carfentanyl and acetyl fentanyl were 
responsible for numbers of deaths in Canada.[42] 
1.4 Classification of NPS 
The United Nations Office on Drugs and Crime (UNODC) Early Warning 
Advisory on New Psychoactive Substances (2019) [43] detailed the main 
substance groups of NPS: 
(i) phencyclidine-type substances e.g. methoxetamine (MXE) [44] 
(ii) phenethylamines e.g. p-methoxymethamphetamine (PMMA) [45] 
(iii) piperazines e.g. 1-benzylpiperazine (BZP) [46] 
(iv) plant-based substances e.g. Khat [47] 
(v) aminoindanes (such as 2-aminoindane (2-AI)) [48] 
(vi) synthetic cannabinoids e.g. ‘HU-210’ synthetic analogue of THC [49] 
(vii) synthetic cathinones e.g. mephedrone [50] 
(viii) tryptamines e.g. N,N-diethyltryptamine (DET) [51] 
(ix) other substances (structurally diverse) e.g. benzodiazepines 
This study will specifically focus on developing methods of analysis for 
emerging substances within the phencyclidine-type – which are colloquially 
known as dissociative anaesthetics. [52] Dissociative anaesthetics are 
examples of these types of substances e.g., Diphenidine (1), 2-
methoxphenidine (2), 3-methoxphenidine (3), 4-methoxphenidine (4), 
phencyclidine (PCP, 5) [53], methoxetamine (MXE, 6) and ketamine (7) [54], 





Figure 4. Chemical structures of common dissociative anaesthetics 
 
1.5 Diphenidine (legal status, chemistry, synthesis, pharmacology, toxicology, 
metabolism and intoxication) 
At present, 1 is used illegally as an NPS.[56] In addition to 1, the category of 
dissociative substances also includes many drugs such as 2-7, as outlined in 
1.4.1. These drugs are a kind of hallucinogen that modify perceptions of sight 
and sound and create emotional state of detachment from reality.[57, 58]  
Diphenidine has entered the European, American and Japanese drug scene 
throughout the last years.[59, 60] In Europe (since 2013), seizures of 1 have 
been reported,[61] and similarly for Japan.[62, 63] 1 is not approved to be used 
as a medicine.[64] Additionally, 1 is unlawfully sold via the Internet; many drug 
users tend to discuss its use at fora and websites.[65] Intoxications of various 
degrees of severity caused by 1 have been documented in many countries 
such as Sweden,[66] Italy [67] and Japan.[62, 63, 68] 1 is now controlled in the 
United Kingdom due to the reported cases linked to its misuse and also the 
concerns raised by the authorities.[69] It is difficult to predict the exact figure 
of the increasing cases of abuse related to 1 and its derivatives, therefore, 
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determination of these compounds by applying specific analytical approaches 
is urgently required. 
1.5.1 The legal status of diphenidine and its derivatives 
At the international level, 1 is currently considered as a legal grey area drug, 
as 1 can be purchased straightforwardly from many websites. Possession of 
this drug is illegal in many countries.  
In the United kingdom, it is illegal to produce, supply, or import 1 and 
methoxphenidine (MXP) under the Psychoactive Substance Act, 2016.[7] 
Whereas, in Italy MXP is banned according to the Italian legislative instrument 
‘Table of Drugs’ since 2016, similarly in Sweden (2015) this substance is 
banned and it is a controlled substance in China since October 2015. While, in 
Canada since March 2016, 1 is a Schedule I controlled substance, [70] and 
also MXP is a Schedule I controlled substance that can only be possessed by 
authorised persons.[71]  
In the United Kingdom, ephenidine (Figure 5) is illegal to produce, supply, or 
import under PSA, while, in the United States, ephenidine might feasibly be 
considered a positional isomer of lefetamine, which is a Schedule 4 drug.[71] 
Ephenidine (the derivative of diphenidine where the piperidine ring is replaced 
with a simple N-ethyl side chain) is also prohibited in many countries as a 
structural isomer of the banned opioid substance lefetamine; in Canada, as of 
March 2016, ephenidine is Schedule 1 controlled substance, while in Sweden, 
ephenidine became a scheduled drug as of August 2015, [72] (see ephenidine 
structure and the structures of the 2-, 3- and 4-fluoronated isomers of 
ephenidine 8, 9 and 10, Figure 5, and see also the study of these three 




Figure 5. Chemical structure of ephenidine and its fluorinated regioisomers 8, 
9 and 10 
1.5.2 Chemistry of diphenidine 
In the structure of 1, there is a phenyl group and a piperidine ring linked to 
the phenylethylamine. The IUPAC name of 1 is 1-(1,2-diphenylethylethyl) 
piperidine, additionally there are many acronyms for diphenidine such as 
DIPH, DPH and DPD.  Diphenidine (1) is a molecule of the diarylethylamine 
class which includes 5-7. In addition, 1 is structurally analogous to MXP, 
lacking a 2-methoxy substitution on one of its phenyl rings. 5 was discovered 
in 1956 and soon became a popular street drug. Dissociative anaesthetics 
including 1, 5 and 6 have similar chemical structures of phencyclidine.[73] 
 
The diphenidine derivatives (compounds that contain a diphenylethylamine 
nucleus in their structures) are available currently as NPS include, 
methoxphenidine (MXP), trifluoromethoxphenidine (TFMXP), mesophenidine, 
IAS-013, 2-chlorodiphenidine (2-CLDP), methylenedioxydiphenidine, 
naphthadine and ephenidine. Ephenidine is a lesser-known novel dissociative 
substance of the diarylethylamine class and is an N-Methyl-D-aspartate 
receptor (NMDAR) antagonist.[74],[71] (See Figure 5). 
Compound 1 and its derivatives are phenylethylamine substances, (see Figure 
6), examples include methoxphenidines (MXP), (2, 3 and 4),[75] phencyclidine 
(5), methoxetamine (6), ketamine (7),  fluephenidines (FEP, 8, 9 and 10, See 
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Chapter 4), fluorocyanoephenidines (FCEP, 11, 12 and 13, See Chapter 5) 
and the halogenated diphenidine compounds (halogenated DP, 14-25 See 
Chapter 6). The compounds 5, 6 and 7 were not tested/investigated in this 
study.  
 
Figure 6. Chemical structures of diphenidine and 21 of its derived compounds tested 
in this research project 
1.5.3 Synthesis of diphenidine  
Diphenidine 1 was first synthesised by Christian in 1924 via a reaction of 
benzylmagnesium bromide with the corresponding α-arylamino nitrile, 1 was 
first synthesized as an anaesthetic agent, [76]  but it was also synthesised in 
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2015 (Wallach et al.), [71] and in 2016 (Geyer et al.), [74] using two different 
synthetic procedures (Figure 7). 
In 2016, Geyer performed the synthesis of 1 by reaction of benzyl bromide with 
piperidine and benzaldehyde in acetonitrile, zinc and trifluoroacetic acid (TFA) 
at room temperature for one hour. The free-base of 1 was obtained as a 
yellowish oil, dissolved in ether, treated with hydrogen chloride to give off-white 
powder of the hydrochloride salt that was then fully structurally characterised 
by chromatographic techniques infrared and NMR spectroscopy.[74]  
 
Figure 7. Synthesis of diphenidine according to Wallach et al.,[72] and Geyer et al.[68]  
 
1.5.4 Pharmacology of diphenidine 
In a pharmacological study by Wallach et al.[71], the results suggest that 1, 2, 
3, 4 and 15 are selective N-methyl-D-aspartate receptor antagonists 
(NMDAR).[71] In addition, 1 has dopamine and serotonin reuptake inhibition 
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activities. It is also an agonist for the µ-opioid receptor, and it possesses an 
affinity for the σ1 receptor, σ2 receptor and dopamine transporter.[71, 77] [56] 
The in vitro studies of 1 and other diarylethylamines such as the compounds 
that are used in treating neurotoxic injury revealed that these compounds act 
as NMDA receptor antagonists.[78-80] In comparison to codeine phosphate, 
in dogs 1 is more potent as an antitussive agent.[81] The (S)-enantiomer of 1 
has affinity of 40 times greater than that of the (R)-enantiomer for blocking the 
NMDA receptors.[77] 
1.5.5 Toxicology of diphenidine  
The data about the history of toxicity due to human usage of 1 is very limited. 
Trying 1 in low or moderate doses produces no negative health effects; this 
was anecdotal evidence from some the drug users. While using 1 chronically 
can cause tolerance and addiction, and if the drug was stopped suddenly, the 
withdrawal effects might happen. The co-administration of 1 with other 
dissociatives leads to cross-tolerance, consequently lowering the effect of the 
latter.[69]  
Dangerous interactions can be produced as a result of administering 
stimulants and dissociative agents leading to unwanted psychological effects 
such as delusions, mania, anxiety and psychosis, these effects are worsened 
by taking a combination of these substances. While, the co-administration of 
the dissociatives such as 1 with depressant drugs can cause augmented risk 
of unconsciousness, vomiting and death because of respiratory depression. 
The subcutaneous injection of 1 in mice produced lethality in a dose of 325 
mg/kg, whereas in humans the toxic dose is still unknown [64], while the exact 
toxic dose for humans is still unknown. The most frequently revealed effects 
defined in the literature that can lead to hospitalization in some users, include 
tachycardia, tachypnea, anxiety, confusion, disorientation, hallucinations, and 
high body temperature.[66, 67]  
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1.5.6 Metabolism of diphenidine  
There are no comprehensive studies on 1 metabolism in humans due to ethical 
reasons.[69] In 2015, through the investigation of an autopsy urine sample by 
means of matrix-assisted laser desorption ionization (MALDI) quadrupole time-
of-flight (QTOF)/MS, Minakata et al., confirmed that 1 metabolites occur 
through oxidation of the piperidine ring followed by the phenyl ring (Figure 
8).[82] Again in 2015, Elliot et al. investigated the biotransformation of 2-MXP 
and reported a hydroxylated 1 metabolite.[83]  
 
  
Figure 8. Biotransformation pathways of diphenidine in humans suggested by 
Minakata et al.[82] and Kusano et al.[68] 
 
In 2018, Kusano et al., investigated the biotransformation pathways of 1 in 
humans by testing [68] a post-mortem urine sample utilising the LC–QTOF/MS 
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technique. The results of this study showed that from the fragmentation of the 
resulted mono- and dihydroxylated metabolites and ion intensities; the 
monohydroxylation (and similarly the dihydroxylation) on the piperidine moiety 
is by and large preferred over the phenyl ring.[68] 
Later in 2016, Wink et al. used GC-MS, LC-MS(n), and LC-HR-MS (Liquid 
chromatography–high resolution n mass spectrometry, which is an LC system 
coupled to the TF LTQ Orbitrap, the Linear Trap Quadropole (LTQ) Orbitrap is 
a high performance LC-MS and MSn system, combining rapid LTQ ion trap 
data acquisition with high mass accuracy Orbitrap mass analysis.) to 
investigate metabolic animal studies in rats. This study suggested that mono- 
and dihydroxylation at different positions occurred in the metabolism of 
diphenidine. This metabolic pathway occurs in a similar manner in humans, 
which was defined by both Minakata et al. [82] and Kusano et al.[68] LC-MS(n) 
refers to multi-stage mass (MSn) fragmentation study, a technique which 
enables a complete fragmentation pathway of the drug to be established in 
order to characterize all the degradation products.[84],[85]  
Wink et al. also concluded that hydroxylation is to some extent followed by 
dehydrogenation or N-dealkylation, or both. This is followed by glucuronidation 
and/or methylation of the dihydroxyphenyl groups. They also found that the 
cytochrome-P450 (CYP) isoenzymes CYP1A2, CYP2B6, CYP2C9 and 
CYP3A4 were involved in the formation of hydroxyaryl, hydroxypiperidine and 
dihydroxypiperidine metabolites, whereas in the formation the hydroxyphenyl 
and hydroxypiperidine metabolites, the CYP2D6 isoenzyme was involved.[84] 
 
1.5.7 Intoxications by diphenidine  
There are many diphenidine-related cases (some fatal) that have been 
reported in many European countries and Japan.[63, 66, 68, 86] In a recent 
investigation in Japan, a fatal ingestion of "liquid aroma" and "bath salt" 
products was confirmed that 1, three substituted cathinones, three 
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benzodiazepines, and alcohol were consumed together and all these drugs 
were associated in this incident.[86] 
In a case of fatal poisoning by a product called Super Lemon, 1, AB-
CHMINACA and 5F-AMB were detected (Figure 9).[63] A further toxicological 
study in Japan by Uchiyama et al., detected the presence of 1 and 1-
benzylpiperidine in a powdered product called “fragrance powder”, whereas 
each sample solution was analysed by ultra-performance liquid 
chromatography–electrospray ionization mass spectrometry (UPLC–ESI-MS) 
and by gas chromatography–mass spectrometry (GC–MS) and also by NMR. 
In this study, a benzofuran derivative, 2-(2-ethylaminopropyl) benzofuran (2-
EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other 
designer drugs were identified in illegal products. Most of the identified 
substances appeared as alternatives to controlled drugs such as narcotics and 
designated substances in Japan.[87]  
Another report determined a large amount of 1, coexisting with a synthetic 









1.6 Methods of analysis of NPS/diphenidine derivatives 
This section provides details of reports that highlight the analytical methods 
being applied to the detection and quantification of 1 and some of its 
derivatives.  
Recently, in a study by Lowdon and Alkirkit et al., the first report of a 
molecularly imprinted polymer (MIP) for a NPS was reported. The MIP was 
synthesized with 2-MXP as a template, styrene and methacrylic acid (MAA) as 
the functional monomers and varying cross linker monomers. Binding 
capacities of the MXP isomers were in the range of 170–190 μmol g−1 as 
determined by optical batch rebinding and chromatographic methods. The 
NPS mixtures were studied by HPLC coupled to UV-vis spectroscopy and this 
technique was also used to validate optical batch rebinding experiments. The 
developed HPLC system allows for a clear separation between the three MXP 
regioisomers, which is a new method that has not been reported in the 
literature previously. It was determined that there is high recovery of all MXP 
isomers in pure solutions (>90%). Selective extraction of the MXP isomers was 
possible in mixtures with numerous percentages of the MXP regioisomers, and 
even in the presence of additional adulterants and other illegal substances. 
This indicates that molecular imprinting is a powerful technology for the 
extraction and quantification of (traces) of psychoactive components in 
complicated samples.[88] 
In a study by McLaughlin et al., three diphenidine derived compounds (2-, 3- 
and 4-MXP) were studied in addition to three powdered samples suspected to 
contain 2-MXP, were subjected to analytical characterization by GC and HPLC 
attached to various forms of mass spectrometry (MS). Nuclear magnetic 
resonance (NMR), infrared spectroscopy (IR) and thin layer chromatography 
(TLC) were also used, this was supported by carrying out two different 
synthetic routes for synthesising all three MXP isomers. The analytical data 
obtained suggested the possibility of differentiation between the isomers.[75] 
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In a different work by Geyer et al., thirteen diphenidine-derived compounds 
were resolved from each other, and in the presence of caffeine, benzocaine 
and procaine as common adulterants, using GC-MS. Calibration standards for 
these thirteen diphenidine-derivatives indicated a linear response (r2=0.996–
0.998) over a 25.0–250.0 μg mL−1 range. The limit of detection (LOD) and limit 
of quantification (LOQ) for the analytes were as follows: 4.23–5.99 and 12.83–
17.51 μg mL−1 correspondingly (based on the slope and standard deviation of 
the response). In this assay, the accuracy (percentage recovery study) was 
determined from spiked samples prepared in triplicate at three levels over a 
range of 80–120% of the target concentration (100 μg mL−1). However, the 
repeatability (%RSD) of this method was considerably less than expected, 
probably because of the manual injection of the calibration standards, the 
validated GC-MS method was considered appropriate for analysing two street 
samples. The assay can be improved if we know the chemical structure of the 
target compound, which will help in choosing the solvent and decide on the 
solubility (polar or non-polar) of the target to be used in the next step and 
perform the extraction. The next step will be the purification of the sample to 
be ready for analysis and then finding a suitable column that matches with the 
chemical structure of the target is essential.[74] 
In a method of determination of 1 and its metabolites using MALDI-Q-TOF/MS 
technique, which is an ionization quadrupole time-of-flight mass spectrometry. 
Matrix-assisted laser desorption/ionization (MALDI) is an ionization system, 
which utilises a laser energy absorbing matrix to produce ions from bulky 
molecules with slight fragmentation. Minakata et al. used this technique 
(MALDI-Q-TOF/MS) to analyse blood and urine samples containing 1 and its 
metabolites; the percentage recovery of the extracted analytes ranged 
between 80-100%. This method was applied to identify and quantify 
diphenidine in samples of post-mortem urine and blood.[82, 89]  
In the target analysis, the use of LC-MS/MS (triple quad) is generally better 
than using TOF in terms of sensitivity and quantitation. TOF is a perfect 
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instrument to use for unknown analysis, metabolism and metabolomics study 
etc. TOF sensitivity if lower in comparison with LC-MS/MS but it depends on 
what kind of instrument (vendor and series).  
In addition to that, sample preparation for mass spectrometry is very important 
for optimization of a sample for analysis because each ionization method has 
certain factors that must be considered for the success of the applied method, 
this includes volume, concentration, sample phase, and composition of the 
analyte solution. The analyte must be purified in some cases before entering 
the ion source. Moreover, mass spectrometry results have remained 
fundamentally dependent on sample preparation and quality, because sample 
ionization and mass measurements are susceptible to a wide range of 
interferences, such as buffers, salts, and detergents. These contaminants also 
impair MS system performance, often demanding time-consuming 
maintenance or costly repairs to restore function.  
In a similar method, LC–Q-TOF/MS and LC–MS/MS techniques were applied 
to quantify 1 and its metabolites in post-mortem blood and urine samples. The 
blood samples were pre-treated, precipitated with methanol, centrifuged, and 
filtered. The results suggested that the method showed adequate linearity.[68] 
In another method, Kudo et al. used samples of whole blood and urine to 
determine 1 with other drugs and metabolites present. After dilution of blood, 
1 was isolated, following centrifugation, and the diluted sample injected into a 
LC–MS/MS, the percentage recovery of each drug in whole blood and urine 
was found to be in the range of around 80-90%. All substances were well 
separated and each chromatogram revealed nearly no impurity peaks. All 
tested drugs showed a satisfactory precision, accuracy data according to ICH 
limits and guidelines, linearity with correlation coefficients (r2) greater than 
0.997 for whole blood and urine. [86] In a similar approach, Hasegawa et al. 
detected and determined 1 in solid tissues and biological fluids, the 
redistributed 1 was also investigated in a post-mortem samples.[63] 
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In another report, diphenidine metabolites were also determined by Wink et al. 
in rat urine samples using a liquid chromatography–high resolution mass 
spectrometry (LC–HRMS) method.[84] In an experimental investigation by 
Gerace et al., [67] 1 was determined in samples of blood and urine of a nonfatal 
subject applying GC-MS and they also detected 1 in a white powder found at 
the patient’s home. The results of this study suggested that the LOD and LOQ 
were 20 and 66 ng/mL in blood, and 25 and 82 ng/mL in urine, respectively. 
Salomone et al. used ultra-performance liquid chromatography-tandem mass 
spectrometer (UPLC-MS/MS) to quantify 1 in hair samples among other 
recreational substances. The UHPLC–MS/MS system technique combines the 
physical separation capabilities of liquid chromatography with the mass 
analysis capabilities of mass spectrometry. The results suggested that limit of 
detection (LOD) and limit of quantification (LOQ) values were 3.4 and 6.8 
pg/mg (pictogram = 10−12 g), respectively. The analytical method was simple, 
fast, specific, sensitive and linear (10–1000 pg/mg), and was successfully 
applied to real hair samples.[90] The disadvantages of hair sampling is the 
high cost and the longer time to obtain results compared with the time required 
by other matrices. 
In a recent review of screening methods for the rapid determination of NPS by 
Graziano et al., it was concluded that the colorimetric and immunochemical 
assays were unsuitable for the rapid and specific detection of these 
substances. Conversely, chromatographic assays showed to be more 
appropriate because of high flexibility, selectivity and sensitivity for detection 
of NPSs and/or their metabolites at low amounts in different biological media. 
The issue is that some NPSs can produce the same metabolites, making more 
challenging the identification. The results suggested that LC–MS appears to 
be the most promising tool for NPS analysis. The HRMS can be utilised due to 
the advantages of its high resolution and mass accuracy data that enable high 
selectivity and specificity. [40] 
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Overall, a review of the literature has shown a number of HPLC and GC 
systems for the identification and determination of diphenidine derivatives. 
However, most of the published methods relate to the detection and do not 
focus on the separation of diphenidine regioisomers by using suitable 
techniques, in particular HPLC methods.   
Because of the existing knowledge gap in NPS research, the research detailed 
in this thesis will explore the development of a simple, appropriate and 
consistent HPLC method that can be validated and applied to detect and 
measure numerous diphenidine-derived NPSs.  
1.7 Chromatography 
Chromatography is a technique for separating the components, or solutes, of 
a mixture based on the relative amounts of each solute distributed between a 
moving fluid stream, called the mobile phase, and a stationary phase. The 
mobile phase may be either a liquid or a gas, while the stationary phase is 
either a solid or a liquid. 
The main types of chromatography include, e.g. liquid chromatography, gas 
chromatography, thin layer chromatography and ion-exchange 
chromatography. HPLC is an example of liquid chromatography, the main 
components of HPLC are, the pump, injector, column and detector (Figure 10). 
 
Figure 10. HPLC system 
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1.7.1 Background on chromatographic theory 
Partitioning in chromatography is understood as a method of separation of 
solutes utilizing the partition of the solutes between two liquid phases. Paper 
chromatography, HPLC and TLC work on the principle of the same. 
Partition chromatography is a method of separation in which the components 
present in the mixture are distributed into two liquid phases because of 
differences in partition coefficients. It is based on differences in retention factor 
as well as distribution coefficient of the analytes. Partition chromatography can 
be divided into liquid-liquid chromatography and bonded-phase liquid 
chromatography. There are two theories to explain chromatography:  
1.7.1.1 Plate theory 
Plate theory is the older (in comparison to rate theory); developed by Martin & 
Synge in 1941. The plate model supposes that the chromatographic column 
contains a large number of separate layers, called theoretical plates. Separate 
equilibrations of the sample between the stationary and mobile phase occur in 
these "plates". The analyte moves down the column by transfer of equilibrated 
mobile phase from one plate to the next. 
1.7.1.2 Rate theory 
This theory is currently in use, proposed by van Deemter in 1956, accounts for 
the dynamics of the separation. 
1.7.2 The hydrophobic-subtraction model of reversed-phase column selectivity 
The hydrophobic subtraction model provides a quantitative description of 
column selectivity in (RP) HPLC columns, it increases our understanding of 
intermolecular interactions in solution. There are seven specific sample–
column interactions that define its selectivity (although five interactions are 
sufficient for most columns).  
This added insight into the basis of sample retention that can guide 
chromatographers during method development and help them to interpret 
unexpected results from routine or research experiments. 
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Different columns can now be compared in terms of selectivity, allowing the 
selection of alternative columns. Other possible applications include the further 
development of chromatographic theory, column design and manufacture, and 
the investigation of practical problems such as column deterioration. [91] 
Upon characterization of a given RP stationary phase, the hydrophobic 
substraction model yields quantitative values for five parameters (H, S*, A, B, 
and C) that describe the physico-chemical nature of that particular phase. 
Specifically: 
H parameter is a measure of the phase hydrophobicity 
S* is a measure of the resistance of the stationary phase to penetration by a 
solute molecule 
A is a measure of the hydrogen-bond acidity of the phase 
B is a measure of the hydrogen-bond basicity of the phase 
C is a measure of the interaction of the phase with ionized solute molecules 
These parameters, along with the companion parameters that describe the 
same characteristics of a given solute (η, σ, β, α, κ) are related to the retention 
of that solute (kx) relative to the retention of a reference compound (in this 
case, ethylbenzene - kEB) by the model. Retention can be described 
quantitatively by the relationship: 
log (kx’/k’EB) = η’H − σ’S∗ + β’A + α’B + κ’C 
where:  
α is a measure of the chromatographic selectivity  
η parameter is a measure of the solute hydrophobicity 
σ is a measure of the bulkiness of the solute molecule 
β is a measure of the hydrogen-bond basicity of the solute 
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α is a measure of the hydrogen-bond acidity of the solute 
κ is a measure of the ionization state of the solute molecule. [92] 
1.7.3 The impact of increasing log P of the solute on retention 
In the physical sciences, a partition coefficient (P) or distribution coefficient (D) 
is the ratio of concentrations of a compound in a mixture of two immiscible 
solvents at equilibrium. This ratio is therefore a comparison of the solubilities 
of the solute in these two liquids. The partition coefficient generally refers to 
the concentration ratio of un-ionized species of compound, whereas the 
distribution coefficient refers to the concentration ratio of all species of the 
compound (ionized plus un-ionized). The log P value is a measure of 
lipophilicity or hydrophilicity. The non-polar phase in such experiments is 
usually dominated by the un-ionized form of the solute, which is electrically 
neutral. To measure the partition coefficient of ionisable solutes, the pH of the 
aqueous phase is adjusted such that the predominant form of the compound 
in solution is un-ionized. Measurement of the partition coefficient at another pH 
of interest requires consideration of all species, un-ionized and ionized. 
Numerous methods exist to measure or estimate the pKa (pKa is the negative 
log of the acid dissociation constant or Ka) and log Pow values. The shake-flask 
method and RP-HPLC method are the main experimental methods to 
determine partition coefficients. The shake-flask procedure is a standard 
method to determine octanol/water partition coefficients in the range of −2 to 
4. There are some theoretical approaches to predict lipophilicity. Most of them 
add up the log Pow contribution from each fragment and then apply structure-
based correction factors. There are at least 20 software packages available at 
present, which provide convenient and fast prediction of lipophilicity for novel 
compounds. [93] 
Purely chromatographic alternatives to the partition coefficient between 
octanol and water have emerged as well because of the potential for 
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automation, higher throughput, and minimising sample preparation efforts. In 
particular, reversed phase-HPLC (RP-HPLC) has been suggested to provide 
a suitable means to directly assess the lipophilic property of an investigational 
compound. As these methods do not involve the shake flask procedure, they 
have the additional advantage of being independent of the concentration 
effects.  
In this setup, RP-HPLC is performed by using a C18-bonded stationary phase 
and a polar mobile phase, the latter being a mixture of water and acetonitrile. 
Chromatographic retention results from the partition of analytes between the 
two phases and can thus directly relate to the lipophilicity of an analyte. i.e. 
retention time is increased by increasing the lipophilicity or hydrophobicity of 
the analyte. For example, high capacity factors are indicative of a strong 
interaction with the lipophilic stationary phase and, thus, the strong lipophilic 
character of an analyte.[94] 
 
1.7.4 Introduction to van Deemter Equation 
In liquid chromatography, the flow rate of the mobile phase is an important 
factor that determines the partition efficiency of solutes under a given set of 
other conditions. The relationship between the partition efficiency and flow rate 
(the relationship between the efficiency of the column and the mechanism 
behind band broadening) could be described by an equation known as the van 
Deemter equation. In a simplified form, the van Deemter equation is: 
H (or HETP) = A + (B / u) + Cu 
Where: 
 H (Height equivalent per theoretical plate) is given as partition efficiency 
in terms of theoretical plate number divided by the length of the 
separation column (H = L / N); u, the flow rate of the mobile phase; and 
A, B, and C are constants. 
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 A is the Eddy-diffusion parameter  
 B is the longitudinal diffusion coefficient  
 C is the resistance to mass transfer of the analyte between mobile and 
stationary phases 
 u is the average mobile phase velocity 
When H is plotted against u in the coordinate, it forms a characteristic U-shape 
curve where the flow rate that gives the highest partition efficiency is at the 
bottom of the curve. A lower flow rate will result in a loss of efficiency due to 
the longitudinal diffusion caused by increased elution time (due to increased 
B/u), whereas a higher flow rate will cause loss of efficiency by insufficient time 
for solute partitioning between the two phases (due to increased Cu). [95], [96] 
1.7.5 Introduction to effects of temperature (Van’t Hoff equation) 
In a study by Edge et al., the use of elevated temperatures led to elution of 
compounds that would otherwise be retained on the column at low 
temperatures in reversed-phase chromatography. The reduction in the 
viscosity of the mobile phase also allowed for higher flow rates, improved the 
mass transfer within the chromatographic system and increased the rate of 
diffusion. Therefore, with increasing temperatures, the optimal flow rate for 
chromatographic efficiency is obtained.  
By increasing temperature there is a reduction in the retention factor, this 
common mechanism can be understood by the use of a Van’t Hoff plot, which 
shows the relationship between the retention factor and the absolute 
temperature. The linearity of the Van’t Hoff plots indicates that the retention 
mechanism is not changing with increasing temperature. Since the Van’t Hoff 
relationship is based on an equilibrium existing between the entropy and 
enthalpy within a system. Entropy (ΔS) is a measure of the random activity in 
a system, whereas enthalpy (ΔH) is a measure of the overall amount of energy 
in the system. 
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Binding is a process controlled by thermodynamics, it is evident that the 
enthalpic optimization of a compound is critical for achieving extremely high 
affinity. In addition, because the enthalpy and entropy changes reflect different 
types of interactions, other drug properties, like selectivity, are also affected by 
the enthalpy/entropy balance of a compound. Enthalpic optimization is difficult 
but can be facilitated by monitoring the enthalpic and entropic consequences 
of introducing or modifying different chemical functionalities. [97], [98]  
Based on the data produced in a study by Edge et al., a model has been 
developed that enables the accurate prediction of pressures across a HPLC 
column at a variety of temperatures and flow rates that would enable rapid 
method development to be performed. This model demonstrates the 
relationship between temperature, flow and pressure. The Van’t Hoff plots for 
the test probes run on the Acquity column in this experiment demonstrated the 
linear relationship that exists between the log of the retention time and 
reciprocal temperature. In addition, the inset shows the point at which the 
elution order is reversed for the compounds analysed. The model compounds 
used in this study were antipyrine, aminohippuric acid, paracetamol, 
hydroxyantipyrine, aminoantipyrine, atenolol, aminobenzoic acid, theophylline, 
phenacetin, and caffeine. 
From the results, it is worth noting the effect that temperature can have on 
chromatographic selectivity. In the plot, two of the test probes are highlighted, 
caffeine and aminoantipyrine, and it can be seen that the plots actually cross, 
indicating that there was a reversal in the elution order. Thus, whilst separated 
at low temperature the peaks coalesced at 113°C but as the temperature was 
raised further they once again start to separate relative to each other, but with 
a reversed elution order. [98] 
1.7.5.1 Modelling the pressure–temperature-flow rate parameter space 
For effective utilisation of temperature as a parameter in HPLC and UPLC it 
was considered to be advantageous to devise a simple, predictive model, 
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which would allow for characterisation of the chromatographic system. This 
model is based around two fundamental concepts. 
Concept 1: Viscosity is the dominant temperature dependent variable within 
the system. It is assumed that the temperature only affects the viscosity 
directly; all other physical parameters are affected indirectly by the change in 
viscosity.  
Concept 2: This concept depends on the flow and pressure drop in the system.  
Thus a plot of ln P versus 1/T will give a linear plot where the gradient is a term 
relating to the physical variation of viscosity of the fluid to temperature. If the 
model is correct then this term will be independent of the column 
characteristics, thus once calculated for one mobile phase, it can be used for 
all columns using that mobile phase. [98] 
 
1.7.6 GC theory and Golay equation 
Gas chromatography (GC) is used for separating and analyzing compounds 
that can be vaporized without decomposition. In GC, the sample is injected 
into the instrument where it is vaporized and mixes with the carrier gas to 
become a part of the mobile phase. This mobile phase is then carried through 
to the chromatographic column where it interacts with the stationary phase of 
the column i.e. the gaseous compounds being analyzed interact with the walls 
of the column, which is coated with a stationary phase. This causes each 
compound to elute at a different time, known as the retention time of the 
compound.  
1.7.6.1 Golay equation 
The van Deemter equation describes the main factors contributing to column 
(packed) band broadening. This was described in Section 1.7.4. In 1958, Golay 
described a similar relationship to deal with capillary gas chromatography 
columns, which contain no packing material and therefore do not possess an 
Eddy-diffusion parameter (A term). Thus the Golay equation is defined as: 
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HETP = B / u + (Cs + CM).u           (Golay equation)  
Where, Cs = mass transfer in the stationary phase and CM = mass transfer in 
the mobile phase [99], [100] 
1.8 Aims and objectives 
The overall aim of this project is to develop analytical methods for the detection 
and quantification of diphenidine-derivatives (see Figure 11 for the chemical 
structures of all the tested compounds in this research project) in the 
laboratory, which can be applied to a real world setting for testing NPS samples 
encountered within a forensic framework.  
The requirement for this study is because 1 and its derivatives are dissociative 
NPS that pose a threat for public health and safety, with many reported deaths 
and toxicities due to their extensive use in addition to the related clinical and 
forensic toxicology case reports in many countries. In general, improving 
efforts in the detection and identification of these dangerous substances have 
become as a global analytical challenge. 
In order to achieve this aim, many diphenidine-derived compounds will be 
screened through the development of new chromatographic methods for the 




Figure 11. Chemical structures of diphenidine and twenty-one derived compounds 
tested in this research project 
 
The main objective of the study is to decide whether HPLC can be used to 
qualitatively and quantitatively test diphenidine-derived compounds, which if 
achieved, would have a wide utility in forensic applications, particularly in 
analysing bulk/seized samples suspected to contain these harmful 
substances.  
In this research project, diphenidine (1) and twenty-one diphenidine derived 
compounds will be tested, the first group to be investigated is 
methoxphenidine, MXP regioisomers (2, 3 and 4, see Figure 11), these will be 
tested on HPLC and GC-MS in order to be detected, quantified and separated. 
While, the second group is the fluorinated ephenidine, FEP regioisomers (8, 9 
and 10), which will be tested using the developed/validated HPLC method that 
was applied for methoxphenidine isomers as stated in the first study. The third 
group is the fluorocyanoephenidine, FCEP regioisomers (11, 12 and 13), which 
will be investigated by both reverse phase and gradient HPLC methods 
together with testing on three different GC columns in order to detect, 
determine and separate them. 
The last group are the halogenated diphenidine, Halo DP regioisomers (14 - 
25). These twelve compounds will be examined using HPLC in four different 
groups (fluoro, chloro, bromo and iodo isomers) in order to test whether the 
developed HPLC method in this study is able to detect and separate all these 
regioisomers with excellent resolution values (equal or greater than 2) i.e. by 
achieving fully base line separation, this aim is not only required in the case of 
Halo DP but also for all diphenidine-derived compounds investigated in this 




Chapter 2:  Materials and Methods 
2.1 Separation of the regioisomers of methoxphenidine (MXP) using Reverse 
Phase HPLC.  
 
2.1.1 General experimental and characterisation of the regioisomeric 
methoxphenidine (MXP) analytes 
All reagents were obtained from Sigma-Aldrich Limited (Gillingham, UK) and 
were used without further purification. Methoxphenidine (2-MXP, 3-MXP and 
4-MXP), were synthesised at Manchester Metropolitan University under UK 
Home Office Licence. 1H-NMR (10 mg/600µL in DMSO-d6) and 13C-NMR 
spectra (20 mg/600µL in DMSO-d6) were acquired on a JEOL AS-400 (JEOL, 
Tokyo, Japan) NMR spectrometer operating at a 1H resonance frequency of 
400 MHz and referenced to the residual solvent peak (1H-NMR, δ = 5.32; 13C-
NMR, δ = 53.84 respectively) [101]. IR spectra were obtained in the range 
4000-400 cm-1 using a Thermo Scietific Nicolet Is10ATR-FTIR instrument 
(Thermo Scientific, Rochester, USA) on an IR spectrometer. GC-MS spectra 
were recorded on an (Agilent 6850 Series GC System, The GC was coupled 
to an Agilent 5973 Network Mass Selective Detector, USA). Ultraviolet spectra 
were obtained using a UV spectrometer (Agilent 8453, UV-VIS), the separate 
MXP regioisomers samples (40 mg/100 mL) were dissolved in mobile phase 
[acetonitrile: ammonium acetate (55:45% v/v)]. The absorbance and maximum 
wavelength for each isomer was detected. Thin layer chromatography (TLC) 
was carried out on aluminum-backed SiO2 plates (Merck, Germany) and spots 
were visualized using ultra-violet light (254 nm). The mobile phase used was 
dichloromethane-methanol (9:1 v/v) containing 0.8% ammonia (7 N in 
methanol).  The developed plate was viewed under UV light (254 nm) and any 
spots noted. The plate was sprayed with modified Dragendorff-Ludy-Tenger 
reagent.[102] The blood-red spots marked with a pencil and the Retention 
Factor (Rf) and Relative Retention Factor (RRf, with respect to diphenidine) 
calculated for each analyte.  The uncorrected melting points were measured 
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using Stuart SMP10 apparatus, (Bibby Sterilin Ltd, Staffordshire, UK). In all 
HPLC experiments, all the compounds (1-25) tested in this project were more 
soluble in acetonitrile, and less soluble in water and methanol. HPLC data was 
collected using a Agilent HP series 1100 Liquid Chromatogram. Two versions 
(2004) are available: one ("online") in connection with the modules of the HPLC 
chain is designed to control instruments and run experiments, and the other 
("offline"), without a connection with the HPLC chain, is designed to analyse 
data (see Table 2 for more details).  
 
Table 2. The HPLC system parameters for method development and validation of 
MXP isomer separation 
 
2.1.2 Synthesis of diphenidine and methoxphenidine 
The hydrochloride salts of diphenidine and its methoxy-substituted derivatives 
were prepared using an adaptation of the method reported by Geyer et al. [74] 
with the following modifications:  To a dried round-bottomed flask (100 mL) 
containing zinc dust (2.0 g, 30 mmol) suspended in acetonitrile (40 mL), was 
added benzyl bromide (0.4 mL) and trifluoroacetic acid (0.2 mL).  The resulting 
solution was stirred for 5 min and then benzyl bromide (3.0 mL, 25 mmol), 
piperidine (0.99 mL, 10 mmol) followed by the pre-requisite benzaldehyde (11 
mmol), were introduced to the mixture, and the solution was stirred at room 
temperature for an additional 1 h (CARE! Exothermic). The resulting solution 
was poured into a saturated aqueous NH4Cl solution (150 mL) and extracted 
Equipment /Part Model/ Description 
HPLC  Agilent HP Series 1100 Liquid Chromatogram 
Degasser In-line degasser 
Auto sampler 100 place auto sampler 
Pump  Binary Pump 
Detector  DAD (Diode-Array Detector)  
Software  ChemStation 
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with dichloromethane (2×100 mL). The combined organic layers were dried 
(MgSO4) and concentrated in vacuo to give a crude yellowish oil. The oil was 
dissolved in diethyl ether (150 mL) and concentrated sulphuric acid (0.75 mL) 
was added dropwise, to the vigorously stirred solution. After five minutes, the 
precipitated ammonium salt was filtered, washed with diethyl ether (2×50 mL) 
and air-dried for 5 – 10 minutes. The ammonium salt was re-dissolved in 
aqueous sodium hydroxide (5% w/v, 150 mL) and then extracted with 
dichloromethane (2×150 mL).  The combined organic fractions were dried 
(MgSO4) and concentrated in vacuo to give a yellowish oil. The oil was 
dissolved in diethyl ether (200 mL), treated with hydrogen chloride (4M in 
dioxane, 3.0 mL, 12 mmol) and left to stand for 5 minutes. The crystallized 
products were filtered and washed sequentially with the minimum volume of 
ice-cold acetone and ice-cold ethyl acetate-diethyl ether (1:5) to afford the 
corresponding hydrochloride salts as colourless to off-white powders (>99.5% 
by elemental analysis), which were fully structurally characterized by 1H-NMR, 
13C-NMR and FTIR. Yields of products (after purification): diphenidine 
hydrochloride (29%); 2-methoxphenidine hydrochloride (2-MXP, 35%); 3-
methoxphenidine hydrochloride (3-MXP, 21%); 4-methoxphenidine 
hydrochloride (4-MXP, 25%).  
2-Methoxphenidine hydrochloride (2): For 1H NMR, 13C NMR, FTIR, GC-EI-
MS, melting point and UV data see Table 3. 
3-Methoxphenidine hydrochloride (3) and 4-Methoxphenidine hydrochloride 
(4): For 1H NMR, 13C NMR, FTIR, GC-EI-MS, melting point and UV data (See 







Table 3. FTIR, GC-EI-MS, melting point and UV* data of 2 
*1H-NMR (400 MHz, DMSO-d6); 
13C-NMR (100 MHz, DMSO-d6); GC-EI-MS: m/z 204 (base peak); UV (0.3 mg/mL in acetonitrile: ammonium acetate 55:45 % v/v), max = 278 nm, abs.= 
1.31, ɛ278= 1290 L mol
-1 cm.-1 
Peak 
1H NMR chemical shift 
(ppm) 



















2 1.80, br.s, 2H 35.86 
3 2.05-2.30, m, 2H 44.33 
4 2.31-2.66, m, 2H 52.81 
5 3.45, d, 2H 55.67 
6 3.53-3.81, m, 2H 111.5 
7 3.98, d, 2H 119.68 
8 5.02, br.s, 1H 126.55 
9 6.96-7.03, m, 3H 128.21 
10 6.85, dd, 2H 129.18 
11 6.99-7.47, m,1H 130.27 
12 7.75, br.s, 1H 136.46 
13 12.33, br.s, 1H 158.43 
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2.1.3 Solutions preparation  
2.1.3.1 Preparation of HPLC column test mixture                                                                                                                                                                                                           
Biphenyl (60 mg, 0.4 mmol), phenanthrene (40 mg, 0.2 mmol) were transferred 
to a 100 mL volumetric flask. To this, dimethyl phthalate (310 µL, 1.9 mmol) 
and toluene (2400 µL) were added. The mixture was then dissolved in 
methanol:water (85:15% v/v) and then made up to100 mL. To act as an injector 
marker, uracil (2.5 mg, 0.02 mmol) was dissolved in methanol: water (85:15% 
v/v, 50 ml). 
2.1.3.2 Preparation of 0.1% formic acid 
To HPLC grade water (500 mL) was added formic acid (500 µL) to achieve a 
concentration of 0.1% v/v for the aqueous part of the mobile phase. Similarly, 
for the organic component, formic acid (500 µL) was added to HPLC grade 
acetonitrile (500 mL) to again achieve a concentration of 0.1% v/v. The 
solutions were then filtered and degassed under vacuum using a Nylon 
membrane filter (Whatman, 0.45 µm, 47 mm diameter). Formic acid 0.1 % is 
added to the improve the chromatographic peak shape and to provide a source 
of protons in reverse phase HPLC experiments.   
2.1.3.3 Preparation of aqueous ammonium acetate  
Ammonium acetate (3.85 g, 50 mmol) was dissolved in HPLC grade water (500 
mL). This created a stock solution of 100 mM ammonium acetate solution 
which would be diluted accordingly for the mobile phase. For the mobile phase 
composition of acetonitrile:20 mM ammonium acetate in water (55:45% v/v), 
100 mL of the stock solution was added to acetonitrile (550 mL) and water (350 
mL), to give a dilution factor of one in five for the ammonium acetate in water 
and a concentration of 20 mM. All mobile phase combinations were filtered 
and de-gassed for 10 minutes at 25°C using an ultrasonic path under vacuum 
using a Nylon membrane filter (Whatman, 0.45 µm, 47 mm diameter). 
Ammonium acetate provides buffering around pH 4.75 (the pKa of acetic acid) 
and around pH 9.25 (the pKa of ammonium). [103] Mobile phase; 
acetonitrile:ammonium acetate (55:45% v/v) was used without preheating or 
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cooling because no band broadening was produced in the run, during method 
development. 
2.1.3.4 Sample preparation (stock solution of 2-, 3- and 4-MXPs) 
Each of the separate MXP isomers (5 mg, 17 mmol) were dissolved in 
acetonitrile (25 mL) and 0.1% formic acid in water (25 mL, prepared as 
described in section 2.1.3.2) to give a total volume of 50 mL. The stock solution 
(1 mL) was used then diluted with water (10 mL) to produce a final stock 
solution which had a concentration of 10 µg mL-1 of each isomer. 
2.1.4 Method development (HPLC separation of MXP isomers) 
The HPLC method conditions: column selection and size, temp, mobile phase 
and run as an isocratic (adapted from McLaughlin’s HPLC method).[75] The 
UV max of MXP isomers is 278 nm (2), 277 nm (3) and  273 nm (4), and the 
278 nm was applied for all 3 isomers (McLaughlin et al. used 210 nm for all 
MXP isomers).HPLC conditions utilised are outlined in the following table: 
Table 4. The HPLC conditions used in the injection of the linearity samples of 
methoxphenidine 
2.1.5 HPLC method validation of MXP isomers 
The HPLC method was validated in accordance with the ICH guidelines, Q 2 
(R1) Validation of Analytical Procedures, 2005), using the following 
Parameter Information/Value/Percentage 
Mobile Phase Acetonitrile:20 mM ammonium acetate in water 
(55:45% v/v) 
Temperature                                                            50°C (adapted from McLaughlin’s method) 
Injection Volume 20 µL  
Flow Rate 1.0 mL min-1 
Detection (UV) 
Wavelength 
278 nm (from method development data) 
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parameters: linearity, accuracy, precision, specificity, limit of detection (LOD), 
limit of quantification (LOQ) and system suitability [resolution (Rs), column 
efficiency (N), peak asymmetry (As)]. Linearity, precision and system suitability 
tests: six replicate injections of the calibration standards (vide supra) were 
performed and the data analysed under the same conditions. The %RSD was 
calculated for each replicate sample. Specificity: six replicate injections of the 
specificity standards were performed and the data analysed under the same 
conditions. Limits of detection and quantification: six replicate injections of the 
calibration standards were performed and the data analysed under the same 
conditions. The limits of detection and quantification were calculated based on 
the standard deviation of the response and the slope. 
2.1.6 Calibration standards (for linearity studies)  
2-, 3- or 4-MXP (8 mg, 0.027 mmol) was dissolved in formic acid in acetonitrile 
(50 mL) and formic acid in water (50 ml), (these solutions/solvents were made 
as mentioned in Section 2.1.6.2) to create a stock solution of 80 µg mL-1. A 
dilution scheme was carried using this stock solution to create calibration 
standards in the range of 2.5, 5, 10, 20, 40 µg mL-1. All dilutions were 
performed using HPLC grade water.  The standards were injected using the 
system described in Table 4 and the column ACE 5 C18-AR (150 x 4.6 mm, 5 
µm particle size). They were injected in order of increasing concentration; two 
injections of the blank at the beginning of the calibration series, followed by six 
injections of each concentration. Injecting samples in an increased order to 
avoid any possible trace amounts of the previous sample left in the injector. 
2.1.7 Calibration Standards (for precision and accuracy studies) 
A calibration range of 2.5, 5, 8, 10, 12, 20, 40 µg mL-1 was used in the 
determination of the accuracy and precision samples. As with the linearity 
standards, the solutions 8, 10, 12 µg mL-1 were injected in order of increasing 
concentration with two blank injections at the beginning of the calibration 
series. The HPLC conditions used are the same as described in table 2.  
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2.1.8 Preparation of samples for accuracy and precision studies 
To a 100 mL flask, MXP isomers (5 mg, 0.017 mmol) were dissolved in formic 
acid in acetonitrile (50 mL) and formic acid in water was added (to make a 100 
mL solution), to create a stock containing 100 µg mL-1 of 2-, 3- or 4-MXP.  The 
dilution scheme 2.5, 5, 8, 10, 12, 20, 40 µg mL-1 was carried out from the stock 
solution.  
Each dilution was repeated six times and all were made into HPLC grade 
water. The calibration standards were injected six times each and used in 
method development and validation. While, the concentrations of 8, 10, 12 µg 
mL-1 were used in determination of accuracy.  Each solution (six of each 
concentration, totalling 30 samples) was injected in replicates using the system 
detailed in Table 2 and a C18-AR column. Blank injections (2x) were carried 
out at the beginning of the calibration series. Peak area, %recovery and %RSD 
were determined. 
2.1.9 Robustness studies 
In this study, the following parameters were investigated (the working 
concentration of MXP isomers is 10 µg mL-1): Temperature: 48, 50, 52°C (2 
blanks were injected prior to injecting MXP isomers 10 times each); Flow Rate: 
0.9, 1.0, 1.1 mL min-1 (2 blanks were injected prior to injecting MXP isomers 
10 times each); Mobile Phase: 54:46, 55:45, 56:44 % v/v (2 blanks were 
injected prior to injecting MXP isomers 10 times each); Intra-day (am and pm) 
and Intra-day (am and pm) and inter-day (pm plus am and pm) precision was 
also carried out (2 blank injections were carried out prior to injecting MXP 
isomers 10 times each). Peak area, retention time and relative retention time 
were determined. Retention factor (k) can also be used as a parameter in 
HPLC calculations instead of using retention time (tR). 
2.1.10 Injection of adulterants/diluents for Specificity (MXP isomers) 
In order to assess the specificity of the method, standards of the following 
adulterants: caffeine, paracetamol and benzocaine were prepared at 
concentrations of 100 µg mL-1, in addition to preparing solutions of 4-MMC, 
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diphenidine at concentrations of 100 µg mL-1 and a solution of uracil at a 
concentration of 10 µg mL-1.  
The specificity of the method was performed using two replicate injections of 
the specificity standards and the data analysed under the same conditions. 
The results showed that the strongly UV-absorbing components (benzocaine, 
caffeine and paracetamol) demonstrated baseline separation from the target 
analytes (methoxphenidine isomers, 4-MMC and diphenidine).  
2.1.11 Forensic application  
Two street samples were obtained from independent Internet vendor (BRC 
Fine Chemicals Limited, https://www.brc-finechemicals.com) as white 
crystalline powders in clear zip-lock bags, prior to the legislative change (20th 
May 2016). The samples were weighed accurately (2 times each) and 
dissolved in acetonitrile:ammonium acetate 55:45% v/v in a 50 mL volumetric 
flask, and then diluted with HPLC grade water in a 10 mL volumetric flask to a 
working concentration of 10 µg mL-1. Three injections of each weighing were 
injected into the system. 
2.1.12 Application of the HPLC standard method for separation of some 
diphenidine derivatives present in mixtures 
In this experiment, the following compounds; 2,3 and 4-methoxphenidine 
isomers (MXP), 3,4,5-trimethoxyphenidine (3,4,5-TMXP), 2,3 and 4-
trifluoromethoxphenidine isomers (TFMXP), 1- and 2-naphenidine, 
methylenedioxydiphenidine derivatives, (2,3-MDDP),  (3,4-MDDP), IAS 013  
and uracil (as a void marker) were tested for detection (determination of 
retention time) and separation by applying the HPLC validated standard 
method (Table 5). The compounds were synthesised in-house, by the 
MANchester DRug Analysis & Knowledge Exchange (MANDRAKE) team, 
using the procedures reported by Geyer et al. [74] 
The max for each of the above listed compounds was measured prior to 
commencing HPLC experiments. The experimental parameters were as 
follows: mobile phase is acetonitrile:ammonium 55:45% v/v, temperature 50°C, 
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flow rate 1 mL min-1, sample concentration is 10 µg mL-1. Uracil concentration 
is 1 µg mL-1 (dissolved in MP). Two blank (MP) injections and two injections of 
the mixture were run, respectively. 
Table 5. Application of the HPLC standard method in the separation of two mixtures 
(A and B) containing 12 diphenidine derivatives 
 
2.2 Fluephenidines (FEP) 
The general experimental details for the FEP study were analogous to those 
used in the MXP study (Section 2.1.1.1) with the following modifications: 
The 19F-NMR spectra (20 mg/600 µL in DMSO containing 0.03% v/v 
trifluoroacetic acid, TFA) for FEP compounds were acquired on the same 
instrument and referenced to TFA (19F-NMR, δ = -76.55 ppm). 
2-Fluephenidine (8), 3-Fluephenidine (9) and 4-Fluephenidine (10): For 1H 
NMR, 13C NMR, FTIR, melting point and UV data (See Appendix A 3, Appendix 
A 4 and Appendix A 5). 
 
2.2.1 Forensic Application  
Three bulk forensic samples of FEP were obtained from Greater Manchester 
Police via the MANchester DRug Analysis and Knowledge Exchange 










(MANDRAKE) partnership. The three samples were analysed using the 
developed HPLC method in this study i.e. using acetonitrile:ammonium 
acetate 25:75% v/v as the mobile phase.  
The samples were tested in a working concentration of 50 µg mL-1, each 
sample was injected three times into the HPLC system. For comparison with 
street samples, three samples of the mix of 2-, 3- and 4-FEP isomers were 
injected separately into the system in concentrations of 50 µg mL-1, these were 
taken from the stock solutions of the calibration standards series of FEP 
isomers.  
2.3 Fluorocyanoephenidines (FCEP)  
The general experimental details for the FCEP study were analogous to those 
used in the MXP study (Section 2.1.1) with the following modifications: 
2.3.1 Synthesis of FCEP isomers 
To a dried round-bottomed flask (250 mL) was added a mixture of zinc dust 
(2.0 g, 30 mmol) suspended in acetonitrile (40 mL), to this benzyl bromide (0.4 
mL), and trifluoroacetic acid (0.2 mL) was added.  The resulting solution was 
stirred for an additional 5 min and then benzyl bromide (3.0 mL, 25 mmol), 
aminopropionitrile (0.99 mL, 10 mmol), followed by benzaldehyde (1.17 g, 1.12 
mL, 11 mmol) were introduced to the mixture, and the solution was stirred at 
room temperature for 1h (CARE! Exothermic). Saturated aqueous NH4Cl 
solution (150 mL) was poured into the resulting solution and extracted with 
dichloromethane (2×100 mL). The combined organic layers were dried 
(Na2SO4) and concentrated in vacuo to give a crude yellowish oil.  The oil was 
dissolved in diethyl ether (150 mL) and concentrated sulphuric acid (0.75 mL) 
was added dropwise, cautiously to the vigorously stirred solution.  After five 
minutes, the precipitated ammonium salt was filtered, re-dissolved in aqueous 
sodium hydroxide (5% w/v, 150 mL) and then extracted with dichloromethane 
(2×150 mL).  The combined organic fractions were dried (Na2SO4) and 
concentrated in vacuo to give a yellowish oil.  The oil was dissolved in diethyl 
ether (5 mL), treated with hydrogen chloride (4M in dioxane, 5.0 mL, 20 mmol) 
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and stirred for 30 minutes.  The volatiles were removed in vacuo and the 
products recrystallized from acetone to afford the corresponding hydrochloride 
salts as colourless to off-white powders. 
2-Fluorocyanoephenidine hydrochloride (11), 3-Fluorocyanoephenidine 
hydrochloride (12) and 4-Fluorocyanoephenidine hydrochloride (13): For 1H 
NMR, 13C NMR, 19F NMR, FTIR, melting point and UV data see Appendix A 6, 
Appendix A 7 and Appendix A 8. 
2.4 The halogenated diphenidine isomers  
The general experimental details for the halogenated diphenidine isomers 
study were analogous to those used in the MXP study (Section 2.1.1.1) with 
the following modifications: 
2.4.1 Reagents and Solvents 
All reagents and solvents were obtained as mentioned in Section 2.1.1.1 and 
were used without further purification. The halogenated diphenidine (2-, 3- and 
4-regioisomers); fluorodiphenidine (FDP), chlorodiphenidine (CLDP), 
bromodiphenidine (BrDP) and iododiphenidine (IDP), were synthesised at 
Manchester Metropolitan University under UK Home Office Licence.   
2.4.2 Chromatographic Conditions 
These conditions were analogous to MXP study with the following 
modifications: Acetonitrile:ammonium acetate (67:33% v/v), flow rate (1.5 mL 
min-1) and detection wavelength (220 nm). Two blank injections (30 mins each) 
followed by two injections of each halogenated diphenidine isomer (10 min) 
and one injection of washing solution, acetonitrile:ammonium acetate (50:50% 
v/v, 20 min).  
2.4.3 Standard Solutions 
The standard linearity stock solutions of 2-, 3- and 4-halogenated diphenidine 
isomers were made in 80 µg mL-1 concentration followed by the following serial 
dilution 1.25, 2.5, 5, 10 and 20 µg mL-1 which was injected in the HPLC system 
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mentioned above (see Section 2.4.1.2). Whereas the concentrations 8, 10 and 
12 µg mL-1 were used to determine the method accuracy.   
2.4.4 Forensic application 
Two bulk forensic samples (SS1H and SS2H) were obtained from Greater 
Manchester Police as a white crystalline powder. The samples were tested in 
a working concentration of 10 µg mL-1 (in replicate). Each sample was injected 
three times into the HPLC system. For comparison with street samples, three 
samples of the mix of 2-, 3- and 4-halogenated diphenidine isomers were 
injected separately into the system in concentrations of 10 µg mL-1, these were 
taken from the stock solutions of the calibration standards series of the three 
groups of the halogenated diphenidine isomers.  
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Chapter 3: Development and validation for the separation of the 
regioisomers of methoxphenidine using Reversed Phase HPLC.  
3.1 Methoxphenidine 
Methoxphenidine is a diphenidine (1) derivative; known by the following names 
(methoxydiphenidine, 2-MeO-diphenidine, 2-MXP, (2) and it is also a 
dissociative of the diarylethylamine class that has been sold online as a 
designer drug (see Figure 12 for chemical structures of diphenidine and MXP 
isomers).[105] 
Methoxphenidine was first reported in a 1989 patent where it was tested as a 
treatment for neurotoxic injury. In 2013, the arylcyclohexylamines including 
diphenidine and the related methoxy-substituted compounds, 
methoxphenidine, became available on the black market, where they are 
encountered in both a powder and tablet form. Diphenidine [106] has greater 
affinity for the N-methyl-D-aspartate receptor (NMDA receptor or NMDAR) 
than methoxphenidine. The receptor is a glutamate receptor and ion channel 
protein found in neurons (Figure 13). It is activated when glutamate binds to it, 
and when activated it allows positively charged ions to flow through the cell 
membrane. The NMDAR is very important for controlling synaptic plasticity and 
memory function.[107] Many reports reveal methoxphenidine possesses 
higher oral potency.[78] These drugs mediate their dissociative-psychoactive 
effects via potent N-methyl-D-aspartate receptor antagonism. Monoamine 
transporter inhibition could, however, contribute to their psychoactive 
properties. Methoxphenidine was also studied as it stimulates the tendency of 
the abusers to sabotage less than that caused by diphenidine with more 









Figure 13. Neuron showing glutamate receptors and synaptic plasticity.[109] 
 
The NMDAR is very important for controlling synaptic plasticity and memory 
function.[107] Methoxphenidine (2) is marketed as a legal replacement for 
methoxetamine (6), diphenidine (1) and ketamine (7). Figure 12 shows 
examples of some dissociative anaesthetics. 
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Methoxetamine (6) is a dissociative anaesthetic showing pharmacodynamic 
similarities with its analogue ketamine (7), a medication with demonstrated 
rapid-acting antidepressant effects. Like ketamine and other 
arylcyclohexylamine compounds, MXE is thought to be both a non-competitive 
NMDA antagonist and a dopamine reuptake inhibitor.[55] The receptor 
(NMDAR), is a glutamate receptor and ion channel protein found in neurons 
(Figure 13). It is activated when glutamate binds to it, and when activated it 
allows positively charged ions to flow through the cell membrane. 
There is an urgent requirement to study and analyse these NPSs in more depth 
and detail i.e. diphenidine derivatives such as MXP isomers. This goal can be 
achieved by applying various analytical approaches such as the development 
of HPLC methods to detect, quantify and separate these regioisomers, which 
exist in a given sample(s). The urgent requirement is because of the speed 
and variety of drugs entering the market posing a new complex challenge for 
forensic toxicology as it is considered a threat to public health, especially when 
the content of NPS being sold is not reported on the label or is misleading.[61, 
110] Furthermore, the detection of these substances in biological matrices can 
be difficult as the exact compounds of interest may not be known. Many NPSs 
are sold under the same brand name and therefore users themselves may not 
know what substances they have ingested.  
Besides, concentration variability among the NPS samples and the presence 
of multiple psychoactive substances in single products represent risk factors 
for the users. In some NPS products there is no information on active 
ingredients, all these issues can lead to severe or toxic adverse effects 
produced by NPS especially knowing that only little is known about NPS 
metabolism and interaction with other medicines (drug-drug interaction).[111] 
Therefore, educating the public and raising their awareness about the use of 
these drugs, and also intervention by policy makers particularly in schools and 
universities, is an urgent requirement. [112, 113] 
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Perhaps more importantly is the continued monitoring of new trends in NPS 
(non-prescribed drugs) within the Internet and crypto markets. In addition, 
monitoring the rising market in prescribed drugs, such as benzodiazepine and 
non-benzodiazepine hypnotics (Z-hypnotic drugs), is a further area of 
concern.[114] As mentioned previously, longitudinal integrated monitoring 
systems incorporating international data from emergency departments, 
treatment services, toxicology services, police, sentinel groups and the internet 
are required continuously.[42] 
3.2 Methods of analysis of MXP and other diphenidine derivatives 
In a study by Baron et al., a number of NPS products were analysed by FTIR 
followed by GC-MS (as methanol extracts). The obtained spectra were 
compared to reference standards and the findings have confirmed the absence 
of the active ingredient in 6 out of 7 NPS products in question.[115]  
In a different study by Hofer et al., the acute toxicity produced after the 
recreational use of the NPS methoxphenidine by using LC-MS toxicological 
screening method (plasma and urine samples) was studied. The outcome of 
this study revealed that methoxphenidine has similar toxic effects that are seen 
after administration of arylcyclohexylamine drugs, such as phencyclidine 
(PCP). These effects include hypertension, tachycardia and confusion.[116] 
In forensic casework by Elliot et al., three death cases were related to the 
detection of 2-MXP in post-mortem blood and urine. The 2-, 3- and 4-MXP 
isomers where synthesised and tested to confirm the identity and 
concentration of 2-MXP, in addition to the diphenidine that was also present. 
Analysis of these biofluids allowed the detection and characterisation of 
various metabolites including the suggested presence of hydroxyl 2-MXP 
using UHPLC and LC-MS-MS analysis The involvement of 2-MXP in the 
results of the current case studies are the first published fatalities and it also 
provides analytical information which will assist analytical toxicologists with 
future forensic samples.[83] 
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In Sweden, Helander et al. have reported an observational case series in an 
emergency room. The adverse effects noted have confirmed cases of 
intoxication associated with diphenidine or MXP. Nevertheless, these results 
suggest the probability of polysubstance use. NPS analysis was performed by 
multi-component LC-MS methods. The adverse effects noted in analytically 
confirmed cases of NPS intoxication involving diphenidine or MXP were similar 
to those reported for other dissociative substances such as ketamine and 
methoxetamine.[66]  
In a different study, an autopsy case in which the cause of death was judged 
as poisoning by multiple new psychoactive substances, including AB-
CHMINACA, 5-fluoro-AMB and diphenidine. In this study, LC-MS was used to 
test these compounds.[117] 
In another study, a case of driving under the influence of MXP was studied and 
involved liquid-liquid extraction of MXP. Methoxphenidine serum samples, 
calibration or quality control standards were mixed with ketamine as the 
internal standard. MXP was extracted with ethyl acetate. The organic phase 
was dried under nitrogen, reconstituted in ammonium acetate (pH 
3.2)/methanol/acetonitrile (50:10:40% v/v). Three microliters were injected into 
(LCMS/ MS) system. A five-point calibration curve covering a concentration 
range of 20–100 ng MXP/mL serum was prepared from drug-free serum by 
spiking. Imprecision and accuracy were tested at 20 and 50 ng MXP/mL serum 
(n=5, respectively). Further validation parameters could not be established due 
to the limited size of the powder specimen. Finally, MXP was detected and 
reported using LC-MS/MS.[118] 
3.2.1 Instruments and methods utilised in the detection and separation of MXP 
isomers 
Analysis of MXP was performed by Stachel et al., on a mass spectrometer, 
interfaced to a HPLC pump and an auto sampler. Separation was achieved on 
a Luna C18 column (150×2.0 mm; 5 μm particle size), with ammonium acetate 
(pH 3.2)/methanol/acetonitrile (50:10:40 %v/v) as the mobile phase.[118]  
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From the results of the study performed by Stachel et al., amphetamine, 
MDMA, and MDA were detected in serum samples at a concentration of 111, 
28, and 3 ng/mL, respectively. The concentration of MXP was found to be 57 
ng/mL serum.[118] The concentration of MXP in this study was significantly 
lower than those in fatalities attributed to MXP. So far, the MXP toxicity in 
human has not been studied, but by comparison in structure to PCP or 
ketamine; for example, it is likely that MXP has severe psychotropic action in 
humans.[118] 
In a different work by McLaughlin et al., the preparation of 2-, 3-, and 4-MXP 
isomers (2, 3 and 4) was carried out by using a synthetic route which was first 
published by Le Gall et al. who employed an approach utilising one-step three-
component coupling-reactions between an aromatic organozinc reagent, a 
secondary amine, and an aromatic aldehyde for the preparation of 
diarylmethylamines.[75, 119] The application of this one-step procedure 
provided a convenient route of synthesis of the desired isomers. An alternative 
synthesis method (Figure 14) was also explored for its applicability to the 
synthesis of 2-, 3-, and 4-MXP. This procedure involves the reaction of 
triethylamine (Et3N) with a mixture of 2-methoxybenzoyl chloride and dimethyl 
hydroxylamine plus 4-dimethylaminopyridine (DAMP) to produce the Weinreb 
amide, prior to the addition of benzylmagnesium chloride (PhCH2MgCl), 
ammonium acetate and sodium cyanoborohyrdide (Na(CN)BH3). The last step 
involves the addition of dibromopentane Br(CH2)5Br and potassium carbonate 
to yield the MXP isomers. In this method, piperidine is not required as a 






Figure 14. Synthesis of three MXP isomers 
 
A further experimental approach focused on three samples believed to contain 
2-MXP, which were obtained from three different Internet providers and 
analysed by GC-MS. A comparison with the synthesized reference material 
confirmed that all test purchase samples were consistent with the identity of 
the 2-MXP isomer as indicated on the product label. The employed GC method 
did allow for the separation of all three isomers as well. The samples labelled 
to contain 2-MXP and the MXP standards were also analysed using an 
alternative GC-EI quadrupole MS method. The GC method used was able to 
distinguish between all three isomers and baseline separation was achieved 
between each isomer. The retention times were recorded at 19.15 min, 19.54 
min and 19.86 min for 2-MXP (2), 3-MXP (3) and 4-MXP (4) isomers, 
respectively. HPLC-MS was also utilized for the discrimination of the MXP 
isomers. Early attempts using an Allure® PFP Propyl column failed to resolve 
the isomers. However, switching to a phenyl hexyl column successfully 
permitted differentiation between isomers. The HPLC method achieved 
baseline separation for the 2 isomer and the 3 and 4 isomers were partially 




In a study by Geyer et al, thirteen diphenidine derivatives were synthesised 
and then analysed by GC-MS using other rapid screening methods such as 
presumptive (colour) tests and TLC. Taken together, the results of this study 
have shown the ability of the developed GC–MS method to provide a screening 
protocol, which facilitates the separation and identification of these 13 
substances.[74] In a recent research by Boateng et al, the focus was on 
studying the chromatographic retention behaviour, modelling and optimization 
of a UHPLC-UV separation of the regioisomers of methoxphenidine (2, 3 and 
4).[120] 
In another recent study Lowdon et al., the first developed Molecularly Imprinted 
Polymers (MIPs) for the specific detection of methoxphenidine (MXP) and its 
regioisomers was reported. Selectivity of the MIP towards MXP was studied 
by analysing mixtures and an acquired street sample with HPLC coupled to 
UV detection. The study demonstrates that the engineered polymers 
selectively extract MXP from heterogeneous samples, which makes for a very 
powerful diagnostic tool that can detect traces of MXP in complicated NPS 
samples.[88]  
3.3 Recent studies and research on the positional MXP regioisomers with 
some comparisons with the developed HPLC method in this study 
In 2015, Elliot et al., have studied HPLC-UV retention time (elution) and UV 
spectrum on MXP isomers, using Phenomenex Synergi column, mobile phase 
(the mobile phase consists of acetonitrile and triethylammonium phosphate 
(TEAP) as the buffer solution, at 30°C.[121] The findings from this study on 
HPLC-UV were as the following: the retention time of 2, tR =8.04 mins, at 278 
nm; 3, tR =8.06 mins, at 276 nm and 4, tR =8.08 mins, at 229 and 272 nm. In 
addition, limit of detection, LOD of 0.05 mg/L and a limit of quantification, LOQ 
of 0.10 mg/L.[121] The results of the developed study that the total run time is 
less by more than two minutes in comparison with Elliot’s findings. It is also 
clear that Elliot’s work has not dealt with the separation of MXP isomers i.e. 
just with identification or detection. In 2016, McLaughlin et al., have 
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investigated the RP-LC separation of the MXP regioisomers (2, 3 and 4), which 
has been reported using a superficially porous phenyl hexyl material (i.e. 
2.6 μm Kinetex) coupled with acetonitrile/formic acid gradient at 30 °C. While 
the 2-isomer was well resolved from the other two isomers, only partial 
separation of the 3- and 4-isomers was observed (the elution order was 
reported to be firstly 3, then 4 and finally 2). In contrast, the results of the 
developed HPLC method have shown a well-resolved baseline separation 
between all the three isomers in question (Table 7). 
In 2018, Boateng et al., studied 2D modelling on Agilent 1290 Infinity UHPLC 
(e.g. gradient time versus temperature) to optimize the gradient separation of 
the MXP isomers using a gradient and temperature design space.[120] This 
study has reported many findings: The retention/separation of MXP isomers is 
controlled by electrostatic/hydrophobic mechanisms. The stationary phase 
chemistry is not a major selectivity parameter. There was a synergistic effect 
between the electrostatic and partitioning mechanisms. Enhanced retention 
and separation of all MXP isomers was obtained at intermediate pH (6.8). The 
elution order at low pH (3) and at intermediate pH (6.8) was 2, 3 and 4, 
respectively. But at pH 10.7, MXP isomers were separated in the following 
order 4, 3 and 2 at 278 nm (7 mins). In this project, the elution order in the 
developed HPLC method is 2, 4 and 3.[120] In 2018, a study by Lowdon et al., 
selectivity of the MIP towards MXP is studied by analysing mixtures and an 
acquired street sample with HPLC-UV detection. The study demonstrates that the 
engineered polymers selectively extract MXP from heterogeneous samples, which 
makes for a very powerful diagnostic tool that can detect traces of MXP in 
complicated NPS samples. The developed HPLC method is superior to the 
previously reported GC-MS [74] and HPLC [75, 83] methods in terms of overall 
run time and resolution of the three regioisomers.  
To summarise, and after analysing the prior discussed studies, there is an 
urgent requirement to study and analyse these NPSs (in more depth and 
detail). That is because of the health problems resulting from NPS use and the 
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lack of a quick, HPLC method in this study were superior to Elliot’s method, 
the retention times and maximum wavelengths for methoxphenidine isomers 
were as follows: 2, tR =3.70 mins, at 278 nm; 3, tR = 5.82 mins, at 277 nm and 
4, tR =4.33 mins, at 273 nm. LOD of 0.04-0.15 µg mL-1and a LOQ of 0.38-0.47 
µg mL-1. Furthermore, it can be concluded from the findings of the present 
study that the new validated HPLC method is suitable and robust analytical 
method for MXP separation. This goal can be achieved by applying various 
analytical approaches such as the development of HPLC methods to detect, 
quantify and separate these regioisomers that exist in a given sample(s). 
3.4 Synthesis and analysis of MXP 
The three MXP derivatives were prepared by using the synthetic scheme 
(Figure 15), which shows the reaction of benzyl bromide with piperidine and 
the pre-requisite anisaldehydes (methoxybenzaldehydes) in the presence of 
zinc dust, acetonitrile and TFA. The three compounds were isolated as their 
corresponding hydrochloride salts. The samples were fully characterised and 
gave physical and spectroscopic data that were consistent with their proposed 
structures and the literature. The obtained data were on par with the analytical 
data obtained by McLaughlin et al, where the three MXP isomers were 
subjected to analytical characterization by gas chromatography (GC) and high 
performance liquid chromatography (HPLC) coupled to various forms of mass 
spectrometry (MS).[75] Nuclear magnetic resonance (NMR) spectroscopy, 
infrared (IR) spectroscopy and thin layer chromatography (TLC) were also 
employed. This was supported by the synthesis of all three isomers (2, 3 and 
4) by two different synthetic routes. The obtained results for the three 
purchased samples were consistent with the synthesized 2-MXP standard and 
differentiation between the isomers was possible.[75] Once the provenance of 
the samples had been confirmed the development of a suitable 






Figure 15. Synthesis of three MXP isomers.[78]   
 
 
3.5 Results and discussion 
 
3.5.1 Synthesis 
Samples of the three methoxphenidine regioisomers were prepared as their 
corresponding hydrochloride salts. The hydrochloride salts of diphenidine and 
its methoxy-substituted derivatives were prepared using an adaptation of the 
method reported by McLaughlin et al.[75] 
The actual yield of 2-methoxphenidine hydrochloride (2-MXP, 35%); 3-
methoxphenidine hydrochloride (3-MXP, 21%); 4-methoxphenidine 
hydrochloride (4-MXP, 25%). This yield can be increased or improved in 
several ways such as rinsing glassware three times with reaction solvent, 
adding reagents dropwise if necessary, quenching the reaction exactly when 
it is complete and by storing compounds at low temperature if possible.   
To ensure the authenticity of the materials utilised in this study, the 
synthesised samples (2–4) were fully structurally characterised by 1H-NMR, 




3.5.2 Infrared spectroscopy 
In the present study, the IR spectra of the three MXP regioisomers were 
obtained. The IR spectra of all three MXP isomers are shown in Figure 16, (2), 
Appendix A 9, (3) and Appendix A 10, (4). The C-O stretch can be seen at 
around 1100 cm-1. From the results of the IR, these C-O stretch vibrations 
were: 1114 cm-1 (2), 1154 cm-1 – (3) and finally 1100 cm-1(4). 
The other stretch is C-H, in which the values were as follows: 2935 cm-1 (2), 
2941 cm-1 (3) and 2940 cm-1 (4).  The C=C stretch of the aromatic rings is 
shown as follows: 1492 and 1601 cm-1 (2), 1493 and 1592 cm-1 (3) and 1500 
and 1600 cm-1 (4).  The N-H stretch region is at about 3400 cm-1 to 3500 cm-
1, from the results, firstly, there are two sharp and weak peaks at 3435 and 
3511 cm-1 (2), while in the case of (3) there were no peaks in this region, this 
could be due to reversible hydrogen bonding between the hydrogen in HCl and 
the nitrogen in NH group, as a result, giving rise to a very weak IR signal. 
Finally, there is a broad weak over tone in the region of 3000 to 3500 cm-1 for 
(4). 
In the fingerprint region, which is the region to the right-hand side of the 
diagram (from about 1500 to 500 cm-1) usually contains a very complicated 
series of absorptions. The significance of the fingerprint region is that each 
different compound produces a different configuration of troughs in this part of 
the spectrum.  These are mainly due to all manner of bending vibrations within 
the molecule. (1500-500 cm-1), the bending signals can be noted, the ortho 
isomer has a peak at exactly 780 cm-1 (2), in the meta regioisomer, there are 
two peaks below 800 cm-1, at 707 and 762 cm-1, in addition to the presence of 
one peak at 873  cm-1 (3). The last observation for the para isomer, in this 
region, there is one peak above 800 cm-1, at approximately 900 cm-1 (4). The 
IR findings for MXP isomers have shown the following: The C-O stretch for the 
three isomers located all in the region of about 1100 cm-1. However, there is a 







Figure 16. The ATR-FTIR spectrum of 2
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This could be due to the variation in the position of methoxy group and its 
electronic effect among these positional isomers.  The band at 2935 cm-1 refers 
to C-H stretches (2, 3 and 4). Moreover, the bands at 2940 (strong) and 2840 
cm-1 (weak) are typical for the asymmetric and the symmetric (C-H) vibrations 
of CH2 groups, respectively. The C-H wag (strong) at (770-735 cm-1) is typical 
for ortho-substituted rings, this peak can be clearly seen in the fingerprint 
region for 2, while it is not present in 3 and 4.[122]  However, the C-H stretches 
here are less important for differentiation because they exist in the vast 
majority of the organic compounds.  It can be concluded that the IR spectrum 
gives an idea about the functional groups present in the chemical compound, 
which therefore, facilitates its identification.  
3.5.3 Nuclear magnetic resonance 
The NMR spectral data of the three MXP isomers were obtained (1H and 13C 
NMR spectra) using DMSO as a solvent. In the 1H NMR spectrum of 2-MXP, 
there is a broad peak at δ 10.92; this is assigned to the NH group which is 
present as the compound was isolated as a hydrochloride salt i.e. this is 
possibly because of the formation of reversible hydrogen bond in the 
hydrochloride group with the nitrogen atom in the piperidine ring. In the 
aromatic region, there is a broad singlet that integrates to a single proton, a 
doublet of doublets of doublets (ddd) centred at δ 7.34 that again integrates to 
one proton and a multiplet at 7.16-6.97 ppm that integrates to seven protons. 
The ddd arises from one of the proton nuclei in the methoxybenzene ring 
having similar 3JHH couplings to two unique proton neighbours, and a fourth, 
smaller 4JHH coupling to a third proton nucleus through a “W” coupling. Two 
couplings were identified, one of 7.52 Hz which is a 3JHH coupling and the other 
being 1.46 Hz, which is of the right magnitude for a 4JHH coupling. In the 1H-1H 
COSY (Correlation Spectroscopy) spectrum, this peak possesses three cross-






Figure 17. 1H NMR spectrum of 2
73 
 
The chiral centre present in 2-MXP (2) leads to the CH2 protons becoming 
inequivalent (Figure 17). In the 1H-1H COSY NMR spectrum, the doublet 
located at 4.91 ppm (3JHH = 12.3 Hz) shows two cross peaks; one cross peak 
is to the doublet of doublets at 3.70 ppm (3JHH coupling = 12.19 Hz, 2JHH 
coupling = 3.19 Hz) whilst the other is to the triplet (3JHH = 12.8 Hz) at 4.91 
ppm. All of these environments integrate to one proton each. Further evidence 
for the positioning of these peaks was obtained from the 1H-13C HMBC 
spectrum. The two peaks located at δ 3.70 and 3.19 both show a cross peak 
to two aromatic carbons located at δ 128.9 and 136.6. The former is a CH, as 
identified through DEPT analysis whereas the latter is a quaternary carbon. 
These two peaks are thus located on the benzene ring to which the CH2 is 
attached to as part of the aliphatic backbone of the molecule.  
The piperidine ring consists of 10 proton nuclei. Due to the hindered rotation 
of the bonds, the signals for these environments are not observed as simple 
splitting patterns due to the range of couplings that are present. However, the 
integration of these regions does equal ten, thus matching the proposed 
structure. 
The 13C NMR spectrum (Figure 18) of 2 possesses 16 peaks which 
corresponds to the number of carbon environments in 2. There are 10 aromatic 
peaks, which reduces to 7 in the 13C[120] DEPT-135 spectrum. The reason 
why there is a reduced number of peaks in the 13C{1H} DEPT-135 spectrum is 
because there are three quaternaries in the structure. These are assigned to 
the peaks at 158.1, 136.6 and 119.4 ppm in the 13C NMR spectrum, with the 
peak at 158.1 ppm being the quaternary carbon to which the methoxy group is 
attached to the benzene ring – this was rationalised from the 1H-13C HMBC 
spectrum as it was the only signal that showed this interaction. The remaining 
peaks are all positive in the 13C{1H} DEPT-135 spectrum indicative of either a 
CH or CH3; given their chemical shifts, these are most likely to be aromatic 
CHs. In addition to the aromatic peaks, there are 6 aliphatic peaks, again 
matching that of the proposed structure. The peak at 55.60 ppm is positive in 
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the 13C{1H} DEPT-135 spectrum, suggestive of a CH or CH3. Given the 
deshielded nature of this peak, this is assigned to the methoxy carbon. The 
methoxy protons are observed as a singlet at δ 3.66 in the 1H NMR that 
integrate to three protons. In the 1H-13C HMQC this peak possesses a cross-
peak to a peak at 55.60, thus confirming the proposed assignment. 
HMQC data for the meta and para MXP isomers were as follows: (3.69, 3H, s) 
this proton has a cross-peak to a peak at 55.73 ppm (3-MXP (3)) whereas the 
proton (3.68, 3H, s) possesses a cross-peak to a peak at 55.42 ppm (4-MXP 
(4)). 
Similarly, HMBC data for the two isomers have shown the following: the proton 
at 3.69 ppm has a cross-peak to 159.7 ppm (3) and finally, the proton at 3.68 
ppm possesses a cross-peak to a peak at 160.3 ppm (4). These findings from 






Figure 18. 13C{1H} NMR spectrum of 2 
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Compared with 2, 3 and 4 have similar 1H NMR spectra (Appendix A 11 and 
Appendix A 12). For example, the CH2 protons in the piperidine ring have 
similar chemical shifts in that they are observed as multiplets over the regions 
of 1.0-1.4 ppm and 1.4-1.6 ppm. The methoxy group is also observed in the 
same region, although this peak does show some variation in its chemical shift 
dependent on the regioisomer under review. The 1H NMR chemical shifts for 
the methoxy protons are as follows: 2 = 3.66 ppm, 3 = 3.69 ppm and 4 = 3.68 
The meta-substituted MXP: 4 chemical shifts: 2 doublets and one singlet.(7.1 
– 7.6 ppm). 6.85 (dd, J=8.08, 3.16, 4H). The characteristic J constant for meta 
coupling is between 2 and 3 Hz. The hydrogens are magnetically equivalent 
due to the symmetry in 4-MXP molecule. (Appendix A 12). 
In 4, the aromatic region has 2 sets of protons that are equivalent and produce 
two chemical shifts. The spectrum is a pair of doublets that show second order 
effects. This pair of doublets is readily observed for para-disubstituted benzene 
due to second splitting and less so for ortho- or meta-disubstituted benzenes. 
The latter display much more complex patterns. 
From the multiplicity of the 1H NMR signals for the aromatic protons in the 
range of 6.50-7.50 ppm, the three isomers can be distinguished from each 
other. In the 1H NMR spectra shown in Figure 17, Appendix A 9 and Appendix 
A 10, 7.34-6.97 ppm (2), 7.27-6.91 ppm (3), 7.32-6.90 ppm (4) each multiplet 
integrates to the number of aromatic protons in the corresponding MXP isomer 
e.g. 9 protons in (2). The signal produced by the meta-substituted MXP has a 
similar shape to the signal produced by ortho substituted isomer, with the 
exception of the presence of a singlet at 7.07 ppm (due to the proton in ortho 
position). The signal due to para-substituted MXP shows two symmetrical 
doublets due to the two protons on both sides of the ring i.e. the multiplets 
"lean" towards each other (second order effect, sometimes referred to as the 
"roof" effect). The effect is due to the difference in chemical shift being of the 
same order as the chemical shift, the characteristic J constant for para coupling 
is between 0 and 1 Hz.[123] 
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The spectral data collected for (2) isomer have shown that the methoxy protons 
are observed as singlet at δ 3.66 in the 1H NMR that integrate to three protons. 
This is in agreement with the data reported in the literature (in comparison with 
the McLaughlin et al. study, 3.71 (s; 3 H; OCH3) i.e. 1H and 13C NMR data (HCl 
salt).[75] 
3.5.4 Ultraviolet spectroscopy 
The three isomers were run on a UV spectrophotometer; the UV-visible 
spectrum showed that all three MXP isomers exhibit a max. For 2, this centred 
at 278 nm (See Appendix A 15), whilst for 3 and 4 they were centred at 277 
nm (See Appendix A 16) and 273 nm respectively. There is, therefore, no real 
significant difference in terms of the absorption properties of the three 
regioisomers investigated.  
From the results, the molar absorptivity (ɛ) for each isomer was given from 
the Beer's Law Equation (Absorbance = ɛ.L.c) i.e.  
ɛ = A/L.c, 
ɛ = molar absorptivity, A = absorbance, L = path length, c = concentration  
The values of molar absorptivity for MXP isomers are given below:  
In the case of 2-MXP (2); max = 278 nm, abs. = 1.31, ɛ278= 1290 L mol-1 cm-1, 
while for 3-MXP (3); max = 277 nm, abs. = 1.117, ɛ277= 1100 L mol-1 cm-1 and 
finally for 4-MXP (4); max = 273 nm, abs. = 0.673, ɛ273= 660 L mol-1 cm-1 
It is clear from the results that 2 has greater molar absorptivity (ɛ) than the 
other two isomers. Molar absorptivity is a term used in chemistry to measure 
how a particular chemical absorbs light at a particular wavelength. It is also 
known as molar extinction coefficient denoted by 'ɛ'. The absorbance values 
for all three MXP isomers were within the range of (0.5-1.5) which is acceptable 
according to Beer-Lambert’s law and ICH guidelines. This can be explained by 
the possibility of obtaining an absorbance value of greater than one (if the 
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solution is concentrated). Nevertheless, it is recommended to use diluted 
solution whose absorbance is below one.   
3.5.5 Gas chromatography-mass spectroscopy 
The three MXP regioisomers were studied using GC-MS in order to detect and 
separate the three MXP isomers qualitatively in a mixture and compared to the 
work by Geyer et al.[74] The base peaks observed for 2, 3 and 4 in the MS is 
m/z=204, which is consistent with the literature.[74] The retention times and 
relative retention times of 2, 3 and 4 were determined and found to be 
consistent with Geyer’s results (Table 6).  
Methoxphenidine isomers with some common adulterants were also 
investigated using GC-MS and their retention times (tR) and relative retention 
times (RRT) recorded (Table 6). The adulterants were caffeine, benzocaine 
and procaine. This experiment was performed in order to measure the purity 
of MXP derivatives. The adulterants/diluents are commonly blended to the 
drugs (NPSs) to increase drug volume and therefore drug trafficking 
profits.[124]  
Methoxphenidine isomers with some common adulterants were also 
investigated using GC-MS and their retention times (tR) and relative retention 
times (RRT) recorded (Table 6). The adulterants were caffeine, benzocaine 
and procaine. This experiment was performed in order to measure the purity 
of MXP derivatives. The adulterants/diluents are commonly blended to the 









Table 6. GC-MS Retention times (tR) and Relative Retention Times (RRT) of 2, 3 and 
4 with some common adulterants using Eicosane as a reference. 
 GC-MS (this study) GC-MS (Geyer et al.) 
Analyte tR (min) RRT tR (min) RRT 
2 32.02 1.24 28.06 1.28 
3 34.69 1.35 29.94 1.37 
4 36.81 1.43 31.40 1.43 
Caffeine 19.12 0.74 15.68 0.72 
Benzocaine 12.37 0.48 10.98 0.50 
Eicosane 25.73 1.00 21.85 1.00 
Procaine 27.15 1.06 24.25 1.10 
 
3.5.6 High performance liquid chromatography 
3.5.6.1 HPLC Method Development (MXP isomers)  
The next step after characterisation is developing HPLC method [125, 126] for 
MXP isomers separation. The method was developed by changing different 
HPLC experimental parameters in order to obtain optimum resolution and 
retention time. The flow rate, temperature and mobile phase composition, were 
selected for testing as the parameters for modification. HPLC separation 
conditions were optimised during method development; the most important 
factor is the resolution (Rs) which should be > 1.5 (desirable for quantitative 
analysis), but in this study, the value of Rs > 2.0 was the goal for separation of 
MXP sample mixture. Calculation of resolution in HPLC is shown in (Figure 
19), where tR is the retention time, tW is obtained is from the intersection of the 
tangents (which are drawn at 0.6 times the peak height) with the baseline. 
Resolution in HPLC is defined as the difference in retention times between the 




Figure 19. Calculation of resolution in HPLC 
  
During method development, the HPLC conditions used were as follows: 
mobile phase, acetonitrile:ammonium acetate 55:45% v/v, column ACE 5 C18-
AR (150 x 4.6 mm, 5 µm particle size), flow rate (1.0 mL min-1), temperature 
(50°C), injection volume (20 µL) and detection wavelength (278 nm). Two 
blank injections (30 min each) followed by two injections of MXP mixture (10 
min).  
3.5.6.2 Method Validation (MXP isomers) 
The optimised method was validated in accordance with the ICH 
guidelines.[128] The following parameters: linearity, accuracy, precision, 
specificity, limit of detection (LOD), limit of quantification (LOQ) and system 
suitability [resolution (Rs), column efficiency (N), peak asymmetry (As)]. 
Linearity, precision and system suitability tests were carried out using six 
replicate injections of the calibration standards were performed and the data 
analysed (Table 7). The %RSD was calculated for each replicate sample. 
Moreover, symmetry, relative retention time (RRT), number of theoretical 
plates (N), equation of the straight line, capacity factor (k) which is a measure 
of the retention of a peak that is independent of column geometry or mobile 
phase flow rate. The capacity factor is calculated as: k = (tR - t0)/t0, the height 
equivalent to a theoretical plate H(m); or HETP =  L / N, where, L is the column 
length and N is the plate number. R-squared (r2) = a statistical measure of how 
close the data are to the fitted regression line. Theoretical plate number (N) is 
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an index that indicates column efficiency. It describes the number of plates as 
defined according to plate theory, and can be used to determine column 
efficiency based on calculation in which the larger the theoretical plate number 
the sharper the peaks. These parameters and data are reported in Table 7. In 
this experiment, calibration standards of methoxphenidine regioisomers were 
prepared and tested on HPLC (The results are shown in Table 7).  
Table 7.  Representative validation data for MXP isomers obtained using an ACE 5 
(150 x 4.6 mm i.d, 5µm) column, mobile phase: acetonitrile:ammonium acetate 
55:45% v/v, flow rate: 1.0 mL min-1; Detector: UV-DAD. 
Key: (a) Determined from the retention time of a solution of uracil (1 µg mL-1) eluting from the 
column; (b) limit of detection (based on the standard deviation of the response and the slope); 
(c) limit of quantification (based on the standard deviation of the response and the slope). (d) 
y = 5.7588x + 0.2432; (e) y = 4.6324x + 0.4973; (f) y = 3.1087x - 0.0844. 
Method validation is important to be carried out after the completion of method 
development. The HPLC method was validated using an adaptation of the 
method reported by Geyer et al.[74] The MXP isomers were tested in this study 
to ensure the HPLC: DAD system (or the detector) produced a linear response 
for the repeated injections of the three MXP isomers by testing a series of five 
  2 3 4 
tR (min) (t0=1.50min)a 3.70 5.82 4.33 
RRT 1.58 1 1.34 
Capacity Factor (k’) 2.66 4.81 3.32 
Resolution (Rs) - 7.41 3.88 
Plates (N) 7164 9053 7417 
Asymmetry Factor (As) 0.75 0.97 0.86 
LOD (µg mL-1)b 0.12 0.04 0.15 
LOQ (µg mL-1)c 0.38 0.47 0.45 
Co-efficient of Regression(r2) 0.999 0.999 0.999 
Precision (%RSD) (n = 5) 
2.5 µg mL-1  1.75 2.17 1.79 
5 µg mL-1  0.43 0.92 0.69 
10 µg mL-1 0.09 0.28 0.49 
20 µg mL-1  0.28 0.48 0.62 
40 µg mL-1  0.31 0.39 0.59 
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MXP concentrations using the standard developed method, from which both 
LOD and LOQ were calculated. 
The concentrations were calculated using the equation of the calibration line: 
y = mx + c 
Where, y = Peak Area; x = Concentration of analyte (µg mL-1); m is the gradient 
of the line and c is the y-intercept (where the graph crosses the y-axis). The 
following diagram (Figure 20) shows HPLC separation of MXP regioisomers. 
The order of elution was 2-MXP (2) followed by 4-MXP (4) and then finally 3-
MXP (3). The peak of 2 shows a bit of tailing which might be due to the fact 
that compounds possessing amine and other basic functional groups interact 
strongly with residual silanol groups on the silica producing tailing peaks. 
 
Figure 20, HPLC separation of MXP isomers (concentration = 40 µg mL-1); 2 tR= 3.703 
min; 4 tR = 4.336 min and 3 tR = 5.823 min, respectively. 
 
The method shows excellent linearity i.e. all three substituted 
methoxphenidines demonstrated a linear response (r2 = 0.999) over the 2.5 -
40 µg mL-1 range with good repeatability in each case (%RSD = 0.09 – 2.17 
%, n = 5). The system suitability tests were within the specifications of the ICH. 
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The peak area and relative retention times of the analytes were measured and 
the %RSD calculated to determine the precision. The repeatability (%RSD) of 
the method was high and complies with ICH guidelines (0.09-0.92) for all 
concentrations except for the lowest concentration (i.e. 2.5 μg mL−1, 1.75-
2.17).[128] 
3.5.6.3 Method Robustness (MXP isomers) 
In this experiment the following variations were tested: influence of variations 
temperature; influence of variations in mobile phase composition; flow rate and 
the effect of intra- and inter-day variation as the method should be robust in 
routine operation and usable by all laboratories. Robustness can be assessed 
by measuring some experiment parameters such as temperature, flow rate, 
the percentage of mobile phase composition and the intra- and inter-day 
precision.  
The evaluation of robustness should be considered during the development 
phase. It should show the reliability of an analysis with respect to deliberate 
variations in method parameters. If measurements are susceptible to 
variations in analytical conditions, the analytical conditions should be suitably 
controlled or a precautionary statement should be included in the procedure.  
The peak area and relative retention times of the analytes were measured and 
the %RSD calculated to determine the precision. In all cases (except the 
lowest conc. 2.5 which was >1) both the peak area and the relative retention 
time gave %RSDs which are <1% and within the guidelines stipulated by the 
ICH. The data indicate that the method is robust and should be suitable for use 
in the routine analysis of seized samples (see Table 8, Table 9, Table 10, 





tR (min) using  temp. 48 °C tR (min) using  temp. 50 °C tR (min) using  temp. 52 °C 
Injection  2 3 4 2 3 4 2 3 4 
1 3.904 5.944 4.493 3.911 5.980 4.515 3.915 5.995 4.526 
2 3.913 5.943 4.469 3.911 5.978 4.514 3.917 5.999 4.529 
3 3.913 5.944 4.496 3.915 5.981 4.518 3.918 5.997 4.527 
4 3.912 5.945 4.497 3.912 5.977 4.513 3.916 5.993 4.524 
5 3.909 5.949 4.497 3.914 5.979 4.516 3.920 5.996 4.528 
6 3.916 5.946 4.499 3.914 5.984 4.518 3.920 5.995 4.528 
7 3.914 5.947 4.498 3.912 5.984 4.517 3.918 5.990 4.524 
8 3.917 5.950 4.501 3.921 5.979 4.519 3.923 5.994 4.528 
9 3.917 5.953 4.503 3.916 5.978 4.515 3.921 5.991 4.526 
10 3.919 5.954 4.504 3.921 5.978 4.518 3.922 5.995 4.527 
Average 3.913 5.947 4.495 3.914 5.979 4.516 3.919 5.994 4.526 
STD 0.004 0.003 0.009 0.003 0.002 0.002 0.002 0.002 0.001 
%RSD 0.112 0.064 0.221 0.094 0.041 0.044 0.066 0.044 0.037 
Table 8. Robustness testing (temperature = 48, 50 or 52 °C) for the three MXP analytes using a mobile phase consisting of acetonitrile:ammonium 
acetate 55:45% v/v, concentration of MXP = 10 µg mL-1 
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Table 9. Robustness testing (flow rate = 0.9, 1.0 or 1.1 mL min-1) for the three MXP 
analytes using a mobile phase consisting of acetonitrile:ammonium acetate 55:45% 














tR (min) using  flow 
rate 0.9  mL min-1 
tR (min) using  flow 
rate 1.0  mL min-1 
tR (min) using  flow 
rate 1.1  mL min-1 
1 2 3 4 2 3 4 2 3 4 
2 4.366 6.669 5.037 4.366 6.669 5.037 4.366 6.669 5.037 
3 4.370 6.663 5.035 4.370 6.663 5.035 4.370 6.663 5.035 
4 4.368 6.664 5.035 4.368 6.664 5.035 4.368 6.664 5.035 
5 4.372 6.678 5.045 4.372 6.678 5.045 4.372 6.678 5.045 
6 4.373 6.667 5.040 4.373 6.667 5.040 4.373 6.667 5.040 
7 4.374 6.665 5.039 4.374 6.665 5.039 4.374 6.665 5.039 
8 4.376 6.666 5.040 4.376 6.666 5.040 4.376 6.666 5.040 
9 4.378 6.672 5.044 4.378 6.672 5.044 4.378 6.672 5.044 
10 4.377 6.670 5.042 4.377 6.670 5.042 4.377 6.670 5.042 
Average  4.378 6.671 5.043 4.378 6.671 5.043 4.378 6.671 5.043 
STD 4.373 6.668 5.040 4.373 6.668 5.040 4.373 6.668 5.040 
%RSD 0.004 0.004 0.003 0.004 0.004 0.003 0.004 0.004 0.003 
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Table 10. Robustness testing for MXP isomers (The effect of modifying flow rate) 
 
  
Flow Rate 0.9 mL min-1 2 3 4 
tR (min)(t0=1.50min) 4.37 6.66 5.04 
RRT 1.52 1.00 1.32 
Plates (N) 7250 9400 7550 
Resolution (Rs) - 6.45 3.06 
Flow Rate 1.0 mL min-1 2 3 4 
tR (min)(t0=1.50min) 3.94 6.00 4.54 
RRT 1.52 1.00 1.32 
Resolution (Rs) - 6.30 2.97 
Plates (N) 7120 9150 7340 
Flow Rate 1.1 mL min-1 2 3 4 
tR (min)(t0=1.50min) 3.59 5.46 4.13 
RRT 1.52 1.00 1.32 
Resolution (Rs) - 6.22 2.94 
Plates (N) 6790 9030 7250 
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3.5.6.3.1 Robustness testing (temperature and the application of Van’t Hoff 
equation) 
In this HPLC method robustness testing, three temperatures (48, 50 and 52°C) 
were investigated; the results revealed that by increasing the temperature (see 
Table 8). The retention times (tR) of the three MXP analytes were just slightly 
changed or remained constant e.g. in the case of 2-MXP (2), at 48°C tR was 
3.913 min, at 50°C (3.914 min) and at 52°C (3.319 min). 
By plotting ln k (retention factor) versus 1/T (absolute temperature in kelvins, 
K-1), a linear Van’t Hoff plot is obtained, which suggests that the retention 
mechanism for MXP analytes is the same or constant (parallel trend lines, see 
Figure 21); that is, the values for ΔH and ΔS for the analytes are constant over 
the temperature range under consideration. These findings are in line with the 
literature, Boateng et al. concluded that as the temperature was increased the 
retention time should decrease (i.e. van’t Hoff relationship) and that the 
mechanism controlling the retention and separation of the MXP regioisomers 
was attributed to an electrostatic interaction which facilitated hydrophobic 
interactions.[120], [129] 
 




In thermodynamics, this means that when the temperature of a 
system increases, the kinetic and potential energies of the atoms and 
molecules in the system increase. Accordingly, the internal energy or the 
enthalpy of the system increases; this is true under constant pressure or 
constant volume. Furthermore, when the temperature increases, this will 
increase entropy causing more energy put into the system, which excites the 
molecules and the amount of random activity. A reaction can be predicted 
whether if it will occur spontaneously by combining the entropy, enthalpy, and 
temperature of a system in a Gibbs free energy (G), or (Gibbs equation) 
The change in free energy (ΔG) is the difference between the heat released 
during a process and the heat released for the same process occurring in a 
reversible manner.  
The thermodynamic relation:         ΔG = ΔH - T ΔS            (Gibbs equation) 
Where, (G, Gibbs free energy, T = absolute temperature in kelvins), (ΔH) = 
enthalpy change or internal energy (total heat content) in the thermodynamic 
system. While, (ΔS) = entropy change is the measure of the randomness 
(disorder) of molecules in the system. The ΔH can be calculated from the slope 
of van’t Hoff plot and ΔS is calculated from the intercept of van’t Hoff plots. 
The thermodynamic quantity that governs retention is the free energy (ΔG) 
which has an entropy component (ΔS). At lower temperatures, where the 
mobile phase is hydrogen bonded, there is a favourable entropy change upon 
retention. This is commonly referred to as "hydrophobic effect." However, at 
high temperatures, where there is little or no hydrogen bonding, the entropy 
change would be expected to be much less. As a result, although the enthalpy 
(ΔH) of retention is more favourable at high temperature, it is outweighed by 




3.5.6.3.2 Robustness testing (flow rate and the van Deemter equation) 
By increasing the flow rate from 0.9 to 1.0 mL min-1 and then to 1.1 mL min-1. 
In Table 9, the tR was decreased e.g. tR of 4 was 5.00 min (at 0.9 mL min-1), 
4.50 min (1.0 mL min-1) and 4.10 min (1.1 mL min-1), and similarly, the 
resolution was decreased. For example, the resolution decreased from 6.45 to 
6.30 and then to 6.22 between 2 and 3 and from 3.06 to 2.97 and to 2.94 
between 4 and 3 peaks (Table 9). A lower flow rate will result in a loss of 
efficiency due to the longitudinal diffusion caused by increased retention factor 
(k) and elution time (due to increased B/u) (see van Deemter Equation in 
chapter 1). As a general rule of thumb regarding the van Deemter Equation 
and flow rate: 
I. The smaller the plate height H, the more efficient the column. However, 
at the optimum flow rate (with the lowest H), the analysis time will in 
most cases be unacceptably long. 
II. Below the optimum flow rate the analysis time is too long and the quality 
of the separation suffers because of longitudinal diffusion (contribution 
of the B-term, see introduction chapter). 
III. At extremely high flow rates, both the separation quality and the 
pressure across the column will become unacceptable. 
IV. The practical flow is often two or three times the optimum velocity. At 
these values, the minor loss of efficiency is still acceptable. 
For MXP isomers (see Table 9) the optimum flow rate is 1 mL min-1, because 
the resolution, peak height and number of plates started to decrease when flow 
rate was increased from 1 mL min-1 to 1.1 mL min-1. The ultimate aim in any 
separation is to obtain resolution or optimum distance between peaks of the 







3.5.6.3.3 Robustness testing for MXP isomers (mobile phase composition and 
impact of log P) 
By deliberately modifying mobile phase proportion, there were slight 
changes/reductions in retention times of MXP regioisomers i.e. by increasing 
the organic part (acetonitrile) of the mobile phase (acetonitrile:ammonium 
acetate) from 54 to 55% and then to 56%, the retention time was decreased. 
e.g. tR of 3 from 6.28 min (54:46% v/v) to 6.04 min (55:45% v/v) and then to 
5.77 min (56:44% v/v), in addition, there was also only minor changes in the 
%RSD (Relative standard deviation), which measures the precision of the 
average (tR) of the results, for 3 %RSD was 0.05 (54:46% v/v), 0.10 (55:45% 
v/v) and 0.11 (56:44% v/v), (See Appendix A 17). 
The solutes of MXP isomers (2, 3 and 4) are adsorbed on to the stationary 
phase and by increasing the percentage of the organic modifier (acetonitrile) 
from 54 to 55% and then to 56% the retention time of these solutes decreases. 
The ChemDraw software was used to predict log P of these isomers and was 
found to be 4.58, which is a positive value for log P, this indicates a higher 
concentration in the lipid phase (i.e., the compound is more lipophilic). Again, 
this confirms that MXP isomers possess a hydrophobic effect as a mechanism 
of retention in reverse phase chromatography.   
 The data in Appendix A 17 and Appendix A 18 for all the robustness 
experiments indicate that the method is robust and should be suitable for use 
in the routine analysis of MXP samples. 
Overall, from the results of the robustness of the developed HPLC method, in 
all cases, the measured retention time showed no significant differences, this 
again indicates that the method is robust and should be suitable for use in the 
routine analysis of any samples that contain MXP isomers and can be easily 
transferred for use in another laboratory if necessary.   
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3.5.6.4 Method Accuracy (MXP isomers) 
According to the ICH guidelines, Q2 (R1) Validation of Analytical Procedures, 
2005), accuracy should be reported as percent recovery by the assay of known 
added amount of analyte in the sample. Accuracy is a measure of closeness 
of a calculated result to the known, true value (i.e. 100% of known 
concentration, a minimum of nine determinations over a minimum of three 
concentrations and results should be 98-102% of the true content). An average 
of 6 repeated injections was performed in this experiment (Appendix A 19). 
Additionally, the accuracy (percentage recovery study) of the assay was 
determined from spiked samples prepared at three concentration levels over 
a range of 80–120 % (8, 10 and 12 µg mL-1) of the target concentration (10 
μg mL−1). From the results, the percentage recovery (% assay) and %RSD 
calculated for each of the three replicate samples demonstrated excellent 
recoveries for all 3 analytes within the desired concentration range 
(100 ± 2 %, see Table 8). The percentage recovery for 4 was about 98% in all 
three concentrations tested in this experiment; while for 3 (99-100.5%) and 
(98.5-100.5%) in the case of 2.  
3.5.6.5 Method specificity (MXP isomers) 
The specificity of the method was performed using three replicate injections of 
the specificity standards and the data analysed under the same conditions 
(Table 11). The concentrations of 2, 4 and 3 were 10 µg mL-1, diphenidine, 4-
MMC, paracetamol, caffeine and benzocaine 10 µg mL-1 and common 
adulterants and a seized sample of [10 µg mL-1] using an  ACE 5 C18-AR (150 
x 4.6 mm, 5 µm particle size) column. Mobile Phase: acetonitrile:ammonium 
acetate 55:45% v/v, flow rate: 1 mL min-1; Detector: UV-DAD. The tested 
compounds were injected individually prior to testing them in a mixture (to 
facilitate comparison). 
The results (Table 11) showed that the developed HPLC method is suitable 
for the detection and quantification of the three common adulterants 
(benzocaine, caffeine and paracetamol).  
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Table 11. Representative data obtained for solutions containing regioisomeric MXPs 
in a seized sample and some common adulterants using the concentration of 10 µg 
mL-1 and mobile phase (acetonitrile:ammonium acetate 55:45% v/v). 
 
The results of specificity/adulterants testing revealed that the strongly UV-
absorbing components (benzocaine, caffeine and paracetamol) demonstrated 
baseline separation from the target analytes, with benzocaine being 
distinguishable from other controlled psychoactive substance such as 
mephedrone (4-MMC) or diphenidine. The three MXP isomers were 
completely separated with excellent RRT and resolution; consequently, they 
can be easily distinguished from the adulterants and/or NPSs in a mixture. This 
indicates that the developed HPLC method can be used in detection and 
quantification of the seized samples of MXPs isomers either as individual 
samples or in a mixture that contains adulterants.  
3.6 Forensic application (MXP isomers)  
The street samples supplied were analysed using the GC-MS and HPLC 
methods developed. The first investigation was conducted using GC-MS to 
identify the retention times for the components in the two street samples. The 
results were then compared with Geyer’s GC-MS results of the 13 diphenidine 
derivatives.[74]   
 tR (min) 
Injection Benzocaine Caffeine 4-MMC Paracetamol 2-MXP 3-MXP 4-MXP Diphenidine 
1 2.63 1.70 2.18 1.63 3.85 6.16 4.56 6.13 
2 2.62 1.70 2.18 1.63 3.85 6.16 4.56 6.13 
3 2.62 1.70 2.18 1.63 3.85 6.16 4.56 6.13 
Average tR (min) 2.62 1.70 2.18 1.63 3.85 6.16 4.56 6.13 
RRT 0.68 0.44 0.56 0.42 1.00 1.60 1.18 1.59 
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This qualitative GC-MS analysis confirmed and indicated that the samples 
contained 2-methoxphenidine (SS-1: tR = 32.58 min, m/z (base peak) = 204 
[M+H]+ , 2; Figure 22) and 2-methoxphenidine (SS-2: tR = 32.58 min, m/z (base 
peak) = 204 [M+H]+ , 2) and 3-methoxphenidine (SS-2: tR = 35.22 min, m/z 
(base peak) = 204 [M+H]+ , 3; Figure 23), respectively. In addition to the base 
peak ions, fragmentation ions were also observed. The peak at m/z=65 
represents C5H5+ and the fragment at m/z=91 represents C6H5-CH2+ or the 
tropylium C7H7+; these two fragments are present in the structure of all the 
three MXPs which confirms that these isomers have commonality in terms of 
chemical structure. Eicosane was utilised as an internal standard for both 
street samples and possessed a retention time of 25.95 min (RRT=0.90). 
There is no apparent adulteration in comparison with standards of 2 and 3, 
implying that the samples were essentially pure (Figure 22 and Figure 23).  
To conclude, this finding indicates that 2 and 3 (present in the street sample), 
can be detected and separated using this GC-MS method in the presence of 
both diphenidine and eicosane. Furthermore, the MS fragmentation and GC 
data obtained were consistent with the data reported by Geyer et al.[74]  
 
Figure 22. Chromatograph of St S1 (the sample contains 2 at 32.58 mins and 
Eicosane at 25.95 mins) 
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From the results of GC-MS spectra, St S1 contains 2; St S2 contains both 2 
and 3 and it is clear that the two isomers are separated from each other with 
good resolution (Figure 22). 
 
Figure 23. Chromatograph St S2 on GC-MS (the sample contains 2 at 32.58 mins, 3 
at 35.22 and Eicosane at 25.95 mins) 
 
Another investigation was performed using HPLC to evaluate two street 
samples (St S1 and St S2) obtained from independent Internet vendor BRC 
Fine Chemicals Limited (https://www.brc-finechemicals.com) which presented 
as white crystalline powders in clear zip-lock bags. These samples were 
obtained prior to the legislative change (20th May 2016), the samples were both 
purported to be >99% pure.  
This HPLC analysis of the two street samples indicated that the first sample 
contained one component (St S1, tR = 3.88 min) and the second sample 
contained two components (St S2, peak 1, tR = 3.89 min; 2 and St S2, peak 2, 
tR = 6.18 min; 3). Comparison of the samples with the reference materials (2, 
3 and 4 mix) confirmed the presence of 2 and 3 correspondingly (see Table 
12, Figure 24 and Figure 25). 
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This indicates that the validated HPLC method is quicker (10 min run time, see 
the chromatograms in Figure 24, Figure 25) than Geyer’s GC-MS method (45 
mins).[74] Therefore, this shows that this HPLC method can be utilised to 
identify and separate MXP positional isomers, which are present in any street 
sample (see Figure 24 and Figure 25).  
 
Figure 24. St S1 measured on HPLC (St S1a peak) 
 
Figure 25. St S2 measured on HPLC (St S2 peak a and peak b) 
 
The developed/validated HPLC method was applied to test street samples 
suspected to contain MXP isomers, these samples were quantitatively 
determined and the results are shown in Table 12). From the findings, these 
samples contain 2 and 3. In addition, it is clear that the total run time for these 
compounds using the validated HPLC method is 10 minutes (Figure 24, Figure 
25), while the total run time was greater than 44 minutes when these 







Table 12. Bulk samples tested on HPLC (MXP isomers). Key: tR = Retention time, St 















St S1  2, tR = 3.88 min 58.12 10.20 10.05 98.50 
 2, tR = 3.89 min 64.62 10.20 11.18 109.60 
 2, tR = 3.90 min  35.31 10.20 6.09 59.70 
St S2  3, tR = 6.18 min 17.95 3.03 3.77 124.40 
 2, tR = 3.90 min 40.93 10.20 7.07 75.50 
 3, tR = 6.18 min 18.63 3.92 3.92 100.00 
 
One of the advantages of the HPLC method in this study is that it has shown 
the ability to completely separate 2, 3 and 4 in a mixture in a 10 minute run 
with higher resolution (Rs >3, see Table 12, [128]), and more sensitive 
detection  and quantification. LOD and LOQ were determined as being 0.04–
0.15 µg mL-1 and 0.38–0.47 µg mL-1correspondingly (Table 7). While, in 
Geyer’s method the three MXP regioisomers were partially baseline resolved 
or separated with lower sensitivity (LOD was between 4.58 and 5.71 µg mL-1 
whereas LOQ was between 13.88 and 17.30 µg mL-1).[74] 
In conclusion, after applying the developed HPLC method to test bulk samples 
that were suspected to contain 2, 3 and 4, it has proven its ability to analyse 
these samples qualitatively and quantitatively. i.e. their detection (different 





This chapter details the analysis of three methoxphenidine isomers 
encountered in NPS forensic samples using HPLC and GC-MS. The validated 
HPLC method provides both a general screening method and quantification of 
the active ingredients for seized solid samples, both in their pure form and in 
the presence of common adulterants.  
All analyses were undertaken on reference standards prepared in-house and 
then cross-validated with two bulk samples obtained from an internet vendor. 
One of the main findings is that the validated method has the advantage of a 
rapid single-step detection and separation of these street samples in just a 10 
minute run time.  
The method provided excellent LOD (0.04-0.15 µg mL-1) and LOQ (0.38-0.47 
µg mL-1); it acts as an ideal method for both the qualitative and quantitative 
analysis of MXP isomers, when compared to the previous approaches in the 
literature.   
The unique result, in comparison to the previous published chromatographic 
studies on MXP isomers, which is that 3 and 4 were fully baseline-separated 
with a good resolution (Rs= 3.88, see validation data in Table 7 and Figure 
20).  
From the results, the various spectroscopic information provided herein acts 
as an important source of characterisation data (1H-NMR, 13C-NMR, COSY, 
DEPT, HMQC, HMBC, UV  and ATR-FTIR) for the reference materials 
utilised in this work and serves as an additional resource to the previously 
published data regarding routine analysis of MXP isomers in the laboratory. 
To conclude, the developed HPLC method is suitable for the rapid, specific 
and sensitive detection, quantification and control of 
methoxphenidines present within bulk forensic samples. Finally, further 
research on the relationship between all chromatographic parameters in 
depth to achieve a faster run time is recommended. 
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Chapter 4: Development and validation for the separation of the 
regioisomers of fluephenidine using Reversed Phase HPLC 
 
4.1 Fluephenidine  
Fluephenidines (FEP) are fluorinated diphenidine derivatives and, as such, 
they are new psychoactive substances (NPS).[131-134] NPS are a challenge 
to forensic toxicologists as a large number of drugs are emerging each year 
and they are nowadays repeatedly encountered in clinical and post-mortem 
toxicology investigations and there is a requirement for sensitive and reliable 
techniques to detect and identify these substances in a variety of different 
samples.  
This chapter discusses the experimental investigation of FEP isomers, 8-10 
and the aim of this study is to identify, separate and quantify these substances 
both as separate components or in a mixture in any forensic framework by 
carrying out a full characterisation using a number of analytical instrumentation 
such as HPLC, IR and NMR. This will add to the existing literature of 
diphenidine derivatives. The chemical structures of the fluephenidines, 8-10, 
are shown in Figure 26. 
 
 
Figure 26. The chemical structures of 2-FEP (8), 3-FEP (9) and 4-FEP (10) 
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4.2 Results and Discussion 
4.2.1 Synthesis of FEP isomers 
The three FEP compounds, 8-10, were prepared in-house using an adaption 
of the method reported by Geyer et al.,[135] (see Chapter 3) and isolated as 
their corresponding hydrochloride salts. [MC Hulme, PhD thesis: “"New 
Psychoactive Substances - New Analytical Challenges", Manchester 
Metropolitan University (2019)], [136]. 
In comparison with MXP (2), there is an ethyl group instead of the piperidine 
ring in these compounds (FEP) and a fluorine instead of a methoxy group 
attached to the benzene ring. However, the FEP derivatives possess some 
structural similarities to MXP, such as the molecular backbone. To confirm the 
authenticity of the materials used in this study, these synthesised samples (8-
10) were fully structurally characterised by using 1H-NMR, 13C-NMR, 19F-NMR, 
UV and FTIR.  
4.2.2 Ultraviolet spectroscopy 
The UV-Vis spectra of 8-10 were collected on a UV-Vis spectrophotometer; 
the UV-visible spectrum showed that all three FEP isomers exhibit a max at 
270 nm. Therefore, there is no real significant difference in the absorption 
properties of the three regioisomers investigated (See Appendix A 3, Appendix 
A 4 and Appendix A 5). The absorbance wavelength is higher in energy than 
what was observed for the MXP isomers (e.g. for 2-MXP = 278 nm, see 
Chapter 3). From these data, the molar absorptivity (ɛ) for each isomer was 
calculated. For 8, ɛ270 nm= 501 L mol-1 cm-1, whereas for 9 and 10 ɛ270 nm= 727 
L mol-1 cm-1 and 552 L mol-1 cm-1, respectively. Thus, 8 and 10 have similar 
molar absorptivities whereas 9 has the highest molar absorptivity. As 8 and 10 
are ortho- and para-substituted respectively, with respect to fluorine, the 
electronic effects around the ring would be similar, in contrast to when the ring 
is meta-substituted. These data contrast with the methoxphenidine isomers 
(see Chapter 3) as the molar absorptivities for 2-4 are 1290 L mol-1 cm-1, 1100 
L mol-1 cm-1 and 660 L mol-1 cm-1 respectively. Thus, exchanging the methoxy 
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group for fluorine substituent acts to reduce the molar absorptivity observed. 
i.e. the intensity of absorption of UV light by methyl group in (2-MXP) at a given 
wavelength ( max = 278 nm) is greater than the intensity of absorption of 
fluorine in (2-FEP) at a given wavelength ( max = 270 nm).  
The absorbance for all three isomers at 270 nm were within the range of around 
0.5 and just below 1.5, which is acceptable because the linear absorbance 
range of most spectrometers is between 0.1 and 1. For any measured 
absorbance that is at or above 1.0, this means that the sample needs to be 
diluted. In this experiment, the maximum wavelength at 270 nm was applied 
as one of the parameters used in HPLC method development and validation 
of FEP regioisomers.  
4.2.3 Infrared spectroscopy 
In this study, the ATR-FTIR spectra of the three FEP regioisomers were 
obtained, see Figure 27 (8), Appendix A 20 (9) and Appendix A 21 (10). By 
consideration of the data, the C-H stretches of the three FEP isomers appear 
at the following wave numbers: 2974 cm-1 (8), 2969 cm-1(9) and 2971 cm-1 
(10), respectively. The corresponding aromatic C=C stretches were observed 
at 1580 and 1452 cm-1, 1589 and 1454 cm-1, and 1580 and 1454 cm-1, for 8-
10. The C-H wag (strong) is located at 756 cm-1 (Figure 27) with a 
transmittance of approximately 45%. In comparison, for the other two FEP 
isomers, the same peak is observed at 790 and 753 cm-1 for 9 and 10 
respectively, although these peaks are not strong as they have a transmittance 
of about 75%.  
Peaks in the fingerprint region (1500-400 cm-1) arise from complex 
deformations of the molecule. They may be characteristic of molecular 







Figure 27. The ATR-FTIR spectrum of 8 
The carbon-fluorine stretching region is 785–540 cm-1. In the spectrum of 8 
there is a strong peak at 695 cm-1 which is attributed to the C-F stretch. 
Similarly, stretching frequencies are seen for 9 and 10 (696 and 695 cm-1, 
respectively). The similarity in these stretching frequencies means that the 
compounds cannot be differentiated using this individual stretching mode. The 
bands at about 2860 cm-1 (weak) are possibly due to the symmetric (C-H) 
vibrations of CH2 groups. Taken together, these results suggest that the 
change of position of the fluorine of the phenyl group gives different IR spectra 
depending on the FEP compound under investigation. This facilitates the 
identification of each compound from other FEP isomers. 
4.2.4 Nuclear Magnetic Resonance (NMR) 
The 1H and 13C NMR data of the three FEP isomers (as their hydrochloride 
salts) were obtained using DMSO as a solvent (1H peak at 2.50 ppm, 13C peak 
at 39.5 ppm).  
In the1H NMR spectrum of 8 (Figure 28), there are two broad peaks at δ 10.22 
and 9.69 which are both assigned to NH protons. The observation of two 
different signals entails that the NH protons are inequivalent, which could be 
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brought about by the chiral centre adjacent to this environment. Similar 
chemical shifts for the NH protons are seen for 9 and 10. 
The aromatic region of 8 (Figure 28) is complex due to the seven different 
aromatic 1H NMR environments that it possesses. Despite the presence of 
fluorine, the 1H-19F splittings are not readily visible. In fact, it is difficult to 
discern any notable peaks in this region that would aid structural elucidation. 
It is, however, readily apparent which regioisomer is para-substituted when 
contrasting 8 with 9 and 10; in the case of 10 (Appendix A 24), the aromatic 
region simplifies due to the increased symmetry of the fluorinated ring. 
However, only the 1H nuclei beta to the C-F site possess splitting that can be 
measured (3JHH = 8.8 Hz, 4JHF = 5.5 Hz); the 1H nuclei alpha to the C-F site 
appear as a multiplet.  
The aliphatic region of the 1H NMR spectrum is more readily interpreted, in that 
the chiral CH of 8 is observed at δ 4.7 and the diastereotopic protons that this 
environment couples to are located at δ 3.19 and 3.66. However, when 
compared with 9 and 10, the values for the diastereotopic protons do not show 
significant chemical shift whereas that of the chiral CH are almost identical 
being 4.54 and 4.51 ppm respectively (Appendix A 22 and Appendix A 24). 
The backbone can therefore not be used to discriminate these regioisomers 
from a 1H NMR viewpoint.  
The 13C{1H} NMR spectrum of 8 possesses ten peaks in the aromatic region. 
The peak at 161.3 ppm is the quaternary carbon to which the fluorine 
substituent is attached; it possesses a 1JCF of 245 Hz. Three further peaks, 
located at δ 116.4, 123.3 and 132.5, also possess JCF coupling of 22, 14 and 
8 Hz respectively. The signals at δ 116.4 and 123.3 is the CH and quaternary 
carbon ortho to C-F respectively whereas the peak at δ 132.5 is the CH meta 
to C-F and para to the quaternary ring carbon. The six remaining signals in the 
aromatic region display no C-F coupling.  
The aromatic region of 9 also possesses ten peaks, just like 8. However, due 
to the fluorine substituent now being positioned meta to the quaternary ring 
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carbon, there are more peaks present that possess C-F splitting. The C-F 
carbon is observed at 163.0 ppm and possesses a 1JCF coupling of 243 Hz. 
The two carbons that are alpha to this position are found at 116.8 and 116.5 
ppm and display 2JCF coupling of 21 and 22 Hz respectively. Two further peaks, 
located at 131.7 and 138.5 ppm, show 3JCF coupling of 8 and 7.5 Hz 
respectively.  
In contrast to 8 and 9, 10 only possesses eight peaks in the aromatic region. 
This is because the fluorine is now positioned para to the quaternary ring 
carbon, thus leading to a symmetric system. The peak for the carbon directly 
attached to fluorine is observed at δ 163.1 and possesses JCF coupling of 244 
Hz. This means that this signal would overlap with the same signal of 9 if 
present in the same sample. The three remaining signals for the fluorinated 
ring are located at 116.5, 132.1 and 132.0 ppm. These signals correspond to 
the CH ortho to the C-F, the C-H meta to the C-F and the quaternary ring 
carbon respectively. The value of JCF decreases in the order 21.3, 8.4 and 2.9 
Hz as the carbon-fluorine spin-spin interaction decreases (See Figure 29, 
Appendix A 23 and Appendix A 25). 
Four aliphatic signals are present in the 13C{1H} NMR spectrum of 8 and this 
matches the expected number. The most shielded carbon environment is that 
of the CH3 group of the ethyl chain (δ 12.0), whereas the other three signals at 
δ 39.3, 41.4 and 55.8 are deshielded. The peak at δ 41.4 corresponds to the 
CH2 of the ethyl chain whereas the peaks at δ 39.3 and 55.8 are the remaining 
CH2 and CH respectively. When compared to 9 and 10, there is very little 
change in this part of the spectrum with the exception of the chiral CH 













4.2.5 High performance liquid chromatography (HPLC) 
A HPLC method was developed to separate the FEP isomers (and then 
validated in accordance with the ICH guidelines)[137] using the same 
parameters applied during the method development for MXP isomers; these 
parameters include the mobile phase, temperature, flow rate and the column 
etc. as was shown in Chapter 3. In method development, modelling can be 
applied such as by using computer-aided method-development programs that 
require accurate models to describe retention and to make predictions based 
on a limited number of factors or experiment parameters. No modelling was 
applied to optimisation of the developed HPLC method in this research project.   
4.2.5.1 HPLC Method Optimised (FEP isomers) 
This HPLC method for testing FEP compounds was the HPLC method used 
for testing MXP isomers, by applying the same conditions using mobile phase 
acetonitrile:ammonium acetate 55:45% v/v, flow rate 1.0 mL min-1, 
temperature 50°C and the column ACE 5 C18-AR (150 x 4.6 mm, 5 µm particle 
size). The total run time in this experiment was 10 minutes.  
Due to the poor resolution (0.60), the proportion of the organic modifier was 
reduced to improve the resolution (2.11) between the peaks. In addtion, the 
flow-rate was investigated to improve the run time; the final optimised flow rate 
was 1.5 mL min-1. The UV wavelength of maximum absorbance of FEP 













Table 13. Representative data for the HPLC method development by modifying the 
flow rate and mobile phase percentage for the separation of the FEPs 8-10 using 
acetonitrile:ammonium acetate as the mobile phase. Key: Rs (8 and 9) = Resolution 
between 8 and 9 peaks 
 
As can be seen from the data, the resolution was improved significantly by 
reducing the percentage of acetonitrile in the mobile phase, for example: (1.84-
1.95) in all four flow rates using mobile phase percentage of 30:70% v/v. 
However, after applying the flow rate of 1.5 mL min-1 the resolution decreased 
again to about 1.9, this value also dropped to almost 1.8 when the flow rate of 
1.7 mL min-1 was employed. Lastly, by applying acetonitrile:ammonium acetate 
25:75% v/v proportion using the flow rate 1.5 mL min-1, the resulting resolution 
was 2.11.  
In conclusion, from these four experiments, in which the mobile phase organic 
% Acetonitrile:ammonium 
acetate 
Flow rate (mL 
min-1) 
Rs (8 and 
9) 
Total Run time 
(min) 
55:45% v/v 1.0 0.60 10 
40:60% v/v 1.0 1.28 10 
30:70% v/v 1.2 1.87 20 
1.3 1.95 20 
1.5 1.91 20 
1.7 1.84 15 
25:75% v/v 1.5 2.11 25 
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component was varied along with the flow rate, an optimised mobile phase and 
flow rate (acetonitrile:ammonium acetate 25:75% v/v and 1.5 mL min-1, 
respectively) were identified. These parameters will be applied to the HPLC 
method validation of the FEP isomers, this is despite the total run time being 
long (25 minutes); this is 2.5 times longer than that utilised for the MXP isomers 
(see Chapter 3). The improvement in resolution is because the retention factor 
k is increased by decreasing the percentage of organic modifier in the mobile 
phase.  
Although HPLC method development will continue to be based on 
chromatographer’s experience, software and mathematical models in method 
prediction may save a lot of the laboratory budget for organic solvents, not to 
mention the greener chemistry that will be achieved. For example using the 
statistical Design of Experiment (DOE) to develop a simple and robust 
reversed-phase HPLC technique. [138]  
4.2.5.2 Method Validation of FEP isomers 
This validation was performed according to the optimised method for MXP 
regioisomers (chapter 3), using the same column. This method was also 
validated in accordance with the ICH guidelines [128] using the same 
parameters as detailed previously. The percentage RSD was calculated for 
each replicate sample. The method shows excellent linearity (R2 = 0.999) over 
the 10-60 µg mL-1 range with good repeatability in each case (% RSD = 0.03 




Table 14. Representative validation data for FEP isomers obtained using an ACE 5 
(150 x 4.6 mm i.d, 5 µm) column. Mobile phase: acetonitrile: ammonium acetate 
25:75% v/v, flow-rate: 1.5 mL min-1, measured at 270 nm; detector: UV-DAD 
Key: (a) Determined from the retention time of a solution of uracil (0.5 µg mL-1) eluting from the column; 
(b) limit of detection (based on the standard deviation of the response and the slope); (c) limit of 
quantification (based on the standard deviation of the response and the slope).(d) Y = 0.7497X + 0.0088; 
(e) Y = 2.1963X - 0.4057; (f) Y = 1.871X - 0.8858. 
Sample 10 8 9 
tR (min)(t0=1.29min)
a 17.47 21.45 23.35 
RRT 1.22 1.00 0.91 
Capacity Factor (K’) 16.47 20.45 22.35 
Resolution (Rs) - 5.26 2.16 
Asymmetry (As) 0.75 0.97 0.84 
LOD (µg mL-1)b 0.47 0.23 0.60 
LOQ (µg mL-1)c 1.43 0.70 1.84 
Regression coefficient (r2) 0.9996 0.9999 0.9993 
Equation Y = 0.7497X + 0.0088 Y = 2.1963X - 0.4057 Y = 1.871X - 0.8858 
Precision    (%RSD) 
10 µg mL-1 0.03 1.41 1.38 
20 µg mL-1 0.93 1.38 0.77 
30  µg mL-1 1.38 0.57 0.73 
40  µg mL-1 0.68 0.58 0.27 
50  µg mL-1 0.95 0.21 0.61 
60  µg mL-1 0.32 0.17 0.55 
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Table 14 shows the data for the HPLC method validation of FEP regioisomers 
using an ACE 5 column, acetonitrile:ammonium acetate 25:75 % v/v as the 
mobile phase and a flow rate of 1.5 mL min-1. Six different concentrations 
ranging from 10 to 60 µg mL-1 were tested. Uracil provided a single sharp peak 
at about 1.3 minutes, this is known as t0, which is the time for the unretained 
compound (uracil) to travel through the column or to reach the detector.  
As is observed from the validation table, excellent peak shapes and asymmetry 
factors were obtained (0.75, 0.84 and 0.97) with no fronting or tailing. The limit 
of detection or LOD (0.23-0.60 µg mL-1) represents the lowest detectable 
concentrations and the limit of quantification, whereas LOQ (0.70-1.84 µg mL-
1) is the lowest amount that can be quantified. The resolution was within the 
required range (5.26-2.16), while the retention time ranged from just over 17 
minutes to just below 24 minutes. 
As can be seen in the table, the precision (% RSD) was calculated for all the 
6 concentrations and was just below 1 except for the lowest concentrations, 
such as 10 µg mL-1, where it was approximately 1.40; this is perhaps due to 
low precision with respect to low concentrations. The highest concentrations 
(30-60 µg mL-1) gave good %RSD with values less than 1. 
 
 
Figure 30. HPLC separation of FEP isomers (concentration = 50 µg mL-1). Key: 10 
(17.5 min), 8 (21.5 min) and 9 (23.4 min), respectively.  
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The chromatogram (Figure 30) demonstrates that the three isomers are fully 
baseline separated (Rs > 2) in under 25 minutes run time. The order of elution 
was as follows; 10, 8 and 9, respectively. Among the separated compounds, 
10 was detected at 17.5 minutes, which is about 4 minutes before the 
appearance of 8 at 21.5 minutes and around 2 minutes later, the last peak of 
9 at 23.4 minutes was detected. The obtained resolution values (ranged from 
over 2 to just over 5) are acceptable for separating FEP isomers. Lastly, as 
can be noted from the chromatogram the shape of the peaks was excellent. 
10 shows a bit of tailing which could be due to various mechanisms such as 
nonspecific hydrophobic interactions with the stationary phase. However, polar 
interactions with any ionized residual silanol groups on the silica support 
surface are also common. Compounds possessing amine and other basic 
functional groups interact strongly with such ionised silanol groups. i.e. tailing 
occurs when some sites on the stationary phase retain the solute more strongly 
than other sites. Capacity factors of 8 and 9 (greater than 20) mean that elution 
takes a very long time. Ideally, the capacity factor for an analyte is between 1 
to 5, capacity factors of all three MXP isomers were less than 5 (see Chapter 
3). 
In summary, it can be proposed that the applied HPLC method was able to 
detect and separate the fluephenidine isomers in a reasonable time interval, 
and with good resolution. Gradient method or GC could be possible solutions 
to obtain shorter retention times compared to this isocratic method.  
4.2.5.3 Robustness of the Method (FEP isomers) 
The robustness of the method for separating the FEP isomers was assessed 
by measuring the intra- and inter-day precision, temperature, flow rate and the 
percentage of mobile phase composition, by following the same procedures as 
previously mentioned for the MXP isomers (see Chapter 3), a concentration of 
50 µg mL-1 was used and 10 injections utilised. Firstly, both inter-day and intra-
day precession were tested. Secondly, the used temperatures (48, 50 and 
52°C) were the same as for MXP isomers. Thirdly, the flow rates were as 
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follows: 1.4, 1.5 and 1.6 mL min-1. Finally, the percentages of mobile phase 
(acetonitrile:ammonium acetate) were modified in the following proportions: 
24:76, 25:75 and 26:74% v/v (Table 16).  
4.2.5.3.1 Robustness testing (intra- and inter-day precision)  
The table in Appendix A 26 shows data on the intra- and inter-day precision 
measurements for the three fluephenidine isomers using mobile phase 
acetonitrile:ammonium acetate 25:75% v/v, flow rate 1.5 mL min-1 and at a 
working concentration of 50 µg mL-1 and ten injections in the HPLC. The inter-
day refers to that the measurement is occurring within or between two days, 
while intra-day means that they are occurring within one day. As is observed 
in the table, for both intra- and inter-day measurements, the retention time 
remained almost constant for the three FEP isomers, as relative tR (RRT) for 
10, 8 and 9 were 1.23, 1.00 and 1.08, respectively. The percentage RSD is on 
average from about 0.25-0.30 for intraday measurements and about 0.10-0.15 
for inter-day precision, which refers to a very slight difference in the detection 
precision without affecting the retention times of these isomers. 
In summary, these results indicate that the optimised HPLC method used here 
has a good precision after testing the FEP sample at different times throughout 
the 24 hours. This also means that this method is valid/robust to use at various 
times. 
4.2.5.3.2 Robustness testing (Flow Rate and van Deemter equation)  
The table in Appendix A 27 compares data on the effect of testing three 
different flow rates on the retention times of FEP isomers, 8, 9 and 10, using 
ten injections and a concentration of 50 µg mL-1. It is clear from the results that 
an overall trend is that by increasing the flow rate from 1.4-1.6 mL min-1 the tR 
is decreased. The resolution between 8 and 9 peaks was on average 2.1 for 
all three flow rates utilised, whereas, the value of the resolution between the 
peaks of 10 and 8 was on average 5.1 for all three runs. The optimum flow rate 
in this experiment is 1.5 mL min-1 because the resolution was the highest (5.01) 
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compared to the flow rates 1.4 and 1.6 mL min-1, and because obtaining the 
highest resolution value is the main goal for optimum separation (see van 
Deemter equation in the introduction chapter). 
4.2.5.3.3 Robustness testing (Temperature 48, 50 and 52°C) and the Van’t 
Hoff plot of FEP isomers  
Table 15 and Figure 31 show information relating to robustness testing  
(temperatures used: 48, 50 and 52°C) and the Van’t Hoff plot for the three FEP 
 
Table 15.  Robustness testing (temperature = 48, 50 or 52°C) for the three FEP 
analytes using a mobile phase consisting of acetonitrile:ammonium acetate 25:75% 








tR (min) using temp. 48 °C tR (min) using temp. 50 °C tR (min) using temp. 52 °C 
10 8 9 10 8 9 10 8 9 
1 16.76 20.56 22.38 16.92 20.56 22.39 16.69 20.64 22.44 
2 16.76 20.56 22.38 16.93 20.56 22.38 16.70 20.65 22.45 
3 16.77 20.57 22.39 16.92 20.56 22.39 16.70 20.66 22.45 
4 16.77 20.57 22.39 16.94 20.57 22.39 16.71 20.65 22.45 
5 16.78 20.57 22.38 16.94 20.57 22.39 16.72 20.66 22.46 
6 16.79 20.58 22.40 16.95 20.58 22.41 16.73 20.67 22.47 
7 16.80 20.59 22.41 16.94 20.57 22.40 16.73 20.67 22.47 
8 16.80 20.59 22.41 16.95 20.57 22.40 16.74 20.68 22.48 
9 16.81 20.60 22.42 16.95 20.58 22.40 16.75 20.69 22.49 
10 16.82 20.61 22.43 16.97 20.59 22.41 16.76 20.69 22.50 
Average  16.79 20.58 22.40 16.94 20.57 22.40 16.72 20.67 22.47 
STD 0.022 0.015 0.018 0.015 0.008 0.008 0.023 0.016 0.019 
%RSD 0.136 0.073 0.081 0.088 0.038 0.039 0.139 0.078 0.086 
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analytes using mobile phase (acetonitrile: ammonium acetate 25:75% v/v) and 
concentration of FEP of 50 µg mL-1. It is notable that tR was almost constant 
despite minor changes in the temperatures used in this experiment with an 
average of 16.7, 20.5 and 22.4 minutes, and relative retention times of 1.22, 1 
and 0.92 for 10, 8 and 9 respectively. The resolution values as an average is 
5.1 between the two peaks of 10 and 8, whereas in the case of resolution 
between the peaks of 8 and 9, it was 2.1 by taking the average of the three 
temperature observations. It is interesting to note that the retention time of the 
three compounds 8, 9 and 10 was almost the same (Appendix A 28). The 
overall trend for changing temperature by 2°C (i.e. 50±2°C) did not have any 
significant effect on the retention factor and resolution values. There is difficulty 
associated with the discussion of the effect of temperature and also the 
enthalpy and entropy changes in this narrow temperature range for 8-10. 
As is shown in Figure 31, the three FEP isomers show a linear Van’t Hoff plot 
suggesting that the retention mechanism is the same, which is similar to MXP 
isomers, and Boateng findings (see chapter 3); it can be noted that the trend 
lines of 8, 9 and 10 are almost parallel indicating that these isomers behave in 
the same way chromatographically. i.e. in their binding with the silanol groups 
in the stationary phase (hydrophobic interaction). 
 
 
Figure 31. Van’t Hoff plot of ln k versus 1/T for fluephenidine isomers (8, 9 and 10) 
114 
 
4.2.5.3.4 Effect of minor modifications to mobile phase composition. 
The data presented in Table 16 shows the results of the experimental 
investigation in which the proportion of mobile phase, acetonitrile:ammonium 
acetate, was modified and how this effected the robustness of the HPLC 
method applied to separate 8, 9 and 10. As is observed from the obtained data, 
increasing the percentage of the organic part (acetonitrile) of the mobile phase 
had far better resolution than using less organic solvent. According to the data 
in Table 16, the used percentage of 25:75% v/v (acetonitrile:ammonium 
acetate) gave better retention times and resolutions in this study, for example 
if 25:75% v/v was compared to 26:74% v/v. Nonetheless, the former ratio is 
still better than the latter; when considering the obtained resolution of 2.11 
(relative to 2.04) between the peaks of 8 and 9. Again, the 25:75% v/v 
proportion was far better than the other two proportions with regard to the 
resolution values obtained from the three different experiments. The resolution 
value between the first two eluted peaks (10 and 8) was 4.92 using the 
percentage 24:76% v/v, while between the last eluted two peaks (8 and 9), the 
resolution was 5.01 when 25:75% v/v was applied (see Appendix A 28). The 
solutes of FEP isomers (8-10) are retained in the column; by increasing the 
percentage of the organic modifier (acetonitrile) from 24-26% v/v, the retention 
time of these compounds is decreasing, in agreement with linear Van’t Hoff 
plots.  
By increasing the percentage of the organic modifier (acetonitrile) from 24 to 
25% and then to 26% the retention time of the FEP isomers (8, 9 and 10) are 
decreasing. Similar to MXP isomers, ChemDraw software was used to predict 
log P of FEP isomers, in this case it equals 4.09, which is slightly less than 
MXP isomers (4.58). Again, this confirms that FEP isomers possess a 
hydrophobic effect as a mechanism of retention.  
In conclusion, in all the experiments of robustness testing on HPLC, by 
applying minor changes in experimental parameters such as flow rate, 
temperature and mobile phase composition there were minor changes in tR  
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and resolution, while both RRT and peak area remain constant. The resolution 
values obtained for FEP isomers during the three robustness experiments are 
shown in Appendix A 28, the results displayed in this table represent the 
average of 10 injections in all robustness experiments. 
 
Table 16. Robustness testing (Mobile phase percentage) for the three FEP analytes 
using a mobile phase consisting of acetonitrile:ammonium acetate 24:76% - 26:74% 







tR (min) using 
acetonitrile: 
ammonium acetate 
(24:76 % v/v) 
tR (min) using 
acetonitrile: 
ammonium acetate 
(25:75 % v/v) 
tR (min) using 
acetonitrile: 
ammonium acetate 
(26:74 % v/v) 
10 8 9 10 8 9 10 8 9 
1 18.58 22.70 24.75 17.19 20.99 22.85 15.63 19.08 20.72 
2 18.66 22.72 24.77 17.18 20.98 22.84 15.48 18.92 20.56 
3 18.65 22.72 24.76 17.19 20.98 22.83 15.59 19.00 20.61 
4 18.66 22.73 24.76 17.19 20.97 22.83 15.49 19.15 20.49 
5 18.68 22.73 24.77 17.18 20.97 22.82 15.62 19.03 20.71 
6 18.68 22.73 24.77 17.19 20.96 22.82 15.58 19.10 20.56 
7 18.67 22.74 24.78 17.18 20.96 22.82 15.57 19.20 20.63 
8 18.69 22.74 24.79 17.18 20.96 22.82 15.61 19.02 20.57 
9 18.69 22.75 24.79 17.19 20.97 22.82 15.48 19.10 20.75 
10 18.70 22.75 24.79 17.20 20.97 22.83 15.63 18.98 20.56 
Average  18.67 22.73 24.77 17.19 20.97 22.83 15.57 19.06 20.62 
STD 0.032 0.015 0.014 0.006 0.008 0.009 0.060 0.082 0.084 
%RSD 0.176 0.066 0.060 0.037 0.040 0.041 0.390 0.431 0.408 
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4.2.5.4 Accuracy of the method and determination of percentage recovery 
(FEP isomers) 
Table 17. Determination of % Recovery for the FEP regioisomers 
 
Table 17 presents data regarding the determination of accuracy of HPLC 
method and percentage recovery of three FEP isomers, using three different 
concentrations (40, 50 and 60 µg mL-1) with an average of six injections each. 
From the results of the three concentrations investigated in this experiment, 
the RSD (0.2 – 0.8%), indicated excellent injection repeatability according to 
ICH guidelines.[137] In conclusion, according to these findings, it is obvious 
that the results of percentage recovery were within the ICH limit i.e. 98-102% 
and the percentage RSD was less than one, indicating excellent precision. 
Additionally, this confirms that the applied method for analysis of fluephenidine 
isomers is accurate and suitable for routine analysis of any sample that might 
contain these analytes. 
 
Theoretical conc. = 
40 µg mL-1 
Theoretical conc. = 
50 µg mL-1 
Theoretical conc. = 
60 µg mL-1 
Injection 10 8 9 10 8 9 10 8 9 
1 98.7 98.7 99.2 99.7 98.5 99.8 99.4 98.03 99.32 
2 100.2 98.4 98.9 101.1 98.4 99.8 99.6 98.23 98.7 
3 99.2 98.5 98.9 100.9 98.2 99.8 99.9 98.34 98.7 
4 99.3 97.4 98.5 100.7 98.6 98.7 99.8 98.14 98.1 
5 99.2 98.4 98.8 98.6 98.1 98.8 99.8 98.32 97.7 
6 99.2 97.5 98.9 100.9 98.6 98.7 100.4 98.54 98.55 
Average 99.3 98.1 98.8 100.3 98.4 99.2 99.8 98.2 98.5 
STD 0.489 0.554 0.231 0.976 0.209 0.585 0.337 0.176 0.557 
%RSD 0.493 0.564 0.233 0.973 0.213 0.589 0.337 0.179 0.565 
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4.3 Forensic Application  
Three bulk forensic samples of FEP were obtained from Greater Manchester 
Police via the MANchester DRug Analysis and Knowledge Exchange 
(MANDRAKE) partnership. The three samples were analysed using the 
developed HPLC method i.e. using acetonitrile:ammonium acetate 25:75% v/v 
as the mobile phase (Table 18, Figure 32, Figure 33 and Figure 34). 
Table 18. Bulk samples tested on HPLC (FEP isomers). Key: tR = Retention time, St 
S1-3 = Street Sample 1-3 
 
Table 18 displays qualitative and quantitative data for the three bulk samples   
using the developed HPLC method in this study. The obtained retention times 
(tR), peak areas, actual and found concentrations are presented in units of 
microgram per millilitre, and the percentage of the detected FEP analyte in 
these sample are shown in the table. A representative chromatogram of a 
street sample is shown in (Figure 32). The peak at 1.28 mins is the uracil peak. 
All the three street samples were run three times each; the results show that 
St S1 contains only one FEP compound (8), while St S2 contains two FEP 

















St S1          8, tR = 21.1 94.43 50.16 43.18 86.09 
St S2          8, tR =  21.1 29.37 49.65 13.56 27.31 
                   9, tR =  22.1 59.69 49.65 32.37 65.19 
St S3          8, tR =  21.1 48.76 50.50 20.36 40.31 




Figure 32, Representative HPLC chromatogram of Sample 1 (St S1) containing: uracil 
(peak at 1.28 min) and 8 at 21.07 minutes 
 
As is seen in Table 18, 8 was detected in all the three samples (St S1, 2 and 
3) whereas 9 was only found in St S2 and 3. 10 was not identified in any of the 
street samples. The presence of two FEP isomers in one bulk sample could 
be due to mixing of many substances in one sample. This observation is similar 
to the findings in a study by Cumba, et al., who analysed “Synthacaine” street 
samples by an electroanalytical sensing technique and validated with HPLC, and 
found that it contained a mixture of methiopropamine (MPA) and 2-aminoindane 
(2-AI).[139] 
The St S1 had the highest percentage content of 8 (86.09% w/w) among the 
three tested samples with a peak area of 94.5, the percentage of FEP in St S3 
is just below half of that found in St S1 (40.3%), but represents around two 
thirds of its quantity in St S2 (65.19%). A possible explanation might be 
because of the different degrees of purity of these street samples. The 
chromatogram shows no peaks of other additives/adulterants, this is probably 
because they cannot be detected by using the current HPLC method. 
As can be seen in the two chromatograms below, the first (Figure 33) shows 
two peaks that were assigned to 8 and 9 in bulk sample 2 (St S2), the resolution 
between the two detected/separated peaks is 2.03, whereas in sample 3 (St 





Figure 33. Representative HPLC chromatogram of Sample 2 (St S2) containing: uracil 
(peak at 1.28 min), 8 and 9 at 21.09 and 22.95 minutes, respectively 
These values of resolution are acceptable because they are both over 2 (fully 
resolved peaks). Comparatively, it is clear that the values of peak areas (See 
the third column of the table), were consistent with the calculated percentages 
of FEP in the bulk sample (in the last column in Table 18). 
 
Figure 34. Representative HPLC chromatogram of Sample 3 (St S3) containing: uracil 
(peak at 1.28 min), 8 and 9 at 21.15 and 22.04 minutes, respectively 
In summary, both 8 and 9 were found in the investigated bulk samples and 
were separated by HPLC with good resolution and peak shape. This confirms 
the suitability of the optimised/developed HPLC method in this study for routine 
analysis of these illicit NPS (fluephenidine isomers) either in a mixture or as 
separate components. 
4.4 Conclusion 
The previously developed and validated HPLC method was applied for 
qualitative and quantitative analysis of fluephenidine isomers (FEP), which are 
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new diphenidine derived compounds and belong to NPS. The numerous 
spectroscopic data provided in this experimental investigation can be 
considered as an essential foundation of characterisation data (1H-NMR, 13C-
NMR, UV and ATR-FTIR) for the reference materials exploited in this work. 
This study detailed the analysis of samples of the three fluephenidine isomers, 
which can be encountered in NPS forensic samples using HPLC. Specifically, 
the validated HPLC method which was used to analyse MXP isomers (see 
Chapter 3) was applied with some modifications in experimental parameters, 
to analyse these fluorinated diphenidine isomers, for both qualitative and 
quantitative analysis of these substances as either seized solid samples, as a 
pure form or when mixed with common additives or adulterants.  
All analyses were carried out on reference standards prepared in-house and 
then cross-validated with three bulk samples. One of the main findings is that 
the validated method has the advantage of a rapid single-step detection and 
separation of these street samples in just under 25 minutes run time.  
Additionally, the method provided excellent LOD (0.23-.0.60 µg mL-1) and LOQ 
(0.70-1.84 µg mL-1) for all three isomers; in other words, it acts as an ideal 
method for both the qualitative and quantitative analysis of FEP isomers, 
when compared to the previous approaches in the literature.   
There is no previous published chromatographic studies on FEP isomers, as 
these are new substances synthesised by MANDRAKE at MMU. Therefore, 
the samples were tested and compared to reference standards prepared in-
house at MMU. Consequently, bulk samples containing FEP isomers were not 
encountered by forensic services.  
In conclusion, the developed HPLC method was applied to test three bulk 
samples (St S1, St S2 and St S3), the results confirmed that they all contain 
2-FEP (8) with tR of 21 mins, while 3-FEP (9) was only present in sample 2 
and 3 with a tR of 23 mins. The total run time was 25 mins, which is lengthy, 
but did yield good resolution between the peaks observed. 
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Chapter 5: Analysis of fluorocyanoephenidine regioisomers using 
Reversed Phase HPLC and three types of GC columns 
 
5.1 Fluorocyanoephenidine 
Fluorocyanoephenidine (FCEP) belongs to NPS group and they are 
derivatives of diphenidine. The chemical structure of FCEP is similar to 
fenproporex (See Figure 35, Figure 36 and Figure 37), which is utilised in the 
treatment of obesity by reducing the appetite; however, due to substance 
abuse potential, it is an illicit substance in many countries. Fenproporex has 
been shown to produce amphetamine in the urine of users. Previous studies 
show that the parent compound can be detected in a few hours after 
administration, while the amphetamine can be detected for several days.  
The therapeutic benefits of fenproporex in obesity and losing weight is still not 
supported with the presence of just limited amount of information in the 
literature, and this use poses various potential health issues, the risks that may 
cause is also another concern as an amphetamine derived compound (see 
chemical structure of amphetamine in Figure 38).[140]  
Despite the fact that data on fenproporex is limited, suicide attempts have been 
linked to it in some case reports,[141] addiction,[141, 142] subarachnoid 
hemorrhage (surrounding the brain) [143] and morphea (discoloured patches 
on the skin).[144]  
Given the lack of monitoring of fenproporex use, it is certainly possible that 
other life-threatening events are currently occurring but unrecognized. So, one 
of the motivations of conducting this experimental investigation on FCEP is to 
help gain more information on this class of drugs. FCEP compounds are similar 
to fenproporex and amphetamine in chemical structure and can produce 








Figure 36. General chemical formula of FCEP isomers. 
 
  
Figure 37. Chemical structures of FCEP isomers 
 
 
Figure 38. Chemical structure of amphetamine. 
 
5.2 Results and discussion 
  
5.2.1 Synthesis of fluorocyanoephenidine isomers (FCEP) 
 
The FCEP isomers (or FCEP hydrochloride salts) were synthesised as shown 
in Figure 39, via reaction of benzyl bromide, benzaldehyde (fluorinated), zinc 




Figure 39. Synthesis of fluorocyanoephenidine isomers (FCEP) 
 
5.2.2 Ultraviolet spectroscopy 
 
The results of testing the FCEP isomers via UV spectroscopy are shown in  
Table 19); which summarises the wavelengths of maximum absorption, 
absorbance and the concentrations used.  
 
Table 19. The UV max measurement of FCEP isomers 
FCEP 
isomer 





(L mol-1 cm-1) 
11 263 0.54 0.20 954 
12 263 0.70 0.21 1178 




Table 19 shows data on UV max measurement of FCEP isomers. As is 
presented in the illustration, the highest absorbance was for 3-FCEP. As is 
presented in the UV spectra, a max of 263 nm was observed for both 2-FCEP 
(11) and 3-FCEP (12) and this value was decreased to 258 nm for 4-FCEP 
(13) (Figure 40 and Figure 41). Furthermore, the absorbance for 4-FCEP was 
around 0.6 with some fluctuations.  
 
 
Figure 40. UV spectrum of 11 
 


























Figure 41. UV spectrum of 12 
 
5.2.3 Infrared spectroscopy 
In this study, the ATR-FTIR spectra of the three FCEP isomers were acquired 
and the results are shown below (See Figure 42, Appendix A 29 and Appendix 
A 30).  
 




























Figure 42. The ATR-FTIR spectrum of 11 
 
The most important result that can be noted in the IR spectra of FCEP isomers 
is the presence of the characteristic functional group, cyano group (C≡N) with 
stretches of intermediate intensity at the 2251 cm-1 (See Figure 42, Appendix 
A 29 and Appendix A 30).  
The IR spectra for the three fluorocyanoephenidines show that the C-H 
stretches of the three FCEP isomers appear at the range of 2960-2970 cm-1. 
The aromatic C=C stretches are seen in the range (1600 and 1450 cm-1). 
The carbon-halogen (C-F) stretching region (785 – 540 cm-1) in the spectra of 
both 11 and 12, both possess a strong peak at 698 cm-1. For 13 this signal was 
at 700 cm-1 (strong). This finding suggests that the peaks of C-F bonds can be 
found easily from the graphs of the IR spectra.  
Taken together, these results suggest that the change of position of the fluoride 
in the phenyl group from ortho, meta or para gives different types of IR spectra 
depending on the FCEP compound under investigation. This facilitates the 
identification of each isomer from other FCEP isomers. 
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These results suggest the requirement of testing these samples on more than 
one technique i.e. apart from IR, for instance, by investigating these 
compounds using NMR, GC and UV can give more detailed characterisation 
data to assist in the confirmation of identity of these isomers.  
5.2.4 Nuclear magnetic resonance 
The samples of FCEP isomers were run on high and low field NMR 
instruments. In this study, the results of NMR experiments (1H and 13C NMR) 
obtained from these two instruments were consistent for all FCEP compounds.  
In the 1H NMR spectra of the three FCEP isomers (Figure 43, Appendix A 31 
and Appendix A 32), there are two broad peaks at around δ 11.00 and 10.00; 
this is assigned to the NH group which is present in FCEP compounds. In the 
aromatic region, there is a triplet that integrates to a single proton, centred at 
δ 7.89 (11, 1 H), 7.40 (12, 2 H) and 7.52 (13, 2 H) and a multiplet at the region 
between 7.25-7.00 ppm that integrates to seven protons for all three FCEP 
compounds. By looking at the 1H NMR spectrum, the value of J coupling for 
the triplet at δ 7.89 (11) equals 12 Hz, and in 12 at δ 7.40 this value was 8 Hz 
and finally, at δ 7.53 in 13 it equals 0-1 Hz. The difference in this value is 
because of the position of the fluoro group in the benzene ring being ortho, 





Figure 43. 1H NMR spectrum of 11 
 
The aliphatic region in 11 consists of 5 proton nuclei, the signals for these 
environments are observed as simple splitting patterns, the integration of these 
regions does equal five, thus matching the proposed structure.  
The 13C NMR spectrum possesses 17 peaks, which correspond to the number 
of carbon environments in FCEP isomers. There are nine aromatic peaks, this 
number decreases to 8 in the 13C {1H} DEPT-135 spectrum due to the 
presence of three quaternaries in the structure of FCEP (See 13C NMR spectra  
Appendix A 33, Appendix A 35 and Appendix A 37), and DEPT spectra in 
Appendix A 34, Appendix A 36 and Appendix A 38). 
In 12, the peaks of the quaternary carbons are assigned to the peaks at 163.7, 
136.2 and 118.2 ppm (present in on the benzene ring), these peaks are not 
present in the DEPT spectrum. In the 13C{1H} NMR spectrum, the peak at 
118.2 ppm is the quaternary carbon to which the fluoro group is attached to 
the benzene ring – this was rationalised from the 1H-13C HMQC spectrum 
(Heteronuclear Multiple-Quantum Correlation) as it was the only signal that 
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showed this interaction (i.e. the peaks of FCEP isomers (7.4-7.9 ppm), all have 
a cross peak with the peak at 118.2 ppm). The advantage of using 2D HMQC 
is that it permits the collection of a 2D heteronuclear chemical shift correlation 
map between directly-bonded 1H and 13C nuclei.   
In 12, the peak at 62.7 ppm is positive in the 13C{1H} DEPT-135 spectrum, 
which suggests a CH or CH3 group. Similarly, this peak is shown for 11 at 56.1 
ppm and at 62.5 ppm in the case of 13. The 1H-13C HMQC data for FCEP 
isomers showed the following cross peaks: in the HMQC spectrum of 11 (See 
Appendix A 40), the cross peak is between peaks at 4.79 and 56.1 ppm, 
whereas for 12 and 13 the cross peaks are between peaks at 4.56 and 62.7 
ppm, and 4.60 and 62.5 ppm respectively. 
In the 1H-1H COSY spectrum, 11 possesses two cross peaks. The first is 
between peaks at 4.79 and 10.9 ppm and another between peaks at 2.45 and 
7.89 ppm (Appendix A 39), while in 12, there are 3 cross peaks (between peaks 
at 4.5 and 4.2 ppm, 7.45 and 1.60 ppm, and 10.99 and 9.95 ppm). For 13, 
cross-peaks were observed between peaks at 4.2 and 4.55 ppm and 7.1- 7.9 
ppm.  
Finally, in the 19F NMR (fluorine NMR) of these compounds, the fluorine is 
observed at δ = -118.67 (11), at δ = -113.93 (12) and at δ -114.56 (13), this 
shows that these three fluorinated diphenidine isomers can be differentiated 
by running 19F NMR as each FCEP isomer has a unique peak. Overall, the 
chemical structures of the three FCEP can be recognized from the NMR data 
collected in these experiments using trifluoroacetic acid (TFA) as a reference 





Figure 44. 19F NMR spectrum of 2-FCEP (11) isomer  
 
5.2.5 High performance liquid chromatography (HPLC) 
  
5.2.5.1 Detection and separation of FCEP isomers on HPLC 
These experiments were carried out after testing the column (ACE 5 C18-AR, 
15 cm) prior to applying the HPLC method and reversed phase 
chromatography in an analogous way as for MXP and FEP (see chapters 3 
and 4). 
5.2.5.2 Column test  
The column was tested and the retention times (tR) and relative retention time 
(RRT) obtained for test samples in this experiment were consistent with the 







Table 20. Column mix test results on HPLC 
 
5.2.5.3 HPLC testing of FCEP isomers using two different percentages of 
mobile phase  
In this study, FCEP isomers were assessed in two experiments using 
acetonitrile: ammonium acetate by reverse phase method. In the first 
experiment, the mobile phase percentage was 55:45 % v/v and in the second 
was 65:35 % v/v, (see Table 21 below). 
Table 21. HPLC results of FCEP isomers using two different percentages of mobile 
phase (acetonitrile:20Mm ammonium acetate) 
 
MP 55:45% v/v  MP 65:35%v/v  
FCEP isomer 
tR (min) Resolution tR (min) Resolution 
11 
4.283 - 4.133 - 
12 
4.512 1.06 4.337 0.99 
13 
4.512 1.06 4.337 0.99 
 
As can be seen from Table 21, the results of this investigation using two 




















1 Dimethyl Phthalate 2.29 0.45 2.27 0.45 
2 Toluene 3.18 0.62 3.13 0.62 
3 Biphenyl 5.09 1.00 5.00 1.00 
4 Phenanthrene 7.18 1.41 6.97 1.40 
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11 was fully separated from the other two isomers (12 and 13) at about 4.28 
mins in the first experiment using mobile phase, acetonitrile:ammonium 
acetate 55:45% v/v. 12 and 13 co-elute at about the same time (4.5 minutes) 
in the first experiment. The results of the second experiment using the same 
mobile phase with a ratio of 65:35% v/v revealed similar findings with slight fall 
in retention time and resolution.  
In spite of the excellent/short retention time obtained in the two experiments, 
however, the resolution was almost 1.00 in both cases, which suggests that 
the current reverse phase method used in these experiments is not suitable 
for separation of samples containing FCEP isomers. As a result, one of the 
possible solutions to solve the issue of low resolution is to try the HPLC 
gradient method.  
 
5.2.5.4 HPLC gradient method (FCEP isomers) 
 
 
Table 22 gives data on HPLC gradient method applied for FCEP isomers using 
aqueous formic acid 0.1%, A (%) and acetonitrile (100% MeCN, B (%)) as the 
mobile phase, each in separate mobile phase bottles. The table also shows 
the time spent (in minutes) by both solvents in a total run time of 36 minutes, 
using flow rate of 1 mL min-1 and the maximum pressure in the column is 400 
bar. The percentages of mixing the two solvents A (%) and B (%) is listed in 
two columns.  
In the gradient method, it is important to use the terms A and B to refer to the 
aqueous and organic solvents respectively. In this experiment, the A solvent is 
HPLC grade water with 0.1% formic acid.  The B solvent is HPLC grade 







Table 22.  HPLC gradient method using aqueous formic acid 0.1% and acetonitrile as 














95 5 1 400 
30.0 
5 95 1 400 
30.1 
1 99 1 400 
33.0 
1 99 1 400 
33.1 
95 5 1 400 
36.0 
95 5 1 400 
 
Table 23 shows data on HPLC detection and separation of FCEP isomers in a 
mixture and as individual components using acetonitrile (MeCN):0.1% 
aqueous formic acid as the mobile phase. 
Table 23. HPLC detection and separation of FCEP isomers in a mixture and as 




These results are also shown below in the following chromatogram (Figure 45), 
which shows HPLC testing of the FCEP mixture by gradient method with 
detection at 263 nm. The first peak was for 11, which eluted at 11.34 minutes, 
It is also clear that resolution between 11 and the other two isomers was too 
low (0.48) with no base line separation, while, both 12 and 13 co-eluted at 
11.47 minutes and appeared as one peak. This last finding suggests the 




Figure 45. Testing a mixture of FCEP isomers by gradient HPLC method at 263 nm 
using formic acid:acetonitrile as the mobile phase (volume of injection = 40 µL) 
 
 
(FCEP mixture) (individual FCEP isomers) 
FCEP isomer 
tR (min) Resolution tR (min) 
11 11.34 - 11.39 
12 11.47 0.48 11.73 
13 11.47 0.48 11.58 
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The following table compares results of HPLC detection and separation of 
FCEP isomers in a mixture and as individual components using 
acetonitrile:100 mM ammonium acetate as the mobile phase (See Table 24 




Table 24. HPLC detection and separation of FCEP isomers in a mixture and as 
individual components using acetonitrile:100mM ammonium acetate as the mobile 
phase. 
 
(FCEP mixture) (individual FCEP 
isomers) 
FCEP isomer 
tR (min) Resolution tR (min) 
11 20.04 - 20.05 
12 20.26 1.32 20.25 
13 20.26 1.32 20.25 
 
 
Figure 46. Testing a mixture of FCEP isomers by gradient HPLC method at 263 nm 
using 100 mM ammonium acetate:acetonitrile as the mobile phase (Volume of 




The table and figure below show HPLC detection and separation of FCEP 
isomers in a mixture and as individual components using acetonitrile: 100 mM 
ammonium formate as the mobile phase (See Table 25  and Figure 47). 
 
Table 25. HPLC detection and separation of FCEP isomers in a mixture and as 
individual components using acetonitrile:100mM ammonium formate as the mobile 
phase. 
 
(FCEP mixture)  (individual FCEP 
isomers) 
FCEP isomer 
tR (min) Resolution tR (min) 
11 19.81 - 19.99 
12 20.00 1.08 20.30 




Figure 47. Testing a mixture of FCEP isomers by gradient HPLC method at 263 nm 
using 100 mM ammonium formate:acetonitrile as the mobile phase (Volume of 
injection = 40 µL) 
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Overall, Table 26 below compares HPLC results obtained from testing a 
mixture of FCEP isomers in three different experiments, applying the gradient 
method; using 100% acetonitrile (MeCN) which is mixed during the run in the 
HPLC instrument with either formic acid, ammonium acetate or ammonium 
formate as the mobile phase. 
Formic acid is used in this HPLC experiment to improve the chromatographic 
peak shape and to provide a source of protons in reverse phase HPLC. As the 
concentration of the formic acid in the eluent increases, the retention time of 
the analytes decreases.[145]  
 
Table 26. HPLC results of FCEP isomers (mixture) applying the gradient method; 
using 100% acetonitrile with formic acid or ammonium acetate or ammonium formate 














 tR (min) 
Rs tR (min) Rs tR (min) Rs 
11 11.34 - 20.04 - 19.81 - 
12 11.47 0.48 20.26 1.32 20.00 1.08 
13 11.47 0.48 20.26 1.32 20.00 1.08 
 
It is clear from the results that the combination of acetonitrile with formic acid 
gave the shortest retention time was almost 11.50 mins with a resolution of just 
below 0.50, in the next experiment by using acetonitrile/ammonium acetate 
combination, the highest resolution was obtained (1.32), nevertheless, the 
retention time was a bit lengthy with values of just over 20 minutes. 
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In the third experiment (acetonitrile:ammonium formate), the retention time 
was similar to that in the (acetonitrile:ammonium acetate run) with almost 20 
minutes, but, the resolution fell to slightly over than one.  
5.2.5.5 Conclusion (FCEP on HPLC) 
In the first study on HPLC, the FCEP compounds were tested by applying the 
reverse phase method for separation of these isomers using two different 
percentages of mobile phase. However, because of both low resolution and 
incomplete separation obtained, one of the possible solutions to be applied 
was the application of HPLC gradient method.   
Overall, as was seen in the results, changing the gradient method parameters 
such as the temperature or flow rate might improve the resolution and give 
rapid analysis time. Another recommendation is by possibly testing these 
isomers using different instrumental techniques such as using gas 
chromatography (GC). The study of FCEP isomers on three kinds of GC 
columns is detailed in the following sections. 
5.2.6 Gas chromatography 
After using HPLC methods discussed earlier, GC is the next technique that will 
be used for the characterisation/analysis of FCEP isomers using different 
temperature programmes on 3 types of GC columns;  
1. Nonpolar GC column, capillary tubing is made of fused silica, (1909IS-433E, 
8890 GC system, length 30 m, inner diameter 0.25 mm, film thickness 0.25 
µm, Agilent Technologies, Inc.). 
2. Semi-polar GC column, (35%-phenyl)-methylpolysiloxane, (7890A GC 
system, 30 m, 0.25 mm, 0.50 µm, Agilent Technologies, Inc.). 
3. Polar GC column, this is a polyethylene glycol (PEG) stationary phase that 
features high polarity, (1909IN-133E, HP-INNOWax S N US86964, 30 m, 0.25 
mm, 0.25 µm, Agilent Technologies, Inc.). 
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The methods used herein are starting at 180°C and increase in different rates 
up to 300°C (for instance using the rate of 1, 2, 3, 5°C min-1 or isothermally at 
180°C.  
5.2.6.1 Detection of FCEP isomers on non-polar, semi-polar and polar GC 
column 
In this study, both a mixture of fluorocyanoephenidine isomers and the internal 
standard eicosane (FCEP + E) and (separate FCEP isomers + E) were tested 
on three different polarities of GC columns in order to detect and separate 
these compounds. In other words, the aim is to find best column, therefore, 
method or temperature programme for separating these regioisomers. The first 
method was applied as a starting point for FCEPs was on the non-polar GC-
MS at 100°C and the temperature was increased up to 300°C in a rate of 10°C 
min-1, flow rate of 1 mL min-1. The elution of the isomers has shown that 180°C 
is the ideal starting temperature for these experiments. The results of this 
method have revealed the following retention times: E (18.19 min), 11 (22.67 
min), 12 (23.96 min) and 13 (24.20 min), (see Figure 48 below). 
 




5.2.6.1.1 Detection and separation of FCEP isomers on non-polar GC column 
 
This experimental investigation was carried out by testing the FCEP isomers 
on a non-polar GC column (GC-MS).The purpose was to begin with testing 
FCEP isomer on nonpolar GC column and then followed by the use of semi- 
or polar GC columns. 
 
 
Figure 49. Chromatogram of FCEP mixture+ E on GC-MS (non-polar column) using 
the isothermal method (180°C) 
 
The chromatogram (Figure 49) above displays data on the retention times 
obtained by applying the isothermal GC-MS method (at 180°C) on a mix of 
three FCEP isomers with eicosane (E) as a reference.  
It is clear from the results on the chromatogram that after using the isothermal 
GC-MS method (at 180°C), there was a better separation and resolution when 
compared to the other methods used in this study (5, 3, 2 and 1°C min-1 
temperature programmes). The retention times of these substances were: E 
(12.38 min), 11 (16.90 min), 12 (18.15 min) and 13 (18.37 min), respectively.  
In summary, despite the fact that the isothermal method at 180 °C was superior 
to the other applied methods in terms of the separation obtained, the degree 
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of this separation is still not acceptable because it is not a fully base line 
separation particularly between 12 and 13.    
The chromatogram above presents data on the retention times obtained by 
applying a 1°C min-1 temperature programme on a mixture of three FCEP 
regioisomers using eicosane (E) as a reference (Appendix A 43). 
By looking at the results from this run, the separation of the three FCEP 
compounds was not achieved with an overlap between the detected peaks.   
The produced peaks represent the retention times of the following substances: 
E (10.18 mins), 11 (13.17 mins), 12 (13.88 mins) and 13 (14.2 mins), 
correspondingly. Overall, this 1°C min-1 method was unable to separate the 
FCEP isomers with an acceptable resolution between their peaks.  
 
 
Figure 50. Chromatogram of FCEP mixture+ E on GC-MS (non-polar column) using 
2°C min-1 method 
 
The chromatogram (Figure 50) displays data on the retention times of FCEP 
mixture, in the presence of E as a reference, on GC-MS (non-polar column) 
using 2°C min-1 method. 
As can be seen from the results, eicosane and all three FCEP were detected 
by applying 2°C min-1 GC-MS method. However, the separation of the three 
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isomers was partially achieved which is similar to what was observed in the 
3°C min-1method results. These findings suggest that this method is not 
suitable for separation but it can be used for identification purposes of the 
individual samples of FCEP substances in any forensic framework cases. The 
order of elution was as the following: E (8.85), 11 (11.12 mins), 12 (11.63 mins) 
and 13 (11.72 mins), respectively.  
In conclusion, this method still needs more changes in the experimental 
conditions in order to obtain a suitable, rapid and robust GC-MS method for 
separation of FCEP analytes. 
The chromatogram (Appendix A 44) exhibits data on the retention times 
obtained by applying a 3°C min-1 temperature programme on a mix of three 
FCEP isomers and the corresponding abundances using eicosane (E) as a 
reference.  
By looking at the graph (See Appendix A 44), even though it is obvious that 
the separation of the three FCEP compounds was achieved, the resolution 
between the three peaks was low. The retention times (in minutes) of the 
signals associated with the following compounds were: E (7.93), 11 (9.78), 12 
(10.16) and 13 (10.24). In summary, this method requires some extra 
modifications in its parameters to achieve complete separation of the 







Figure 51. FCEP mixture + E on GC-MS (non-polar column) using 5°C min-1 method 
 
The graph above (Figure 51) shows the relationship between the time in 
minutes and abundance obtained after injecting a mixture of 11-13 plus E in to 
a GC-MS with a non-polar column and by applying a temperature programme 
of 5°Cmin-1. 
As can be clearly seen from the diagram, the main trend is represented by the 
slight separation of the 11 (8.07 mins) which follows the eicosane peak at (6.69 
mins). The other two fluorocyanoephenidine isomers (12 and 13) had retention 
times of 8.34 and 8.39 mins respectively. 
In conclusion, although this GC-MS method was able to detect the three FCEP 
regioisomers, the complete separation of these compounds was not possible 
by using this protocol. 
The chromatogram (Appendix A 45) shows the retention times produced from 
GC-MS (non-polar column) after the injection of 13 plus eicosane as a 
reference in a concentration of 1 mg mL-1, and using a 3°C min-1 temperature 
procedure.  
As can be seen from the diagram, the two compounds were completely base-
line separated with excellent resolution, the retention time of 13 was 10.21 
mins and E was 7.88 mins.    
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In the same way as for 11 and 13, 12 and eicosane were tested via GC-MS 
(non-polar column) by applying the temperature programme of 3°C min-1. From 
the results of this run, the retention time of 12 was 10.17 mins and for E was 
7.93 mins.  
The chromatogram (Appendix A 46) gives data on the retention times of 12 
and eicosane as a reference, using GC-MS (non-polar column) and the 
temperature programme of 3°C min-1.  
In general, it can be noted from the diagram that the retention time of 11 equals 
9.78 mins, while that of eicosane was 7.92 mins. Similarly, both compounds 
were fully base line separated with significant resolution.  
The diagram (Appendix A 47) gives data on the retention time of E which is 
used as a reference material on GC-MS (non-polar column) and the 
temperature programme of 3°C min-1. As can be seen from the chart, the 
retention time of E is 7.93 mins. 
 
Table 27. FCEP isomers on GC-MS (non-polar column) using 3°C min-1 method 
FCEP isomer Retention Time, tR (mins) Eicosane tR (E) 
11 9.78 7.92 
12 10.17 7.93 
13 10.21 7.88 
 
Table 27 summarises and compares data on the different retention times of 
the three FCEP isomers acquired on a GC-MS (non-polar column) using 
eicosane as a reference and a temperature programme of 3°C min-1.  
From the table, the retention time of E is on average of approximately 7.9 mins, 
whereas the retention times of the fluorocyanoephenidines were as follows: 11 
= 9.78; both 12 and 13 have retention times of around 10.2 mins. 
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To conclude, on one hand, this data suggests the possibility of separating 11 
when it is present in a mixture/sample containing all three FCEP  regioisomers 
using the above GC-MS method. On the other hand, it is not possible to 
separate 12 and 13 by applying the same method.  
Table 28. FCEP mix and eicosane on non-polar column (GC-MS) 
 
Table 28 compares the retention times of fluorocyanoephenidines measured 
in minutes; in several temperature procedures used to detect and quantify 
these compounds. The study was carried out to investigate different 
temperature systems/categories. 
In general, the results obtained from the isothermal method was the best in all 
observed methods due to the best resolution between 12 and 13, followed by 
the 5°C min-1 method and then the 3°C min-1 method. 
Looking at the details, the 1°C min-1 method accounted for the highest run time. 
The 5°C min-1 method and isothermal (180 °C) were faster than the other 
methods. Using the isothermal method, if compared to 11, 12 and 13 eluted 
later, possessing retention times of 18.15 and 18.37 mins respectively.  In 
contrast, the 1°C min-1 method had the longest run time at 125 mins. The order 










5 °C min-1 29 6.69 8.07 8.34 8.39 
3 °C min-1 45 7.93 9.78 10.16 10.24 
2 °C min-1 65 8.85 11.12 11.63 11.72 
1 °C min-1 125 10.18 13.17 13.88 14.02 
Isothermal 
(180°C) 
40 12.38 16.90 18.15 18.37 
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of elution remained the same in that 11 was eluted first followed by 12 and 
lastly by 13. 
In the non-polar GC column study, the isothermal method at 180 °C min-1 was 
the first procedure applied for testing the FCEP regioisomers, followed by 1, 2, 
3 and finally 5 °C min-1 , respectively. It is worth noting that the 4 °C min-1 
method was not used in the whole study/analysis of FCEP isomers on three 
different GC columns due to insufficient time. 
By looking back to the results, in one hand, after applying all these five 
methods, 11 was separated from 12 and 13. On the other hand, the peaks of 
12 and 13 appeared almost as one peak, which shows the overlap between 
the two peaks of these two compounds. 
The most important finding is that the 5 °C min-1 was the quickest method for 
detection and separation of FCEP isomers, with just below 8.5 mins required 
for the appearance of the last separated peak. As opposed to the 5 °C min-1 
method, the isothermal programme at 180 °C min-1 was the slowest method 
for resolving all the FCEP signals with retention time of just below 18.5 mins. 
Finally, the other three methods remaining in this study, as shown in Table 28, 
the last peak in the remaining three methods (3, 2 and 1 °C min-1) appeared at 
exactly (10.2, 11.7, 14.0 mins, respectively). However, the disadvantage of the 
last mentioned three methods is that the total run time is very long (45-125 
mins).    
5.2.6.1.2 Detection and separation of FCEP isomers on semi-polar GC column 
The FCEP isomers were analysed on the semi-polar GC column (phenyl 
methyl siloxane, 0.25 µm, 30 m) by using nitrogen as the carrier gas in the first 
set of experiments and then nitrogen was replaced by helium in the next 




Figure 52. FCEP mixture plus eicosane at 2 °C min-1 on semi-polar GC using nitrogen 
as a carrier gas 
  
Figure 52 shows data on the retention times (in minutes) of FCEP mixture plus 
eicosane and the peak area (pA) using 2°C min-1 method on semi-polar GC 
using nitrogen as a carrier gas. The most striking result to emerge from the 
data is that 11 (at 16.98 mins) was separated from the other isomers, 12 (at 
17.59 mins) and 13 (at 17.73 mins), while the eicosane peak was (at 14.0 
mins). The order of elution was 11, then 12 and finally 13. Additionally, the last 
two peaks of 12 and 13 are not fully base line resolved. Peak areas were 
approximately 192.0 (11), 160.0 (12) and 178.0 (13), correspondingly. 
The chromatogram (Appendix A 48) gives information on the retention times 
(mins) of FCEP mixture plus eicosane at 3 °C min-1on semi-polar GC using 
nitrogen as a carrier gas. As can be seen from the diagram, the retention times 
were eicosane (12.15 mins), 11 (14.4 mins), 12 (14.9 mins) and 13 (15 mins). 
Even though 11 was separated from the rest of the substances in this 
experiment, the peaks of 12 and 13 were only partially resolved as was 
observed in the previous experiment using 2°C min-1 method on semi-polar GC 





Figure 53. FCEP mixture plus eicosane (0.1 mg mL-1) at 3 °C min-1 on semi-polar GC 
using helium as a carrier gas 
Figure 53 shows the retention times of three FCEP isomers and eicosane (0.1 
mg mL-1) at 3 °C min-1on semi-polar GC using helium as a carrier gas. The 
most important finding is the improvement in the shape of the peaks (See 
Figure 53) and the resolution/separation of the 12 and 13 by using 
concentrations of 0.1 mg mL-1 (i.e. 10 times dilution) and helium as a carrier 
gas, instead of nitrogen. As can be noted from the graph, the retention times 
were as follows: eicosane (12.7 mins), 11 (at 15 mins), 12 (15.5 mins) and 13 
(15.6 mins).  
It is also clear that only 11 was completely separated, while, the peaks of the 
isomers 12 and 13 were not fully base-line resolved; these results are similar 
to the findings of the previous experiments using 5 °C min-1 and 3 °C min-1 
techniques on semi-polar GC utilising helium as a carrier gas. 
The chromatogram (Appendix A 49) gives data on the retention times (mins) 
of FCEP mixture and eicosane at 5 °C min-1 on semi-polar GC using nitrogen 
as a carrier gas. As can be seen from the data on the chart, the retention times 
were as the following: eicosane (9.9 mins), 11 (11.5 mins), 12 (11.8 mins) and 
13 (11.9 mins). 
Moreover, in one hand, both total run time and retention time declined by 
increasing the temperature up to 5 °C min-1, on the other hand, 12 and 13 were 
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just partially separated as was seen in the previous experiments using 2 and 
3 °C min-1 protocols on semi-polar GC using nitrogen as a carrier gas. 
Table 29. Individual FCEP isomers with eicosane on GC (semi-polar column) using 5 
°C min-1 method 
FCEP isomer FCEP tR(min) Eicosane (E) tR(min) 
11 11.49 9.86 
12 11.80 9.87 
13 11.85 9.88 
 
Table 29 above exhibits the retention times (mins) of the individual FCEP 
isomers with eicosane, acquired on GC (semi-polar column) using 5°C min-1 
method. 
The key finding from this experiment is that all the 3 isomers in addition to 
eicosane eluted in a time range of about 10 minutes (E) to 12 minutes (FCEP 
isomers). The order of elution is as follows: eicosane, 11, 12 and 13, in 
sequence. As far as the retention times of FCEP isomers is concerned, it can 
be seen clearly that there is a similarity/overlap in the values of tR(min), 
therefore, a different method or some modifications in the current method’s 
parameters is required to perform the separation of the isomers in question.  
Table 30. FCEP isomers mixture with eicosane on GC (semi-polar column) using 5°C 
min-1method 
FCEP isomer FCEP tR(min) Eicosane (E) tR(min) 
11 11.50 9.86 
12 11.79 9.86 




Table 30 shows the retention times (mins) of the mixture of FCEP isomers and 
eicosane, obtained from GC (semi-polar column) using the temperature 
programme, 5°C min-1. In comparison of the results of this experiment (See 
Table 12) with the findings of the individual FCEP compounds (see Table 11), 
it can be clearly noticed that the retention times are almost the same in the two 
experiments; by taking the average for eicosane (9.8 mins), 11 (11.5 mins), 12 
and 13 (11.8 mins), respectively.  
To summarise, these results are consistent for both cases (separate FCEP 
substances or a mix of FCEP isomers) provided that the same GC method was 
used (5 °C min-1 method). 
Table 31. FCEP isomers mixture with eicosane on GC (semi -polar column) using 















(12) and (13) 
5 °C min-1 29 9.880 11.507 11.797 11.866 0.73 
3 °C min-1 45 12.156 14.450 14.898 14.999 0.70 
2 °C min-1 65 14.083 16.990 17.599 17.732 0.69 
1 °C min-1 125 17.180 21.372 22.491 22.569 0.67 
Isothermal 
(180°C) 
40 26.814 34.074 36.487 37.023 0.69 
 
Table 31 summarises and compares data on the retention times of a mixture 
of FCEP isomers with eicosane tested on GC (semi-polar column) using four 
different temperature-programmed methods and nitrogen as a carrier gas.  
Looking back at the details of this study, apart from the isothermal method (at 
180°C), the main trend is by increasing the temperature the retention time and 
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the total run time are decreasing. For instance, using the 5 °C min-1 
temperature-programmed method, the retention times were as the following: 
11 (11.5 mins) this figure was almost 10 minutes less using 1°C min-1 protocol 
(21.3 mins). While for both 12 and 13, the retention time was ca. 11.8 mins; 
this figure is nearly 25 minutes quicker than using the isothermal procedure 
(about 37.0 mins).  
What is more, the retention times obtained from the use of the isothermal 
method were: 11 (34 mins), 12 (36 mins) and 13 (37 mins); these times are 
two and a half times higher than those observed while using the 3 °C min-1 GC 
method.  
From the most important findings in this study is that all the applied four 
methods have all given almost an average of approximately 0.7 as the 
resolution between the 12 and 13, i.e. increasing the temperature rate does 
not affect resolution. To improve the resolution of earlier eluting peak, it is 
possible to decrease the initial temperature or increase the initial hold time. 
Decreasing the initial temperature usually results in the largest resolution 
improvement, but analysis times are substantially increased.
153 
 
Table 32.FCEP isomers mixture with eicosane on GC (semi-polar column) using 
different temperature-programmed methods (Comparison between nitrogen and 




















 3  °C min-1 45 12.15 14.45 14.89 14.99 3.08 0.70 
Nitrogen 2 °C min-1 65 14.08 16.99 17.59 17.73 3.26 0.69 
 1 °C min-1 125 17.18 21.37 22.49 22.56 5.16 0.67 
 Isothermal 
(180°C) 
40 26.81 34.07 36.48 37.02 3.82 0.69 
 3  °C min-1 45 12.75 15.08 15.52 15.63 4.80 1.14 
Helium 2 °C min-1 65 14.80 17.79 18.42 18.56 5.26 1.15 
 1 °C min-1 125 18.26 22.60 23.60 23.83 5.75 1.28 
 Isothermal 
(180°C) 
40 26.09 35.05 37.66 38.22 6.72 1.40 
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Table 32 summarises and compares the use of nitrogen or helium as the 
carrier gases on FCEP isomers mix with eicosane on semi-polar GC column, 
by applying different temperature-programmed methods. The abbreviation, Rs 
(2:3) shown in the table above refers to resolution between 11 and 12, while 
Rs (3:4) represents the resolution between 12 and 13.  
In semi-polar GC column experiments, the four applied methods (1, 2, 3 °C 
min-1 methods and isothermal procedure at 180 °C were run on a total run time 
from 40 to 125 mins).   
These experiments were conducted by using nitrogen as a carrier gas which 
was then replaced by helium in order to obtain faster retention times and better 
resolution particularly between 12 and 13 (Rs refers to resolution between 12 
and 13).  
From the results, it is clear that by using nitrogen as a carrier gas, the fastest 
method was the isothermal at 180 °C with just 40 minutes total run time, while 
the slowest method was the 1°C min-1with 125 minutes. 
The main finding is that 11 was fully separated with excellent resolution with 
just over 3 to just over 5, but the issue here is that the peaks of 12 and 13 were 
partially base line resolved with a resolution of about 0.7 in all four applied 
temperature programmes. 
The second set of experiments used helium as a carrier gas, the results 
revealed a significant improvement in resolution especially between the two 
peaks of 12 and 13. The highest resolution obtained between 13 and 14 was 
1.40 by using the isothermal method at 180 °C. 
Taken together, by comparing nitrogen and helium experiments, the retention 
times were slightly decreased in case of using helium, however, the resolution 
was doubled from just about 0.70 t0 1.40. These results suggest that helium is 
superior to nitrogen as the carrier gas (in this study), the resolution of 1.40 is 
acceptable for separating FCEP isomers, but it is preferred to be above 1.5 i.e. 
around 2 or more according to ICH guidelines. 
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In summary, it is recommended to re-run these experiments by using helium 
as the carrier gas in addition to increasing the temperature rate greater than 5 
°C min-1, in order to obtain a suitable and rapid separation method for FCEP 
isomers. 
5.2.6.1.3 Detection and separation of FCEP isomers on polar GC column 
The FCEP isomers were investigated on the polar GC column (polyethylene 
glycol, 0.25 µm, 30 m) by both detection of the individual isomers separately 
and in a mixture, using many temperature programmed protocols. These are 
1, 2, 3, 5 °C min-1and the isothermal method at 180 °C. The results of this 
experimental study are detailed below. 
 
 
Figure 54. 2-FCEP (11), (1 mg mL-1) on polar GC at 1°C min-1 
 
The chromatogram (See Figure 54) provides data on the retention time of 11 
and eicosane (1 mg mL-1) versus peak area (pA) on polar GC at 1°C min-1. 
From the results, tR of 11 = 48.7 mins and tR of E = 4.2 mins. 
The chromatogram (Appendix A 50) shows data on the retention time of 12 
and eicosane (1 mg mL-1) versus peak area (pA) on polar GC at 1°C min-1. 
From the chromatogram, tR of 12 = 52.9 mins, tR of E = 4.2 mins. The total run 





Figure 55. 4-FCEP (13), (1 mg mL-1) on polar GC at 1°C min-1 
 
Figure 55 gives information on the retention time of 13 and eicosane (1 mg mL-
1) versus peak area (pA) on polar GC at 1°C min-1. From the chart, tR of 13 = 
53.3 mins and tR of E = 4.2 mins. 
The chromatogram (Appendix A 51) gives data on the retention times (mins, 
x-axis) of FCEP mix (1 mg mL-1) versus peak area (pA) on polar GC at 1°C 
min-1; with a total run time of over than an hour. It is clear from the 
chromatogram that the retention times were as follows: eicosane (4.2 mins), 
11 (48.7 mins), 12 (53.0 mins) and 13 (53.3 mins). As can be noted from the 
data, the highest peak area was for eicosane with almost four folds of the peak 
area of each FCEP isomer. However, the same issue still exists because only 
11 was separated from the rest of the isomers in FCEP mixture, with just a 
partial separation of 12 and 13, as was observed in the previous experiments 
on both nonpolar and semi-polar GC. 
Furthermore, the retention times obtained in this run (FCEP mix) is consistent 
with the retention times measured for the individual FCEP isomers.  
In conclusion, these results suggest that the use of polar GC is not suitable to 
separate the three FCEP isomers with a high resolution especially between 12 
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and 13. What is more, the lengthy run time of 65 mins is one of the 
disadvantages of this method. 
 
Table 33. Individual FCEP isomers with eicosane on GC (polar column) using 1°C 
min-1 method 
FCEP isomer FCEP tR(min) Eicosane (E) tR(min) 
11 48.776 4.259 
12 52.991 4.244 
13 53.322 4.222 
 
Table 34. FCEP isomers mixture with eicosane on GC (polar column) using 1°C min-
1 method 
FCEP isomer FCEP tR(min) Eicosane (E) tR(min) 
11 48.769 4.244 
12 53.005 4.244 
13 53.332 4.244 
 
 
Table 33 and Table 34 summarise and compare data on the retention times 
obtained from different runs for the individual versus the mixture of FCEP in 
the presence of E as a reference. The findings in these tables suggest that 







Table 35. FCEP isomers mixture with eicosane on GC (polar column) using different 
temperature-programmed methods 












5 °C min-1 17 3.617  14.599  - 
3 °C min-1 25 3.899  -  - 
2 °C min-1 35 4.038  32.760  - 
1 °C min-1 65 4.244 48.769 53.005 53.332 0.84 
Isothermal 
(180°C) 
40 4.418  -  - 
 
Table 35 lists the total run time of FCEP isomers mixture with eicosane on GC 
(polar column) using different temperature-programmed techniques. 
It is obvious that the fastest method was the 5 °C min-1 with just 17 minutes 
and the 1 °C min-1 protocol with over than an hour. While, 3 °C min-1, 2 °C min-
1 and isothermal method at 180 °C were carried out within 25, 35 and 40 
minutes, respectively. Apart from the isothermal method, the possible 
explanation of these findings might be because of the greater the temperature  
the less the retention time. 
With reference to Table 35, there was only one peak at 4.4 min after applying 
the isothermal method at 180°C. Whereas, after using the 5°C min-1method, 
there were only two peaks representing the three tested compounds plus 
eicosane as a reference at 3.6 and 14.5 mins (See Table 35). While, when the 




From the results, in the 2°C min-1 method, there were two peaks at 4.0 and 
32.7 mins. The last method was the 1°C min-1method, the separate FCEP 
isomers in presence of eicosane were injected on the polar GC system using 
1°C min-1 method. The order of elution was in the following sequence; 11, 12 
and 13. Whereas, the retention times were 11 (48.7 min), 12 (52,9 min), 13 ( 
53.3 min) and eicosane (4.2 min). 
In the polar GC column experiments, the 1°C min-1 method was the only 
procedure that gave all the peaks of three FCEP mixture and the eicosane 
peak, whereas, there were no peaks detected for the FCEP isomers when 
using both the isothermal (180°C) and 3°C min-1  methods. While, for the 2°C 
min-1 and 5°C min-1 methods there were only one peak detected for each 
method (other than the eicosane peak at 4.2 and 3.6 mins) at 32.7 mins and 
14.5 mins, respectively. 
5.2.6.1.4 Summary of FCEP experiments on 3 different GC systems 
Firstly, in nonpolar GC column study, the fastest method was the 5 °C min-1 
with just 29 minutes, Secondly, in semi-polar column study; the fastest method 
was the isothermal method at 180 °C with just 40 minutes. Finally, in polar 
column study, the fastest method was the 5 °C min-1 with just 17 minutes. 
Secondly, in semi-polar GC column, one of the key findings in this investigation 
was the improvement noted in resolution after switching from nitrogen to 
helium as a carrier gas using the isothermal method at 180 °C (from just under 
0.70 to 1.40 between 3- and 4-FCEP) which means that the resolution is 
doubled.  
Thirdly, in polar GC column, It is clear from the outcome of the experimental 
scrutiny that using this type of GC column is not suitable for 
analysis/separation of FCEP isomers due to either lengthy run time or absence 
of the peaks of FCEP analytes.  
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5.2.6.1.5 The impact of helium and nitrogen as carrier gases with reference to 
Golay Equation 
The Golay equation relates plate height to linear velocity of the mobile phase 
flowing through the GC capillary column. The height equivalent of a theoretical 
plate is one measure of column efficiency (see Golay equation in chapter 1). 
HETP depends on the nature of the carrier gas and its linear velocity (not 
volume flow rate). The smaller the HETP, the more efficient the separation. It 
is possible to obtain the highest efficiency – best separating power – from GC 
when the carrier gas linear velocity is set at the value where HETP is the 
lowest.  
The three most important carrier gases used in GC are nitrogen, helium and 
hydrogen. Nitrogen is the poorest of the three gases as a carrier gas for 
temperature-programmed chromatography because slight changes in the 
linear velocity during a run can lead to significant degradation of efficiency 
(coalescing of the two peaks).  
The minimum HETP with hydrogen is insensitive to large changes in the linear 
velocity. The linear velocity can be set at any value between about 30 cm/sec 
and 60 cm/sec without losing separation efficiency during the run. On balance, 
hydrogen is the preferred carrier gas for capillary columns. 
The optimum gas velocity is inversely proportional to the column diameter, 
narrow-bore columns are faster than medium or wide-bore columns. A further 
advantage of capillary columns over packed columns is that the gas velocity 
and/or the column temperature can be increased quite easily if the resolution 
allows. This leads to an even greater increase in analysis speed. In addition, 
this relationship shows that a lighter carrier gas such as hydrogen or helium 
provides quicker analysis time without a substantial loss in resolution. Lastly, 
carrier gas viscosity is a temperature dependent parameter. As temperature 
increases, the viscosity of the gas increases. When using a constant pressure 
mode for carrier gas and temperature programming, the viscosity of the gas 




In the first study on HPLC, the FCEP compounds were tested by applying the 
reverse phase method for separation of FCEP isomers. Because of both low 
resolution and incomplete separation, the gradient method was applied to find 
out the optimum percentage for both acetonitrile and the buffer.  In this HPLC 
study, three different buffers (formic acid, ammonium acetate and ammonium 
formate) were tested in a combination with the organic solvent (acetonitrile) by 
carrying out three different experiments; the aim was to examine the effect of 
changing the buffer solution on the HPLC separation process. 
The results of the gradient method suggested that the best resolution between 
2-FCEP (11) and the other two isomers (3-FCEP (12) and 4-FCEP (13) was 
(1.32) obtained using acetonitrile/ammonium acetate combination, the highest 
resolution was obtained (1.32), yet, the retention time was a bit lengthy with 
values of just below 21 minutes. 
After using HPLC techniques, the next study was by using three GC methods, 
applying 3 different column polarities. The most important finding was when 
helium was used as a carrier gas utilising the isothermal method at 180 °C in 
semi-polar GC column (the resolution between the peaks of 12 and 13 went 
from just under 0.70 to 1.40). However, the aim in the FCEP isomers study 
was to achieve a resolution value of around 2. 
From the GC results, although 11 was fully resolved by using GC methods, the 
separation of 12 and 13 was difficult using five different methods on three 
different GC columns. 
In conclusion, HPLC and GC approaches used in this study were not suitable 
for separation of FCEP isomers using the above-detailed programmes. 
Although, the scope of this study was limited in terms of the tested parameters, 
however, the current findings add to a growing body of literature on 
fluorocyanoephenidine isomers, especially that this study has gone some way 
towards enhancing our understanding of the behaviour of these isomers on 
many devices such as GC and HPLC. 
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As a result, more research is required to analyse/separate the 
fluorocyanoephenidine isomers. Finally, it is suggested that the association of 





























Chapter 6: Development and validation for the separation of the 
regioisomers of the halogenated diphenidine using Reversed 
Phase HPLC.  
 
As discussed in previous chapters, NPS have become a significant threat to 
public health that requires a detailed and focussed analytical investigation to 
help tackle all the problems arising from these drugs. This chapter discusses 
in detail the application of the validated HPLC method on 12 halogenated 
diphenidine (DP) regioisomers, which belong to the NPS category. The terms 
‘halogenated diphenidine (halo-DP) isomers’, ‘halophenidines and 
halodiphenidines’ are also used interchangeably to refer to these compounds. 
The utility of HPLC to separate, detect and quantify a number of other 
diphenidine derivatives such as MXP, FEP and FCEP has been demonstrated 
(See chapters 3, 4 and 5 for details) and as such this approach was applied to 
the halogenated DP derivatives. The twelve halogenated DP regioisomers 
investigated in this chapter are 2-, 3- and 4-fluorodiphenidine (FDP), 2-, 3- and 
4-chlorodiphenidine (CLDP), 2-, 3- and 4-bromodiphenidine (BrDP) and 2-, 3- 
and 4-iododiphenidine (IDP) (Figure 56).  
In spite of a considerable amount of literature on diphenidine and its 
derivatives, there are only few studies/research so far that have been 
conducted on the halogenated derivatives and primarily focus on the ortho-
isomer of chlorodiphenidine (2-chlorodiphenidine, 2-CLDP (15)).[71] In 2016, 
Wallach and co-workers investigated (pharmacologically) the binding affinities 
of the dissociative ‘legal highs’ diphenidine, MXP isomers and 15 as 
antagonists for NMDAR.[71] In this pharmacological investigation (on the 
forebrain homogenate of male Sprague–Dawley rats), the binding affinity 
reported by Wallach et al. [71] was substantially lower than the affinity constant  
reported by Gray and Cheng, and Berger et al., in previous studies.[147] The 
binding affinity can be defined as the maximum amount of drug or radio ligand, 
usually expressed as picomoles (pM) per mg protein, which can bind 
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specifically to the receptors in a membrane preparation.[148, 149] 
Furthermore, these experimental data are rather controversial, because Gray 
and Cheng reported 2-CLPH to have higher affinity binding than other known 
NMDAR antagonists. This reported finding for 15 prompted Wallach et al. to 
reinvestigate this compound. In Wallach’s study, 15 was found to have potent 
low affinity for NMDAR which was substantially less than the affinity reported 
previously by Gray and Cheng. One of the probable explanations is due to the 
discrepancies in affinities of these compounds for different NMDAR subunit 
combinations. Apart from this single pharmacological study on 15, there have 
been no studies concerned with the chemical analysis (spectroscopic and 
chromatographic) of the isomers of chlorodiphenidine or any other 
halophenidines. The lack of suitable spectroscopic and chromatographic 
studies into these compounds highlights the need to develop methods for the 
analysis of such drugs to be prepared to detect and quantify the substances 




Figure 56. The chemical structures of the halogenated diphenidine compounds 
The aim of this study is to examine the detection and separation of the 12 
possible halogenated diphenidine derivatives, with the key research question 
being whether HPLC is a suitable method for the separation of these 
compounds and whether the method can be extended to allow us to quantify 
the materials in seized samples. 
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6.1 Characterisation of halophenidines 
The halogenated diphenidine isomers were synthesised in-house at MMU by 
the MANchester DRug Analysis & Knowledge Exchange (MANDRAKE) unit 
and were fully structurally characterised [J Ainsworth-Mcmillan, “Guilty by 
dissociation – synthesis of halogenated diphenidine derivatives”, MChem 
Thesis (2018)], and then these compounds were investigated/tested on HPLC 
in this study. 
6.1.1 The UV measurement of halophenidines 
The UV spectra for the halodiphenidine isomers were extracted using the 
diode-array detector (DAD) within the range of 190-400 nm. The DAD scanned 
four selected wavelengths (270, 258, 254 and 220 nm), which have been 
demonstrated in chapters (3, 4 and 5) of this thesis to represent the maximum 
absorbance of many diphenidine derived compounds for example, MXP 
isomers (278 nm) and FEP isomers (270 nm). In addition, benzene rings 
absorb strongly at 254 nm. In this study, the mobile phase 
acetonitrile:ammonium acetate 55:45% v/v (blank/solvent) was tested via UV-
vis spectroscopy and the result showed the acetonitrile cut-off wavelength at 
190 nm (Figure 57), and then it was used in HPLC as a solvent for the 
halogenated diphenidine compounds in the range (190-400 nm). By using the 
HPLC-DAD, the data showed that the halophenidine isomers absorb UV light 
at 220 nm more than at the other three selected points. The optimum 
wavelength was therefore determined to be 220 nm; this wavelength was 
applied in the HPLC method development. At lower wavelengths, the 
decreased UV absorbance of acetonitrile provided better signal-to-noise and 





Figure 57. The UV spectrum of acetonitrile:ammonium acetate 55:45% v/v 
 
6.2 HPLC method development  
In order to develop an HPLC method to analyse these 12 isomers, a number 
of flow rates were studied using a similar mobile phase (acetonitrile:ammonium 
acetate 55:45% v/v) used to separate the three MXP isomers (Chapter 3). The 
twelve compounds were split into as either ortho (four examples), meta (four 
examples) and para-halogenated (four examples) derivatives. Figure 58 
exemplifies the separation and detection of the 2-halophenidines using HPLC-
DAD.  Prior to starting the HPLC analysis, the analyst should consider the cut-
off point of the solvent and make sure that there is no impurity peaks near the 
solvent peak, which means that any peaks that appear after the solvent peak 
belong to the analytes.  
In Figure 58, the UV-DAD detector is an analyte specific property detector, 
therefore, responding to analytes that absorb UV light at a particular 
wavelength (i.e. specific), in this case 2-halogenated diphenidine isomers at 
220 nm. 




Figure 58. Detection and separation of the 2-halophenidines at a flow rate of 1.5 mL 
min-1 and at four different wavelengths using HPLC-DAD 
From the results, the order of elution (which is governed by polarity) was as 
follows: 14, 15, 16 and 17. The order of elution is related to partitioning of the 
analytes between the solid phase (C18) and the mobile phase, therefore in this 
experiment, the most strongly retained halogenated compound is the most 
non-polar (or lipophilic) of the diphenidine isomers investigated. Under 
reverse-phase conditions, 17 eluted last because this isomer is the most 
lipophilic and as such it is this derivative, which is retained more strongly, 
relative to the other halogenated derivatives. The resolution between each of 
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the derivatives was determined to be greater than 2 in all cases, which 
indicates that this method is able to satisfactorily resolve the four compounds. 
However, the run time is far too long for routine analysis and as such this might 
be possible by changing the flow rates to decrease the run time and maintain 
a satisfactory resolution. In Figure 58, there are three tiny peaks at 
approximately 1 min, 4.5 min and 5 min, the first peak at 1 min is assigned to 
uracil, the other two peaks were eluted as impurities accompanied with 2-BrDP 
before recrystallization. The following chromatogram (Figure 59) shows the 
isomer after recrystallisation at a flow rate of 1.5 mL min-1 (at 220 nm), using 
acetonitrile:ammonium acetate 67:33% v/v, in this chromatogram, there are no 
impurity peaks detected after recrystallization. When the mixture of these 2-
halogenated diphenidine isomers was injected in to the HPLC after 















Table 36. Retention times and resolution of the 2-, 3- and 4-halodiphenidine isomers 






 Flow rate 1.5 
mL min-1 
Flow rate 1.7 
mL min-1 
Flow rate 1.9 
mL min-1 
Flow rate 2.0 
mL min-1 
  tR (min) Rs tR (min) Rs tR (min) Rs tR (min) Rs 
2-halo 14 7.13 - 6.30 - 5.65 - 5.26 - 
 15 11.06 8.55 9.75 8.50 8.74 8.42 8.11 8.33 
 16 13.33 4.15 11.75 4.10 10.53 4.08 9.75 4.01 
 17 17.56 6.63 15.48 6.53 13.86 6.46 12.79 6.38 
  tR (min) Rs tR (min) Rs tR (min) Rs tR (min) Rs 
3-halo 18 7.25 - 6.41 - 5.63 - 5.36 - 
 19 11.01 7.88 9.73 7.80 8.49 7.48 8.09 7.58 
 20 12.54 2.82 11.08 2.78 9.66 2.66 9.19 2.70 
 21 14.56 3.50 12.85 3.43 11.20 3.31 10.66 3.34 
  tR (min) Rs tR (min) Rs tR (min) Rs tR (min) Rs 
4-halo 22 5.59 - 4.89 - 4.32 - 4.11 - 
 23 9.73 13.71 8.55 10.23 7.50 9.89 7.13 9.88 
 24 11.34 4.13 9.97 3.28 8.73 3.18 8.31 3.18 





Figure 59. Chromatogram of 2-BrDP acquired after recrystallization 
 
6.2.1 HPLC method development (changing the flow rate) 
The flow rate experiments were carried out by employing four different flow 
rates (1.5, 1.7, 1.9 and 2.0 mL min1). The findings of this study showed 
completely resolved peaks between the tested isomers with good resolution 
(Table 36).  
Table 36, Figure 60, Figure 61 and Figure 62 present the experimental data 
on retention times and resolution of the mixture of the 2-, 3- and 4-halogenated 
diphenidine isomers (halo DP isomers) by HPLC, using the flow rates; 1.5, 1.7, 
1.9 and 2.0 mL min1, mobile phase (acetonitrile:ammonium acetate, 55:45% 
v/v). 
By comparing the data of the three groups of the halo DP isomers (12 
compounds), for example, in the case of the retention times of the fluoro 
isomers and the resolution between the peaks of the fluoro and the chloro 
isomers i.e. for 14, the tR dropped from 7.13 (1.5 mL min1) to 5.26 mins (2 mL 
min1). Whereas, the resolution fluctuated between 8.55 and 8.33 for the first 
two peaks of 14 and 15 (See Figure 60).  
Figure 60 shows the retention times (tR in minutes) of the 2-halodiphenidine 
isomers versus the absorbance using acetonitrile:ammonium acetate, 55:45% 
v/v (flow rate 1.5 mL min-1). From the results the retention times where as 
follows: 14 = 7.13, 15 = 11.06, 16 = 13.33 and 17 =17.56 mins, respectively. 
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In summary, the greater the flow rate the less the retention time and resolution. 
In addition, the elution order is the same in all three tested groups was as 
follows (FDP, CLDP, BrDP and IDP, respectively), (See Figure 60,Figure 61 
and Figure 62). 
To conclude, the tR and resolution decreased significantly by increasing the 
flow rate from 1.5 to 2.0 mL min1. The optimum flow rate is 1.5 mL min-1 
because the highest values of resolution were obtained by using this flow rate 
(Table 36).  
The following chromatograms (Figure 60, Figure 61 and Figure 62) show the 
retention times of the three groups of the 2-, 3- and 4-halodiphenidines (4 
isomers each), using mobile phase acetonitrile:ammonium acetate 55:45% v/v 
(flow rate 1.5 mL min-1). 
Taken together, by comparing the method development of the three distinct 
groups, it can be noticed that the retention times for the 2-isomers were the 
longest among the other two groups with an average range of about 7.0-17.0 
min. In contrast, the 4-isomers eluted the quickest as they had retention times 
ranging from 5.5 to 13.5 min, while the third group (3-isomers) had 
intermediary retention times in the range of 7.3-14.3 min. Overall, the trend in 
the order of elution and tR is due to the different degrees of lipophilicity and 
polarity among these isomers. Overall, by using the flow rate 1.5 mL min1, the 
retention times and resolution were decreased compared to the flow rates 1.7, 
1.9 and 2.0 mL min1. 
Provided that these are new compounds with no previous HPLC experiments 
conducted on them, the obtained data is acceptable. However, the overall run 
times of these experiments were generally a bit lengthy (20 minutes). The next 
set of experiments were carried out by increasing the percentage of the organic 
part (acetonitrile) in the mobile phase to be greater than 55% in order to reduce 





Figure 60. HPLC separation of the 2-halo diphenidine isomers using a mobile phase 




Figure 61. HPLC separation of the 3-halo diphenidine isomers using a mobile phase 






Figure 62.HPLC separation of the 4-halo diphenidine isomers using a mobile phase 
consisting of acetonitrile:ammonium acetate, 55:45% v/v, and a non-polar stationary 
phase 
 
6.2.2 HPLC method development (changing the percentage of mobile phase) 
The purpose of this new experimental investigation focused on obtaining the 
optimum mobile phase composition. The percentages of mobile phase that 
were used in this study were as follows: acetonitrile:ammonium acetate 
60:40% v/v, 65:35% v/v, 70:30% v/v and 75:25% v/v, using a flow rate of 1.5 
mL min-1 as a constant variable in all studies. This flow rate was chosen 
because it led to less pressure in the instrument, therefore leading to lower 
load on the column in comparison with using higher flow rates. The average 
pressure during the different flow rate experiments of the HPLC method 
development for these compounds was as the following: 75, 90, 100, 110 bar 
for 1.5 mL min-1, 1.7 mL min-1, 1.9 mL min-1 and 2.0 mL min-1, respectively.[151] 
The role of pressure in HPLC is to push the mobile phase through the small 
particles filled into the column. Normally, moderate to high pressure is used to 
flow the solvent through the chromatographic column, while low pressure is 
usually because of a leak in the system, and high back pressure is an 
unexpected increase in the pressure during normal HPLC operation that 
approach or exceed the maximum pressure ability of the system.  
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The results of these four experiments can be summarised in the following 
tables and figures. The data for the 2-haloDP isomers is shown below in a 
detailed way, and because of the similarities in the experiments, the 3- and 4-
isomers data are discussed in less detail in order to facilitate the comparison 
between all the three groups of halo DP isomers: 
Figure 63 below shows the effect of changing the percentage of mobile phase 
on detection and separation of 2-haloDP isomers, using a flow rate of 1.5 mL 
min-1 and concentrations of 100 µg mL-1. Firstly, using 55:45 and 60:40% v/v 
gave a total run time of 20 and 15 minutes, respectively. Therefore, these two 
percentages were not chosen as the optimum proportions of mobile phase to 
be used in halophenidines detection and separation. Whereas, by applying 
65:35, 70:30 and 75:25% v/v, the run time was only 10 minutes. The resolution 
in these last three percentages was very good, the minimum resolution value 
was 1.72 between 16 and 15 using mobile phase 75:25%, 2.08 using mobile 




Figure 63. Chromatograms showing the effect of changing the percentage of mobile 
phase on the detection and separation of 2-haloDP isomers
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The goal of this experiment was to obtain a resolution value of about 2 or just 
above 2 using a quick method. From these results, the 10 minutes total run 
time meant of the goals was achieved, but in order to improve the resolution 
mentioned above, it was decided in this experiment to try a mobile phase 
percentage of 67:33% v/v, which is between 65 and 70% v/v. The 12 
halodiphenidine isomers were tested by applying the mobile phase, 
acetonitrile:ammonium acetate 67:33% v/v; the results of these experiments 
are shown in Figure 64. 
 
 
Figure 64. Chromatograms detailing the comparison of using a flow rate of 1.5 mL 
min-1 and a mobile phase consisting of acetonitrile:ammonium acetate, 67:33% v/v, 
on the separation of 2-, 3- and 4-halo DP isomers 
 
As can be seen in Figure 64, all the peaks in this investigation on 2-, 3- and 4-
halo DP isomers were completely base line resolved and the resolution value 
between 16 and 15 was 2.35, while the resolution value between 20 and 19 
was 1.81 and lastly between 24 and 23 it was 2.11. As a result, the second 
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aim of this investigation was achieved because the resolution was over 2 for 
the 2- and 4-isomers; the resolution of 1.81 in the case of 3-isomers is still 
acceptable.  
6.2.3 Summary of the three experiments (wavelength, flow rate and mobile 
phase composition): 
The developed HPLC method; using the combination of mobile phase 
acetonitrile:ammonium acetate, 67:33% v/v, flow rate of 1.5 mL min-1 and 
concentration range of 1.25-20 µg mL -1 was used in the analysis/validation of 
this method on 2-, 3- and 4-halo DP isomers due to the following reasons:  
Wavelength: All the 12 halophenidine isomers have the maximum UV at 220 
nm in comparison with their absorption at the other tested wavelengths (254, 
258 and 270 nm). 
Flow rate: despite the 1.5 mL min-1 being the slowest flow rate, this flow rate 
produced the highest resolutions in comparison with the other flow rates (1.7, 
1.9 and 2.0 mL min-1) examined in these experiments. 
Mobile phase composition: by increasing the percentage of acetonitrile in 
the mobile phase, both the retention time and the total run time were 
decreased. The percentage of mobile phase acetonitrile:ammonium acetate 
67:33% v/v (between 65 and 70% v/v) was decided to be used in the method 
validation in a combination with using the flow rate 1.5 mL min-1 and 
wavelength 220 nm. 
6.3 HPLC method validation of 2-, 3- and 4-halogenated diphenidine isomers 
The table in Appendix A 52 outlines the validation data of the 12 halogenated 
diphenidine isomers. To prove/confirm that the method is suitable for its 
intended use, is the purpose of validating analytical protocols,[152] therefore, 
the current HPLC method was validated according to the ICH guidelines.[135] 
Parameters such as retention time, resolution, limit of detection (LOD), limit of 
quantification (LOQ) and percentage relative standard deviation (%RSD) were 
assessed in this experiment. 
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As can be noted in in the table, the most important finding is that the limit of 
detection (LOD) for the 2-isomers was just below 0.08 µg mL-1, whereas for 
the 3- and 4-isomers this value was between 0.55-070 and 0.60-0.90 µg mL-1 
respectively. The limit of quantification, LOQ for the 2-isomers was just below 
0.24 µg mL-1, 0.16-0.21 µg mL-1 for the 3-isomers and lastly, it was 0.17-0.26 
µg mL-1 for the 4-isomers. These values can be considered as good 
values/measures for these new compounds in this new HPLC method/study 
because very small amounts in micrograms of these substances (around 0.10 
and 0.25 µg mL-1) can be detected and determined. In addition, there is no 
specific detection threshold limit for these new substances.   
It is clear that the retention times of these halogenated diphenidine derivatives 
were ranging between just over 3.5 minutes in the case of 22, up to 
approximately 8.5 minutes in the case of 17. The resolution was also good, 
with a minimum of 2.6 between the peaks of 20 and 19.  
It can be concluded that there are different degrees of interaction between the 
isomers and the column employed, most likely due to the variance in both the 
type of halogen atom present in the diphenidine derivative, and its location on 
the ring. 
In summary, the overall run time required to identify and separate the four NPS 
in question, was just 10 minutes which represents an excellent period of time 
for analysis. It is also clear that all the peaks were fully resolved with excellent 
peak symmetry/shape and one of the advantages of this method is the 
detection of halogenated diphenidine isomers at concentrations of as low as 
1.25 µg mL-1.   
The equations of the lines are included in the table, showing the relationship 
between peak area (y) and the concentration (x). On average, all of the given 
four compounds had an average r2 of 0.9999. 
There were hardly any differences between the values of theoretical plates for 
all the 12 isomers, which was on average 9000-11500, this reflects that the 
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peaks are sharp with no fronting or tailing. In a separation process, a 
theoretical/hypothetical plate produced from two phases refers to a state of 
equilibrium between two levels.[153] 
With regard to the %RSD, generally it is noticeable that it accounted for almost 
below 1.000 for all the concentrations under investigation (1.25-20 µg mL-1). 
This is because they shared nearly the same patterns of percentage injection 
precision in all five categories, which explains that deviation or the variance 
from the mean is acceptable as it is below one in all cases/concentrations; this 
is an indicator of good injection precision values in this experiment. 
The validation chromatograms of 2-, 3- and 4-halogenated diphenidine 
isomers (in concentrations of 10 µg mL-1) are shown in Figure 65, Figure 66 
and Figure 67. 
 
 
Figure 65. Validation chromatogram of the 2-halogenated diphenidine isomers 





Figure 66. Validation chromatogram of the 3-halogenated diphenidine isomers 
(concentration=10 µg mL-1) 
  
 
Figure 67. Validation chromatogram of the 4-halogenated diphenidine isomers 
(concentration=10 µg mL-1) 
  
6.4 Robustness of HPLC Method (2-halo DP isomers) 
The robustness parameters tested in this study are the intra-day and inter-day 
precision, flow rate, temperature and the composition/percentage of mobile 
phase. 
6.4.1 Intra- and inter-day precision  
In this experiment, two blanks were injected prior to injecting halogenated 
diphenidine isomers 10 times; Intra-day (am and pm) and Inter-day (the 
average of pm plus am and pm). The table in (Appendix A 53) shows the 
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intraday and inter-day precision measurements for the 2-halogenated 
diphenidine analytes using the mobile phase acetonitrile:ammonium acetate 
67:33% v/v, a flow rate of 1.5 mL min-1 and a concentration of 10 µg mL-1 (see  
The retention time remained almost constant for the isomers of all four groups 
with just a slight/insignificant difference between the inter- and intra-day 
precision of the iodo-isomers. According to the table in (Appendix A 53), the 
retention times of these compounds ranged from just over 4 mins (14) to just 
over 8 mins (17). The %RSD is on average of almost 0.11 for intraday 
measurements and about 0.14 for inter-day precision, which refers to a slight 
difference in the injection precision without affecting the retention times of 
these isomers. To conclude, changing the testing time during the day does not 
have any substantial effect on the robustness of the HPLC applied for analysis 
of 2-halogenated diphenidine derived isomers.   
6.4.2 Flow rate 
The flow rates 1.4, 1.5 and 1.6 mL min-1 were assessed in this investigation 
(See Table 37).These findings are in agreement with the linear van Deemter 
equation, by increasing the flow rate the retention time is decreased slightly for 
all the halodiphenidine isomers (14, 15, 16 and 17) in the flow range examined 
in this experiment. 
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Table 37. Robustness testing (flow rate 1.4, 1.5 or 1.6 mL min-1) for the 2-halogenated 
diphenidine isomers using a mobile phase consisting of acetonitrile:ammonium 
acetate, 67:33 % v/v. Key: tR = Retention time (min). 
 
Injection 
tR (min) using flow rate 1.4  
mL min-1 
tR (min) using flow rate 1.5  
mL min-1 
tR (min) using flow rate 1.6  
mL min-1 
 14 15 16 17 14 15 16 17 14 15 16 17 
1 4.47 6.34 7.32 9.04 4.17 5.91 6.81 8.41 3.91 5.54 6.39 7.89 
2 4.47 6.34 7.32 9.05 4.16 5.90 6.81 8.41 3.92 5.55 6.40 7.90 
3 4.47 6.34 7.32 9.05 4.17 5.90 6.80 8.40 3.91 5.54 6.39 7.90 
4 4.47 6.34 7.32 9.04 4.17 5.91 6.82 8.42 3.91 5.54 6.40 7.90 
5 4.47 6.34 7.32 9.05 4.16 5.90 6.81 8.41 3.92 5.55 6.40 7.91 
6 4.47 6.34 7.32 9.05 4.17 5.91 6.81 8.41 3.91 5.54 6.40 7.90 
7 4.47 6.34 7.31 9.04 4.16 5.90 6.80 8.40 3.92 5.55 6.40 7.91 
8 4.48 6.35 7.33 9.06 4.17 5.91 6.82 8.42 3.92 5.55 6.40 7.91 
9 4.48 6.35 7.32 9.04 4.17 5.91 6.82 8.41 3.91 5.54 6.40 7.90 
10 4.48 6.35 7.33 9.05 4.16 5.88 6.78 8.36 3.92 5.55 6.40 7.91 
Average  4.47 6.34 7.32 9.05 4.17 5.90 6.81 8.40 3.91 5.55 6.40 7.90 
STD 0.004 0.004 0.004 0.005 0.004 0.007 0.010 0.015 0.004 0.004 0.004 0.005 
%RSD 0.093 0.073 0.061 0.057 0.110 0.129 0.157 0.188 0.110 0.087 0.077 0.069 
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Table 37 presents robustness testing (flow rate) for the 2-halogenated 
diphenidine analytes in four different groups over the course of a ten minute 
run. According to the table, as flow rate increases, the retention time 
decreases. As can be seen in the tables, by increasing the flow rate from 1.4 
to 1.5 and then to 1.6 mL min-1, the retention time drops dramatically for 14, 
15, 16 and 17 by about (0.5, 0.8, 0.9 and 1.1 min), respectively.  
Overall, separation time varies relatively across the four compounds, which 
contain different halogens in their chemical structures; therefore, they have 
different ways of separation i.e. this could be because of the interaction of the 
halogenated structure with the column. The order of elution is as follows: (F, 
Cl, Br and I); this might be because the degree of the hydrophobicity for these 
halogens follows the following order: fluoro <chloro < bromo < iodo. This 
means that the iodo group has the highest hydrophobicity. As a result, a 
hydrophobic molecule (e.g. iodo) in the polar mobile phase 
(acetonitrile:ammonium acetate) will adsorb to the hydrophobic stationary 
phase, and thus will pass through the column slower than the other 
halogenated compounds - therefore the iododiphenidine elutes last. In 
contrast, the fluorinated diphenidine elutes first because it possesses the 
lowest hydrophobicity among the four halogenated substances in this study.  
All things considered, the flow rate of 1.5 mL min-1 has been chosen to 
separate these isomers, as the retention time and resolution are slightly 
improved when compared to the other two rates in this experiment.  
6.4.3 Temperature effect and Van’t Hoff equation 
Three different temperatures, 48, 50 and 52°C, were examined in this 
experiment (see Appendix A 54). applying slight changes in the temperature 
caused slight changes in the tR (and Rs). Overall, the 50°C programme was 
selected for the validation of the HPLC method of analysis for these 
compounds. This temperature was applied in the HPLC method validation of 




Figure 68. Van’t Hoff plot of ln k versus 1/T for the 2-halogenated diphenidine isomers 
(17, 18, 19 and 20) 
As is observed from the information in (Appendix A 54), by increasing the 
temperature by 2°C, the retention time decreased slightly. The resolution was 
also slightly increased by employing a temperature of 50°C, whilst a decrease 
was observed when the temperature was increased to 52°C. However, the 
change in resolution was not significant. These results are on par with the Van’t 
Hoff behaviour (see Figure 68), the retention mechanism is constant with 
increasing the temperature, which is based on the equilibrium between 
enthalpy and entropy changes in the thermodynamic system for the 2-
halodiphenidine isomers under investigation (14, 15, 16 and 17). For the Van’t 
Hoff plots of ln k versus 1/T for the 3- and 4-halogenated diphenidine isomers 
see Appendix A 55 and Appendix A 56.  
Finally, all three isomers were plotted for each halogen (ortho, meta and para) 
to see if the position of the halogen has an influence on the Van’t Hoff 
relationship using temperatures (48, 50 and 52°C). Figure 69 shows the effect 
of changing temperature on retention factor of the fluorinated diphenidine 




Figure 69. Van’t Hoff plot of ln k versus 1/T for the fluorinated diphenidine isomers 
(14, 18 and 22) 
 
It can be noted that the para-substituted isomer possesses the lowest value of 
retention factor. In addition, the parallel lines suggest similar retention 
mechanism for these compounds. The ortho and meta isomers appear as a 
one line due to similar retention times. Similarly, see plots of the chlorinated 
(Appendix A 57), brominated (Appendix A 58) and iodinated (Appendix A 59) 
diphenidine isomers. The general trend with all the 12 halogenated diphenidine 
isomers investigated in this work is that the order of elution is as follows: para, 
meta and ortho, respectively. 
6.4.4 Robustness of the method relative to mobile phase composition 
The following mobile phase compositions: (66:34, 67:33 and 68:32% v/v) were 
used in this study. Table 38 lists the data of robustness testing (by varying 
mobile phase compositions) for the four 2-halogenated diphenidine isomers. 
The tested mobile phase proportions were sorted into different categories; 





Figure 70. ln k versus % organic modifier (acetonitrile) for 2-halodiphenidine isomers 
 
The plot of ln retention factor (k) versus the percentage of organic modifier 
(acetonitrile) for 2-halodiphenidine isomers is shown in Figure 70, it is a useful 
measure to understand the effect of the nature of the halogen on retention 
mechanisms.  It is clear that the retention time decreases when the percentage 
of acetonitrile increases.  
By increasing the percentage of the organic modifier (acetonitrile) from 66 -
68% the retention time of the 2-halogenated diphenidine isomers (14, 15, 16 
and 17) are decreasing. Log P values of these compounds were calculated 
using ChemDraw software. Log P values were as follows: 4.86 (14), 4.86 (15), 
4.86 (16) and 5.26 (17), which is slightly higher than FEP isomers (4.09) and 
MXP isomers (4.58). Similarly, this indicates these isomers possess a 
hydrophobic effect as a mechanism of retention. It is obvious that the iodo 
isomer (2-iododiphenidine, 17) has higher Log P (5.26), and therefore it is more 
hydrophobic with greater retention time than 14, 15 and 16. 
All in all, in spite of the change in the proportions of mobile phase components, 
there was not much difference in the obtained values of tR. A mobile phase of 
67:33% v/v was selected to be used for detection and separation of these 
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analytes, as this percentage of mobile phase produced excellent average 
resolution values for the ten injections of the mixture of the 2-halogenated 
diphenidine isomers. The average value of tR for 14 was 4.1, for 15 was 5.9, 
for 16 was 6.8 and lastly for 17 was 8.4 minutes.  
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Table 38. Robustness testing (% mobile phase (acetonitrile:ammonium acetate) = 66:34, 67:33 or 
68:32% v/v) for the 2-halogenated diphenidine isomers 
 
6.4.5 Robustness of the Method (3- and 4-halo DP isomers) 
In this experiment, the same parameters employed for the 2-isomers were 
utilised. The average tR, standard deviation (STD) and %RSD were displayed 
just to simplify the tables and make the comparison much easier between the 
12 isomers in this study; the results are shown in Table 39, Table 40, Table 41 
and Appendix A 60. The plots of ln k versus the percentage of organic modifier 
for 3- and 4-halo diphenidine isomers are shown in (Appendix A 61 and 
Appendix A 62). The calculated/predicted log P values for 3-halo DP isomers 
were as follows: 18, 19 (5.26) and 20, 21 (5.53). While, log P for 3-halo DP 
isomers were (5.53) for 22 and (6.06) for 23, 24 and 25. This indicates similar 
 
 
tR (min) using acetonitrile: 
ammonium acetate (66:34% 
v/v) 
tR (min) using acetonitrile: 
ammonium acetate (67:33% 
v/v) 
tR (min) using acetonitrile: 
ammonium acetate (68:32% 
v/v) 
Injection 14 15 16 17 14 15 16 17 14 15 16 17 
1 4.35 6.24 7.25 9.04 4.17 5.91 6.81 8.41 4.05 5.69 6.54 8.04 
2 4.35 6.24 7.24 9.02 4.16 5.90 6.81 8.41 4.05 5.66 6.55 8.04 
3 4.35 6.24 7.24 9.02 4.17 5.90 6.80 8.40 4.04 5.66 6.54 8.04 
4 4.35 6.24 7.24 9.03 4.17 5.91 6.82 8.42 4.05 5.69 6.54 8.04 
5 4.35 6.23 7.24 9.03 4.16 5.90 6.81 8.41 4.04 5.69 6.55 8.05 
6 4.35 6.23 7.23 9.01 4.17 5.91 6.81 8.41 4.04 5.68 6.53 8.04 
7 4.35 6.24 7.25 9.03 4.16 5.90 6.80 8.40 4.04 5.68 6.53 8.02 
8 4.36 6.25 7.25 9.02 4.17 5.91 6.82 8.42 4.05 5.71 6.57 8.08 
9 4.36 6.24 7.25 9.03 4.17 5.91 6.82 8.41 4.05 5.71 6.56 8.07 
10 4.35 6.24 7.25 9.02 4.16 5.88 6.78 8.36 4.04 5.69 6.55 8.06 
Average  4.35 6.24 7.24 9.02 4.17 5.90 6.81 8.40 4.04 5.69 6.55 8.05 
STD 0.004 0.005 0.005 0.006 0.004 0.007 0.010 0.015 0.005 0.016 0.011 0.017 
%RSD 0.092 0.086 0.081 0.076 0.110 0.129 0.157 0.188 0.125 0.286 0.175 0.211 
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hydrophobic effects for these compounds in comparison with 2-halo DP 
isomers. 
6.4.6 Conclusion of robustness testing 
The HPLC method used in this study is robust because the minor deliberate 
changes in the chromatographic conditions have little effect on the method. 
For instance, increasing flow rate resulted in a decrease in retention time 
(faster elution of analytes), this is because the component molecules have little 
time to interact with the stationary phase as they are quickly pushed through 
the column. 
Similarly, increasing the temperature caused a decrease in retention time (the 
elevated temperature increases the solubility of compounds in the eluting 
solvent and decreases solvent viscosity, which leads to lower back pressure). 
Lastly, increasing the percentage of organic modifier causes a reduction in 
retention time because the interaction of polar analytes with nonpolar (more 
hydrophobic) column is weaker than that of the nonpolar compounds, as a 
result, polar (less hydrophobic) components spend less time travelling into the 
column and therefore elute first.  
The robustness of the developed RP-HPLC method was evaluated based on 
the %RSD values obtained after introducing deliberate changes in the flow rate 
(±0.1 mL min-1), column temperature (±2°C) and mobile phase composition 
(±2%). The results of robustness data are represented in Table 37, Appendix 
A 54 and Table 38 for 2-halogenated diphenidine isomers and in Table 39, 
Table 40, Table 41 and Appendix A 60 for 3- and 4-isomers. It was observed 
that the %RSD values (<1) remained unaffected and was well within the 
acceptance criteria. In addition, the relative retention time of the 12 
halogenated diphenidine compounds is constant, which confirms the 
robustness of the developed method and provides an indication of its reliability 
during the normal usage. 
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Table 39. Intra- and inter-day precision measurements for 3- and 4-halogenated diphenidine analytes (using 10 µg mL-1 concentration 





18 19 20 21 
 Intraday 
precision 
22 23 24 25 
tR (min) 4.22 5.81 6.44 7.30  tR (min) 3.55 5.41 6.10 7.13 
STD 0.011 0.009 0.015 0.018  STD 0.002 0.003 0.003 0.003 
% RSD 0.262 0.157 0.242 0.256  % RSD 0.080 0.058 0.052 0.051 
   
Inter-day precision 
18 19 20 21 
 Inter-day 
precision 
22 23 24 25 
tR (min) 4.23 5.81 6.43 7.27  tR (min) 3.54 5.39 6.09 7.12 
STD 0.003 0.004 0.005 0.006  STD 0.002 0.004 0.005 0.006 
% RSD 0.092 0.076 0.080 0.086  % RSD 0.078 0.074 0.084 0.089 
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FR  (1.4 mL min-1) 18 19 20 21  FR  (1.4 mL min-1) 22 23 24 25 
tR (min) 4.549 6.234 6.904 7.820 tR (min) 3.804 5.800 6.546 7.653 
RRT 0.729 1.000 1.107 1.254 RRT 0.655 1.000 1.128 1.319 
Resolution (Rs) - 8.200 2.743 3.409 Resolution (Rs) - 10.283 3.102 4.036 
 
 
FR (1.5 mL min-1) 18 19 20 21 FR (1.5 mL min-1) 22 23 24 25 
tR (min) 4.245 5.811 6.434 7.287 tR (min) 3.543 5.399 6.092 7.123 
RRT 0.730 1.000 1.107 1.254 RRT 0.656 1.000 1.128 1.319 
Resolution (Rs) - 8.115 2.724 3.39 Resolution (Rs) - 10.334 3.134 4.105 
 
 
FR (1.6 mL min-1) 18 19 20 21 FR (1.6 mL min-1) 22 23 24 25 
tR (min) 3.983 5.452 6.035 6.835 tR (min) 3.327 5.068 5.717 6.681 
RRT 0.730 1.000 1.106 1.253 RRT 0.656 1.000 1.128 1.318 
Resolution (Rs) - 7.921 2.660 3.318 Resolution (Rs) - 10.556 3.113 4.038 
Table 40. Summary of robustness testing (Flow Rate 1.4, 1.5 and 1.6 mL min-1) for the 3- and 4-halogenated diphenidine isomers 
(using 10 µg mL-1 concentration and 10 injections). Key: FR = Flow rate, tR = Retention Time (min), RRT =Relative retention time
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Table 41. Summary of robustness testing (temperature; 48, 50 or 52°C) for the 3-
halogenated diphenidine isomers (using 10 µg mL-1 concentration and 10 injections). 
Key: tR = Retention Time (min), RRT =Relative retention time 
 
Temperature 48 °C 18 19 20 21  Temperature 
48 °C 
22 23 24 25 
tR (min) 4.196 5.782 6.412 7.258  tR (min) 3.556 5.436 6.140 7.184 
RRT 0.725 1 1.109 1.255  RRT 0.654 1 1.129 1.321 
Resolution - 8.588 2.832 3.373  Resolution - 10.336 3.132 4.082 
           
Temperature 50 °C 18 19 20 21  Temperature 
50 °C 
22 23 24 25 
tR (min) 4.189 5.747 6.367 7.209  tR (min) 3.543 5.399 6.092 7.123 
RRT 0.728 1 1.107 1.254  RRT 0.656 1 1.128 1.319 
Resolution - 7.937 2.66 3.296  Resolution - 10.334 3.134 4.105 
           
Temperature 52 °C 18 19 20 21  Temperature 
52 °C 
22 23 24 25 
tR (min) 4.147 5.670 6.273 7.096  tR (min) 3.538 5.375 6.060 7.079 
RRT 0.731 1 1.106 1.251  RRT 0.658 1 1.127 1.317 
Resolution - 7.920 2.647 3.265  Resolution - 10.482 3.103 4.016 
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6.5 Method specificity 
The HPLC method specificity was carried out by testing the adulterant 
(caffeine, benzocaine and paracetamol) in the presence of diphenidine. The 
table below displays the adulterant testing of the halophenidines (using the 
concentration of 10 µg mL-1 and mobile phase acetonitrile:ammonium acetate, 
67:33% v/v).    
Table 42. Adulterant testing of the halophenidines (Using the concentration of 10 µg 
mL-1 and mobile phase (acetonitrile:ammonium acetate, 67:33% v/v). 
 
Moreover, uracil peaks were seen at around 1.032 and the injection peak at 
the range of approximately 0.92-1.30 in the case of all three mixtures of the 
halophenidines. The mobile phase 67:33% v/v and flow rate 1.5 mL min-1 were 
utilised for this study as well as the conditions/parameters applied in the 
validation experiments of these substances.  
In Table 42 above, the retention times of the three adulterants are overlapping 
with the injection peak and uracil peak in this region as well. Although all the 
halophenidines were separated using this HPLC method, this finding is 
considered as a limitation of this study. One possible solution to this issue 
 tR (min) 
Injection Diphenidine Caffeine Benzocaine Paracetamol 
1 3.03 1.46 1.46 1.45 
2 3.05 1.44 1.45 1.46 
3 3.05 1.44 1.46 1.45 
Average 3.04 1.45 1.46 1.45 
RRT 2.09 1.00 1.01 1.01 
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might be by changing/reducing both the percentage of mobile phase and flow 
rate or by modifying the rest of experimental parameters.  
6.6 Forensic application  
In order to test the developed method, it was applied to analyse two bulk 
forensic samples that were obtained as a white crystalline powder in a clear 
zip-lock bag from Greater Manchester Police via the MANDRAKE programme. 
The two samples, which were purported to contain 2-chlorodiphenidine (15), 
were weighed and diluted to a working concentration of 10 µg mL-1 (in 
replicate).  
 
Table 43. Bulk samples measured on HPLC (Halo DP isomers). Key: SS = Street 
sample, 15 = 2-CLDP 
 
Firstly, by comparing actual and found concentration, these results suggest 
that the purity of these two street samples is very different; SS1H with an 
average of around 93% w/w, whilst for SS2H about the purity was found to be 
27% w/w. Secondly, by comparing the retention times of the resulted peaks to 
the results of the retention times of all 12 halophenidine isomers in this study, 
and from the retention times obtained (5.96 mins) for the individual isomers, it 
can be confirmed that both bulk forensic samples (SS1H and SS2H) contain 












Analysis (% w/w) 
(µg mL-1) (µg mL-1) 
SS1H 
 
15, tR = 
5.96 min 
209.032 9.8 8.911 90.93 




15, tR = 
5.96 min 
76.009 11 3.236 29.42 
58.983 10.4 2.51 24.13 
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Figure 71 shows the chromatogram obtained by testing the street ample 
(SS1H), which was confirmed from its retention time (5.96 mins) to be 15, in 
addition to the presence of other peaks; one with retention time of 0.92 min 
which could be uracil, and another peak at 1.47 min which could be one of the 
following known additives/adulterants (caffeine, benzocaine or paracetamol), 
this is an indicator to that this bulk sample contains some impurities. The purity 
of 15 in this bulk sample (SS1H) was calculated as shown in the table above 
to be between 90 and 97% w/w.  
 
Figure 71. Chromatogram of street sample (SS1H) obtained using HPLC (Halo DPH 
isomers) 
 
The second bulk sample contains 15, and its peak eluted at (5.96 mins) which 
is the same as for the first street sample (SS1H). However, SS2H was less 
pure than SS1H, as the content of 15 in the sample was found to be between 
24 and 30% v/v. It is also found that there are some impurity peaks (at 1.5 
mins), which could be because of the presence of adulterants such as caffeine, 





The current experimental investigation focuses on the HPLC detection and 
separation of halogenated diphenidine compounds, by applying the developed 
HPLC method to analyse these isomers either as individual compounds or in 
bulk samples. By comparing the retention times obtained in the validation data 
for all three groups of halophenidines, it can be concluded that the 4-
halogenated diphenidine isomers had the lowest retention values as 22 was 
retained for just 3.5 minutes, while the longest was for the 2-halo DP 
compounds (17 eluted in 8.5 mins). The total run time was 10 minutes to elute 
all the compounds (14-25).  
After applying the method, the most remarkable result to emerge from the data 
is  not only the rapid total run time (less than 10 minutes) but also the excellent 
LOD (0.05 -0.09 µg mL-1) and LOQ (0.16-0.26 µg mL-1) as an average for all 
twelve halophenidines. The evidence from this study suggests that the 12 
isomers were fully baseline-separated with a resolution values (Rs) of greater 
than 2 in all three groups of halogenated DP in question, this confirms that the 
results are in accordance with the ICH standards and it should be suitable for 
the rapid detection, quantification and control of halophenidines. 
The developed HPLC method in this study was applied to analyse two street 
samples (SS1H) and (SS2H), it was confirmed that they contain the illicit 
substance 15 in a content of around 95 and 30% w/w, respectively. Some 
adulterants were also detected in these two street samples by using the same 
technique, which suggests that this method can be applied to real world 
samples. 
Another possible area of future research would be to investigate the 
halophenidine isomers by carrying out a full analytical characterisation such 
as FTIR, GCMS and NMR. Generally, this might involve plans to enhance the 
detection and separation of these new psychoactive substances. In 
summary, these results hold significance for potential focus on applying new 







This research project aimed to develop novel validated methods for the 
detection and quantification of diphenidine derived new psychoactive 
substances. These compounds were fully characterised using different 
techniques such as infrared, NMR spectroscopy and gas chromatography, 
then an HPLC method was developed to analyse four groups of new 
psychoactive substances (NPS); methoxphenidine (MXP), fluephenidine 
(FEP), fluorocyanoephenidine (FCEP) and halogenated diphenidine 
regioisomers (Halo DP), respectively, in four separate studies. 
In these analyses, reverse phase HPLC method (RP-HPLC) was 
developed/optimised by modifying many experimental conditions/variables 
such as: mobile phase, acetonitrile:ammonium acetate and the other 
experimental parameters such as flow rate (mL min-1), temperature, injection 
volume (µL) and detection wavelength (nm) were optimized according to each 
group of these compounds,  the column ACE 5 C18-AR (150 x 4.6 mm, 5 µm 
particle size) was used in this research.  
The developed HPLC method is able to detect, separate diphenidine 
derivatives (MXP, FEP and halogenated diphenidine isomers, this is because 
the obtained resolution between the separated peaks was greater than 2 in the 
case of MXP, FEP and Halo DP isomers and also the rapid overall analysis 
time obtained in the case of MXP and twelve Halo DP regioisomers was just 
10 minutes. In addition, this method was successful in both qualitative and 
quantitative analyses of street samples that contain diphenidine derivatives. 
In the MXP study, the limit of detection,  LOD was (0.04-0.15 µg mL-1) and limit 






HPLC procedure acts as an ideal method for both the qualitative and 
quantitative analysis of MXP isomers, when compared to the previous 
approaches in the literature. In the halogenated diphenidine isomers study, 
the LOD was (0.05 -0.09 µg mL-1) and LOQ was (0.16-0.26 µg mL-1) as an 
average for all twelve halophenidines; again which is similar to the findings of 
MXP experiments. For the FEP study, the forensic application of the developed 
HPLC method on three bulk samples confirmed that 8 was present in all three 
samples (SS1, 2 and 3), and 9 was only detected in samples 2 and 3. 
For fluorocyanoephenidine, FCEP, both an isocratic and gradient HPLC 
method was investigated to separate these isomers, with limited success.  
Though gas chromatographic techniques were investigated using a variety of 
stationary phases (polar, semi-polar and non-polar) the separation of these 
compounds proved challenging.  Despite being unable to fully resolve the 
isomers, there was an improvement noted in resolution by employing the semi-
polar GC column, after switching from nitrogen to helium as a carrier gas using 
the isothermal method at 180°C (from just under 0.70 to 1.40 between 12 and 
13). However, the obtained resolution was still below 2, which indicates that 
both HPLC and GC were not suitable to analyse FCEP isomers. 
Three validated chromatographic methods have been developed for a range 
of diphenidine derivatives, increased our understanding, and add to the 
existing research in the field of chromatography in general and HPLC methods 
in particular. The novelty in this research is that the new developed HPLC was 
superior to the previously reported methods in the literature, in addition to that 
is the fact that FEP, FCEP and halogenated DP isomers are all new 
substances investigated for the first time in this research project. The results 






to real life setup such as in toxicology and forensic framework to analyse any 
samples that are suspected to contain diphenidine-derived substances.  
If the debate is to be moved forward, it is important to continue research in this 
area of emerging NPSs, so a better understanding of HPLC analysis needs to 
be developed by changing various experimental parameters in this method. 
Moreover, these findings provide a good starting point for discussion and 
further research, which should aim to replicate results of these experiments 
and shed more light on detection and separation of a broader range of 
diphenidine derivatives and NPS classes. 
Further studies could also focus on the study of the metabolites of diphenidine 
and its derivatives using the current method, for which HPLC analysis could 
be used to distinguish between different metabolites/regioisomers of these 
substances in terms of their retention times and resolution values. These 
values can be reported/recorded by creating a new library for this class of NPS, 
which is readily expanded to other classes. Thus, the collected data can be 
grouped together and used as a database and source of information for any 
future studies in the field of HPLC and forensic science. Another 
recommendation could be by attaching HPLC to other techniques such as 
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*1H-NMR (400 MHz, DMSO-d6); 
13C-NMR (100 MHz, DMSO-d6); GC-EI-MS: m/z 258 (base peak); UV (0.3 mg/mL in acetonitrile:ammonium acetate 55:45% v/v), max = 277 nm, abs. = 
1.117, ɛ277= 1100 L mol
-1 cm.-1 
Peak 1H NMR chemical shift (ppm) 13C NMR chemical shift (ppm) FTIR frequency (cm-1) GC-EI-MS (m/z) Mpt (uncorrected), (°C) 
1 1.27, d, 2H 22.32 1592.98 258 151-152   
2 1.66-1.98, m, 2H 22.77 2400.02 175  
3 2.05-2.30, m, 2H 36.51 2600.01 91  
4 2.32-2.67, m, 2H 49.14 2900.14 69  
5 3.34-3.51, dd, 2H 55.54    
6 3.62, d, 2H 72.50    
7 3.96, dd, 2H 115.98    
8 4.06,m, 1H 122.50    
9 6.86-6.96, m, 2H 126.73    
10 7.01-7.19, m, 2H 129.97    
11 7.27, t, 2H 132.95    
12 7.35-7.43, m, 1H 136.30    







Appendix A 2. 1H NMR, 13C NMR, IR, melting point and UV* data of 4 
 
*1H-NMR (400 MHz, DMSO-d6); 
13C-NMR (100 MHz, DMSO-d6); GC-EI-MS: m/z 204 (base peak); UV (0.3 mg/mL in acetonitrile:ammonium acetate 55:45% v/v) , max = 273 nm, abs. = 
0.673, ɛ273= 660 L mol
-1 cm.-1 
Peak 1H NMR chemical shift (ppm) 13C NMR chemical shift (ppm) FTIR frequency (cm-1) GC-EI-MS (m/z) Mpt (uncorrected), (°C) 
1 1.08-1.29, m, 2H 11.96 1600.01 204 141-142  
2 1.66, m, 2H 39.86 2475.02 188  
3 1.82, d, 2H 40.91 2600.01 121  
4 2.15-2.31, m, 2H 41.31 2900.03 91  
5 3.78, s, 3H 62.59  65  
6 4.00, d, 2H 116.39    
7 4.10-4.27, m, 1H 126.13    
8 7.25-7.32, m, 1H 129.26    
9 6.82-6.95, m, 2H 136.80    
10 6.98-7.20, m, 2H 138.47    
11 7.35-7.48, m, 1H  161.76    































1H NMR chemical shift (ppm) 
 
13C NMR chemical shift (ppm) 
 
FTIR frequency (cm-1)  
 
Mpt (uncorrected), (°C) 
1 1.23, t,4H 11.95 1617.96 220-222 
2 2.66-2.79, m, 1H 39.24 2468.65  
3 2.80-2.97, m, 1H 39.87 2714.02  
4 3.19, t, 1H 40.08 2974.14  
5 3.38, br.s, 1H 40.91   
6 3.66, dd, 1H 41.12   
7 4.51-4.56, m, 1H 116.30   
8 4.72,d, 1H 126.04   
9 6.96-7.03, m, 3H 127.73   
10 7.05-7.20, m, 5H 129.25   
11 7.26-7.33, m,1H 136.60   
12 7.34-7.42, m, 1H 160.09   






























1H NMR chemical shift (ppm) 
 
13C NMR chemical shift (ppm) 
 
FTIR frequency (cm-1)  
 
Mpt (uncorrected), (°C) 
1 2.64, br.s, 1H 11.96 1618.82 232-234 
2 2.83, br.s, 1H 39.86 2475.42  
3 3.17, t, 1H 40.91 2708.57  
4 3.64, dd, 1H 41.31 2969.94  
5 4.54, br.s, 1H 62.59   
6 7.02, d, 2H 116.39   
7 7.09-7.22, m, 4H 126.13   
8 7.25-7.32, m, 1H 129.26   
9 7.33-7.42, m, 1H 136.80   
10 7.44, d, 1H 138.47   
11 9.73, br.s, 1H  161.76   



































1H NMR chemical shift (ppm) 
 
 
13C NMR chemical shift (ppm) 
 
 
FTIR frequency (cm-1)  
 
 
Mpt (uncorrected), (°C) 
1 1.22, t, 1H 11.95 1610.76 232-234 
2 2.54-2.69, m, 5H 39.87 2479.66  
3 2.82, dtd, 1H 40.91 2710.79  
4 3.16, dd, 1H 62.59 2971.06  
5 3.64, dd, 1H 116.39   
6 3.43-4.60, m, 1H 127.62   
7 6.95-7.06, m, 4H 129.26   
8 7.09-7.25, m, 1H 130.11   
9 7.50-7.61, m, 1H 138.47   






Appendix A 6. 1H NMR, 13C NMR, 19F NMR, IR, melting point and UV* data of 11 








1H NMR chemical shift (ppm) 
 
 
13C NMR chemical shift (ppm) 
 
 
19F NMR chemical shift (ppm) 
 
 
FTIR frequency (cm-1) 
 
 
Mpt (uncorrected), (°C) 
1 3.58,  br.s, 6H 15.12 -118.67 1576  217-220 
2 4.74, br.s, 5H 39.40  1618  
3 6.97, s, 2H 41.13  2251  
4 7.03-7.06, m, 1H 56.16  2739  
5 7.06-7.11, m, 2H 115.94  2968  
6 7.13-7.14, m, 1H 116.16    
7 7.31-7.38, m, 1H 118.16    
8 7.86, t, 1H 125.55    
9 10.06, br.s, 1H 128.79    
10 10.55, br.s, 1H 130.07    
11 - 135.92    
12 - 159.58    






























1H NMR chemical shift (ppm) 
 
13C NMR chemical shift (ppm) 
 
19F NMR chemical shift (ppm) 
 
FTIR frequency (cm-1)  
 
Mpt (uncorrected), (°C) 
1 3.07-3.26, m, 6H 15.07 -113.93 1575 217-220 
2 3.16, s, 6H 39.01  1618  
3 3.44-3.70, m, 1H 40.64  2251  
4 4.36-4.69, m, 11H 62.70  2738  
5 6.97, d, 1H 116.16  2968  
6 7.04-7.30, m, 1H 118.23    
7 7.27-7.47, m, 1H 125.71    
8 7.34-7.54, m, 1H 128.82    
9 7.86, t, 1H 129.66    
10 10.04, br.s, 1H 131.21    
11 10.54, br.s, 1H 136.25    
12 - 161.31    






























1H NMR chemical shift (ppm) 
 
13C NMR chemical shift (ppm) 
 
19F NMR chemical shift (ppm) 
 
FTIR frequency (cm-1)  
 
Mpt (uncorrected), (°C) 
1 2.93, m, 1H 14.98 -114.56 1568 194-197 
2 3.59, m, 1H 35.34  1611  
3 4.55-4.57, d, 1H 40.44  2251  
4 6.97, d, 1H 62.50  2739  
5 7.01-7.16, m, 1H 116.24  2964  
6 7.18-7.20, m, 1H 118.21    
7 7.53-7.55, m, 1H 127.16    
8 7.86, t, 1H 128.81    
9 10.05, br.s, 1H 129.67    
10 10.55, br.s, 1H 131.61    
11 - 136.36    
12 - 161.53    





























Appendix A 15. UV-vis spectrum of 2 





















































Appendix A 17. Robustness testing (Mobile phase percentage) for the three MXP analytes using a mobile phase consisting of acetonitrile:ammonium acetate 54:46% 





tR (min) using acetonitrile: 
ammonium acetate (54:46% v/v) 
tR (min) using acetonitrile: 
ammonium acetate (55:45% v/v) 
tR (min) using acetonitrile: 
ammonium acetate (56:44% v/v) 
 2 3 4 2 3 4 2 3 4 
1 4.095 6.279 4.721 3.959 6.042 4.568 3.806 5.768 4.387 
2 4.099 6.281 4.724 3.961 6.041 4.567 3.812 5.791 4.391 
3 4.099 6.288 4.728 3.961 6.037 4.566 3.811 5.769 4.389 
4 4.105 6.284 4.728 3.963 6.039 4.567 3.811 5.773 4.390 
5 4.105 6.286 4.729 3.967 6.035 4.567 3.814 5.771 4.391 
6 4.106 6.288 4.731 3.966 6.045 4.572 3.818 5.777 4.396 
7 4.105 6.284 4.728 3.965 6.047 4.572 3.816 5.776 4.394 
8 4.106 6.285 4.729 3.962 6.047 4.569 3.818 5.779 4.397 
9 4.109 6.285 4.730 3.964 6.056 4.576 3.819 5.779 4.397 
10 4.109 6.290 4.733 3.967 6.052 4.576 3.822 5.774 4.396 
Average 4.103 6.285 4.728 3.963 6.044 4.570 3.814 5.775 4.392 
STD 0.004 0.003 0.003 0.002 0.006 0.003 0.004 0.006 0.003 
%RSD 0.112 0.052 0.072 0.069 0.109 0.082 0.125 0.114 0.082 
231 
 
Appendix A 18. Intraday and inter-day precision measurements for the methoxphenidine analytes using mobile phase 
acetonitrile:ammonium acetate 55:45% v/v and flow rate 1.0 mL min-1 
 
Injection   Intraday Precision  tR       (min) Interday Precision  tR       (min) 
 2 3 4 2 3 4 
1 3.72 5.83 4.35 3.70 5.82 4.34 
2 3.72 5.84 4.36 3.70 5.82 4.34 
3 3.72 5.83 4.35 3.70 5.83 4.34 
4 3.72 5.83 4.35 3.71 5.83 4.35 
5 3.72 5.83 4.35 3.71 5.83 4.35 
6 3.72 5.83 4.35 3.71 5.83 4.35 
7 3.72 5.83 4.35 3.71 5.83 4.35 
8 3.72 5.83 4.35 3.72 5.83 4.35 
9 3.71 5.84 4.35 3.72 5.84 4.35 
10 3.71 5.83 4.34 3.72 5.83 4.35 
Average 3.71 5.83 4.35 3.71 5.82 4.34 
STD 0.004 0.004 0.004 0.008 0.005 0.004 
%RSD 0.11 0.072 0.108 0.220 0.097 0.111 
232 
 
Appendix A 19. Determination of % Recovery for the MXP regioisomers 
 
Theoretical conc. = 8 µg mL-1 Theoretical conc. = 10 µg mL-1 Theoretical conc. = 12 µg mL-1 
Injection 2 3 4 2 3 4 2 3 4 
1 100.6 98.4 97.6 100.2 99.6 96.9 98.3 100.8 98.9 
2 100.7 99.1 98.3 101.1 99.9 97.0 98.1 99.7 98.1 
3 101.1 98.6 97.6 97.8 99.7 96.9 98.6 100.4 98.7 
4 100.9 99.4 98.5 97.6 99.6 98.3 97.3 100.2 98.8 
5 100.5 99.7 98.5 97.6 100.3 99.1 99.0 99.5 97.6 
6 99.6 100.0 97.8 97.8 99.6 99.7 99.3 101.8 96.5 
Average 100.5 99.2 98.1 98.7 99.8 98.0 98.4 100.4 98.1 
STD 0.494 0.611 0.417 1.568 0.306 1.233 0.696 0.829 0.926 
































Appendix A 26. Intraday and inter-day precision measurements for the fluephenidine analytes using mobile phase acetonitrile: 






  Intraday Precision  tR       (min) Interday Precision  tR       (min) 
10 8 9 10 8 9 
1 17.04 20.97 22.81 16.95 20.87 22.70 
2 17.06 20.98 22.83 16.96 20.88 22.71 
3 17.06 20.99 22.84 16.98 20.88 22.72 
4 17.06 20.99 22.84 16.99 20.89 22.73 
5 17.08 20.99 22.84 16.99 20.90 22.74 
6 17.08 21.00 22.85 17.00 20.91 22.75 
7 17.10 21.01 22.86 17.01 20.91 22.76 
8 17.11 21.01 22.87 17.03 20.91 22.76 
9 17.11 21.01 22.87 17.03 20.92 22.78 
10 17.12 21.03 22.88 17.01 20.94 22.78 
Average  17.03 20.95 22.80 17.00 20.90 22.74 
STD 0.051 0.052 0.059 0.025 0.020 0.025 
%RSD 0.302 0.252 0.262 0.152 0.098 0.112 
240 
 
Appendix A 27. Robustness testing (flow rate = 1.4, 1.5 or 1.6 mL min-1) for the three FEP analytes using a mobile phase consisting 
of acetonitrile:ammonium acetate 25:75% v/v, concentration of FEP = 50 µg mL-1 
 
Injection 
tR (min) using flow rate 1.4 
mL min-1 
tR (min) using flow rate 1.5 
mL min-1 
tR (min) using flow rate 1.6 
mL min-1 
 10 8 9 10 8 9 10 8 9 
1 17.769 21.820  23.734 16.955 20.580  22.413 15.636 19.179 20.842 
2 17.787 21.843 23.762 16.948 20.537 22.405 15.613 19.169 20.846 
3 17.802 21.853 23.773 16.951 20.578 22.403 15.622 19.171 20.848 
4 17.813 21.869 23.786 16.951 20.580  22.405 15.618 19.166 20.850  
5 17.832 21.880  23.806 16.971 20.591 22.413 15.622 19.175 20.853 
6 17.847 21.895 23.814 16.961 20.581 22.411 15.633 19.177 20.859 
7 17.839 21.891 23.813 16.954 20.578 22.409 15.623 19.170  20.847 
8 17.836 21.885 23.806 16.949 20.582 22.407 15.621 19.170  20.844 
9 17.852 21.909 23.826 16.952 20.583 22.405 15.619 19.162 20.842 
10 17.851 21.903 23.821 16.947 20.579 22.410  15.622 19.174 20.851 
Average  17.822 21.874 23.794 16.953 20.576 22.408 15.622 19.171 20.848 
STD 0.028 0.028 0.029 0.007 0.014 0.003 0.006 0.005 0.005 
%RSD 0.161 0.130 0.124 0.042 0.070 0.016 0.043 0.026 0.025 
241 
 
Appendix A 28. Comparison of the resolution values obtained for the FEP regioisomers for the three robustness experiments performed 
 
Resolution using Flow Rate 
(mL min-1) 
Resolution using Temperature 
(°C) 
Resolution using % Mobile Phase 
Acetonitrile:ammonium acetate  
(% v/v) 
FEP isomer 1.4 1.5 1.6 48 50 52 24:76 25:75 26:74 
10 - - - - - - - - - 
8 5.22 4.81 5.14 5.08 4.81 5.38 4.92 5.01 5.00 























































































































Appendix A 52. Validation of 2-, 3- and 4-halogenated diphenidine isomers 
 
14 15 16 17 18 19 20 21 22 23 24 25 
tR (min) 4.150 5.891 6.804 8.414 4.217 5.815 6.451 7.309 3.551 5.406 6.098 7.126 
RRT 0.704 1 1.154 1.428 0.725 1 1.109 1.257 0.656` 1 1.127 1.318 
Capacity 
factor 
3.150 4.891 5.804 7.414 3.217 4.815 5.451 6.309 2.551 4.406 5.098 6.126 
N (plates) 9655.0 10972.5 11314.5 11479.9 9742.7 10413.9 10796.0 10975.8 9044.8 10933.2 11177.8 11578.2 
H(m) (x10-5) 1.55 x10-5 1.37 x10-5 1.33 x10-5 1.31 x10-5 1.54 x10-5 1.44 x10-5 1.39 x10-5 1.37 x10-5 1.66 x10-5 1.37 x10-5 1.34 x10-5 1.30 x10-5 
Resolution - 8.822 3.790 5.636 - 7.994 2.663 3.249 - 10.395 3.155 4.140 
Symmetry 0.888 0.895 0.910 0.921 0.876 0.866 0.896 0.903 0.902 0.902 0.909 0.897 
LOQ 0.237 0.226 0.222 0.234 0.180 0.166 0.212 0.183 0.262 0.223 0.178 0.264 
LOD 0.078 0.074 0.073 0.077 0.059 0.055 0.069 0.060 0.086 0.073 0.059 0.087 








0.9998 0.9999 0.9999 0.9998 
Equation 
y = 12.79 
x + 0.7256 
y = 23.44 x 
+ 0.1481 
y = 21.52x 
- 1.5042 
y = 21.55 x 
+ 0.921 
y = 14.24 
x - 0.0476 
y = 24.86 x 
+ 0.0177 
y = 23.78 x 
- 2.0693 
y = 22.67 x 
- 0.1191 
y = 13.54 
x - 0.2874 
y = 28.47 x 
- 0.5569 
y = 25.26 x 
- 1.2813 
y = 18.42 x 
- 1.7425 
Precision (%RSD) Precision (%RSD) Precision (%RSD) 
1.25 µg mL-1 0.969 0.913 0.461 0.780 0.782 0.735 0.999 0.522 0.536 0.730 0.545 0.657 
2.5 µg mL-1 0.987 0.918 0.948 0.938 0.629 0.982 0.887 0.633  0.993 0.746 0.765 0.819 
5  µg mL-1 0.977 0.495 0.593 0.934 0.629 0.982 0.887 0.633 0.905 0.618 0.825 0.601 
10  µg mL-1 0.987 0.755 0.488 0.441 0.814 0.814 0.842 0.298 0.743 0.744 0.290 0.576 
20 µg mL-1 0.645 0.838 0.827 0.595 0.366 0.289 0.515 0.113 0.353 0.237 0.360 0.246  
266 
 
Appendix A 53.  Intraday and inter-day precision measurements for the 2-halogenated diphenidine analytes using a mobile phase 
consisting of acetonitrile:ammonium acetate, 67:33% v/v, a flow rate of 1.5 mL min-1 and a concentration of 10 µg mL-1 
 
 Intraday Precision  tR       (min) Interday Precision  tR       (min) 
Injection  14 15 16 17 14 15 16 17 
1 4.16 5.90 6.81 8.42 4.17 5.91 6.81 8.41 
2 4.17 5.91 6.82 8.43 4.16 5.90 6.81 8.41 
3 4.17 5.91 6.82 8.42 4.17 5.90 6.80 8.41 
4 4.17 5.92 6.83 8.43 4.17 5.91 6.82 8.42 
5 4.17 5.91 6.82 8.42 4.16 5.90 6.81 8.41 
6 4.17 5.92 6.83 8.43 4.17 5.91 6.81 8.41 
7 4.17 5.91 6.82 8.42 4.16 5.90 6.80 8.40 
8 4.16 5.90 6.81 8.42 4.17 5.91 6.82 8.42 
9 4.16 5.90 6.81 8.41 4.17 5.91 6.82 8.41 
10 4.17 5.91 6.82 8.42 4.16 5.88 6.78 8.36 
Average  4.17 5.91 6.82 8.42 4.17 5.90 6.81 8.41 
STD 0.004 0.006 0.006 0.005 0.004 0.007 0.010 0.015 
%RSD 0.099 0.105 0.100 0.067 0.110 0.129 0.157 0.188 
267 
 
Appendix A 54. Robustness testing (temperature 48, 50 and 52°C) for the 2-halogenated diphenidine isomers using a mobile phase 
consisting of acetonitrile:ammonium acetate, 67:33 % v/v. Key: tR = Retention time (min). 
 
 
Injection tR (min) using temperature 48°C  tR (min) using temperature 50°C tR (min) using temperature 52°C 
 14 15 16 17 14 15 16 17 14 15 16 17 
1 4.19 5.96 6.90 8.56 4.17 5.91 6.81 8.41 4.13 5.86 6.75 8.33 
2 4.19 5.97 6.91 8.57 4.16 5.90 6.81 8.41 4.13 5.85 6.75 8.32 
3 4.18 5.96 6.90 8.56 4.17 5.90 6.80 8.40 4.13 5.86 6.76 8.34 
4 4.18 5.96 6.90 8.56 4.17 5.91 6.82 8.42 4.14 5.87 6.77 8.34 
5 4.18 5.97 6.91 8.57 4.16 5.90 6.81 8.41 4.14 5.87 6.77 8.36 
6 4.19 5.98 6.92 8.58 4.17 5.91 6.81 8.41 4.13 5.86 6.75 8.34 
7 4.17 5.96 6.90 8.56 4.16 5.90 6.80 8.40 4.14 5.86 6.76 8.34 
8 4.19 5.97 6.91 8.57 4.17 5.91 6.82 8.42 4.14 5.86 6.76 8.34 
9 4.18 5.97 6.91 8.58 4.17 5.91 6.82 8.41 4.14 5.86 6.76 8.34 
10 4.19 5.97 6.71 8.59 4.16 5.88 6.78 8.36 4.14 5.86 6.76 8.34 
Average 4.19 5.97 6.89 8.57 4.17 5.90 6.81 8.40 4.14 5.86 6.76 8.34 
STD 0.006 0.006 0.061 0.010 0.004 0.007 0.010 0.015 0.004 0.005 0.007 0.008 













































Appendix A 60. Summary of robustness testing (% mobile phase (acetonitrile:ammonium acetate) = 66:34, 67:33 or 68:32% v/v) for the 3-
halogenated diphenidine isomers (using 10 µg mL-1 concentration and 10 injections). Key: tR = Retention time (min), RRT =Relative retention time. 
 
Mobile phase (66:34% v/v)  18 19 20 21  Mobile phase (66:34% v/v)  22 23 24 25 
tR (min) 4.401 6.100 6.777 7.691  tR (min) 3.697 5.711 6.465 7.582 
RRT 0.721 1.000 1.110 1.260  RRT 0.647 1.000 1.131 1.327 
Resolution 0 8.192 2.723 3.320  Resolution 0 10.765 3.260 4.228 
           
Mobile phase (67:33% v/v) 18 19 20 21  Mobile phase (67:33% v/v) 22 23 24 25 
tR (min) 4.189 5.747 6.367 7.209  tR (min) 3.543 5.399 6.092 7.123 
RRT 0.728 1.000 1.107 1.254  RRT 0.656 1.000 1.128 1.319 
Resolution 0 7.937 2.660 3.296  Resolution 0 10.334 3.134 4.105 
           
Mobile phase (68:32% v/v) 18 19 20 21  Mobile phase (68:32% v/v) 22 23 24 25 
tR (min) 4.054 5.530 6.116 6.916  tR (min) 3.501 5.273 5.934 6.917 
RRT 0.733 1.000 1.105 1.250  RRT 0.663 1.000 1.125 1.311 








Appendix A 62. ln k versus % organic modifier (acetonitrile) for 4-halodiphenidine isomers (22, 23, 24 and 25)  
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